<SEC-DOCUMENT>0001193125-23-103731.txt : 20230417
<SEC-HEADER>0001193125-23-103731.hdr.sgml : 20230417
<ACCEPTANCE-DATETIME>20230417164757
ACCESSION NUMBER:		0001193125-23-103731
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20230606
FILED AS OF DATE:		20230417
DATE AS OF CHANGE:		20230417

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aeglea BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001636282
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				464312787
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37722
		FILM NUMBER:		23824483

	BUSINESS ADDRESS:	
		STREET 1:		805 LAS CIMAS PARKWAY
		STREET 2:		SUITE 100
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78746
		BUSINESS PHONE:		(512) 942-2935

	MAIL ADDRESS:	
		STREET 1:		805 LAS CIMAS PARKWAY
		STREET 2:		SUITE 100
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78746
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d449732ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
INFORMATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a party other than the Registrant&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only&nbsp;(as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material under <FONT STYLE="white-space:nowrap">&#167;&nbsp;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Aeglea BioTherapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement if Other Than The Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed in exhibit required by&nbsp;Item 25(b)&nbsp;per Exchange Act Rules
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
   <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>805 Las Cimas Parkway </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 100 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Austin, TX
78746 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE&nbsp;6, 2023 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Stockholders: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cordially invited to attend the 2023
Annual Meeting of Stockholders of Aeglea BioTherapeutics, Inc. (&#147;<B><I>Aeglea</I></B>,&#148; &#147;<B><I>we</I></B>,&#148; &#147;<B><I>our</I></B>&#148; or &#147;<B><I>us</I></B>&#148;). You will be able to participate in the 2023 Annual
Meeting and vote during the 2023 Annual Meeting via live webcast by visiting <U>www.virtualshareholdermeeting.com/AGLE2023</U> on Tuesday, June&nbsp;6, 2023 at 9:00 a.m. (Central Time). It is important that you retain a copy of the control number
found on the proxy card, voting instruction form or Notice, as such number will be required in order for stockholders to gain access to the virtual meeting. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are holding the meeting for the following purposes, which are more fully described in the accompanying proxy statement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect two Class&nbsp;I directors of Aeglea, each to serve until the 2026 annual meeting of stockholders.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm
for the fiscal year ending December&nbsp;31, 2023. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve, on a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory basis, the compensation of
Aeglea&#146;s named executive officers as disclosed in the proxy statement for the 2023 Annual Meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve an amendment to Aeglea&#146;s restated certificate of incorporation (the &#147;<B><I>Restated
Certificate of Incorporation</I></B>&#148;) to effect a reverse stock split of Aeglea&#146;s common stock at a ratio ranging from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-10</FONT></FONT> shares up to a ratio of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-25</FONT></FONT> shares, which ratio will be selected by Aeglea&#146;s board of directors (the &#147;<B><I>Reverse Stock Split</I></B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve an amendment and restatement of our 2016 Equity Incentive Plan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To transact such other business as may properly come before the Annual Meeting or any adjournment or
postponement thereof. </P></TD></TR></TABLE>  <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only stockholders of record at the close of business on April&nbsp;10, 2023 are entitled to notice of, and to
vote at, the meeting and any adjournments thereof. This Notice and the accompanying proxy statement are being mailed out to stockholders as of the record date beginning on or about April 17, 2023. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For ten days prior to the meeting, stockholders can request the list of stockholders through our investor relations website at <U><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://ir.aeglea.com/financials/annual-reports-and-proxy/default.aspx</FONT></FONT></U>. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your vote as an Aeglea stockholder is very important. Each share of stock that you own represents one vote. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For questions regarding your stock ownership, you may contact us through our website at <U>http://ir.aeglea.com</U> or, if you are a registered holder, our
transfer agent, American Stock Transfer&nbsp;&amp; Trust Company, by email through their website at <U>www.astfinancial.com</U> or by phone at (800) <FONT STYLE="white-space:nowrap">937-5449.</FONT> If you have any questions about
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
submitting your proxy or require assistance, please contact our proxy solicitor, Innisfree M&amp;A Incorporated (&#147;<B><I>Innisfree</I></B>&#148;) at: </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Innisfree M&amp;A Incorporated </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">501 Madison Avenue, 20th floor
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders may call toll free:
(877) 750-8310 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Banks and Brokers may call collect: (212) 750-5833 </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By Order of the Board of Directors, </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jeffrey M. Goldberg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey M. Goldberg</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin, Texas </P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 17,
2023 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YOUR VOTE IS IMPORTANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WE CURRENTLY PLAN TO HOLD THE ANNUAL MEETING VIA LIVE WEBCAST. WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING, WE ENCOURAGE YOU TO VOTE AND SUBMIT
YOUR PROXY BY INTERNET, TELEPHONE OR BY MAIL. FOR ADDITIONAL INSTRUCTIONS ON VOTING BY TELEPHONE OR THE INTERNET, PLEASE REFER TO YOUR PROXY CARD. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TO VOTE AND SUBMIT YOUR PROXY BY MAIL, PLEASE COMPLETE, SIGN AND DATE THE ENCLOSED PROXY CARD AND RETURN IT IN THE ENCLOSED ENVELOPE. IF YOU ATTEND THE
ANNUAL MEETING, YOU MAY REVOKE YOUR PROXY AND VOTE IN PERSON. IF YOU HOLD YOUR SHARES THROUGH AN ACCOUNT WITH A BROKERAGE FIRM, BANK OR OTHER NOMINEE, PLEASE FOLLOW THE INSTRUCTIONS YOU RECEIVE FROM YOUR ACCOUNT MANAGER TO VOTE YOUR SHARES. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IT IS IMPORTANT THAT YOU RETAIN A COPY OF THE CONTROL NUMBER FOUND ON THE PROXY CARD, VOTING INSTRUCTION FORM OR NOTICE, AS SUCH NUMBER WILL BE REQUIRED IN
ORDER FOR STOCKHOLDERS TO GAIN ACCESS TO THE VIRTUAL MEETING. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT FOR 2023 ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>Table of Contents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_1">INFORMATION ABOUT SOLICITATION AND VOTING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_2">GENERAL INFORMATION ABOUT THE ANNUAL MEETING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_3">NOMINATIONS PROCESS AND DIRECTOR QUALIFICATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_4">PROPOSAL NO. 1&nbsp;ELECTION OF DIRECTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_5">PROPOSAL NO. 2&nbsp;
RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING&nbsp;FIRM</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_6">PROPOSAL NO. 3 <FONT STYLE="white-space:nowrap">NON-BINDING</FONT> ADVISORY VOTE
 ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_7">PROPOSAL NO. 4 APPROVAL AND ADOPTION OF THE REVERSE STOCK SPLIT
AMENDMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_8">PROPOSAL NO. 5 APPROVAL OF AMENDMENT AND RESTATEMENT OF THE 2016 EQUITY INCENTIVE
 PLAN</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_9">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_10">EXECUTIVE OFFICERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_11">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_12">EQUITY COMPENSATION PLAN INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_13">RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_14">REPORT OF THE AUDIT COMMITTEE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_15">ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_16">OTHER MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_17">ANNEX A</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx449732_18">ANNEX B</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">B-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
   <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>805 Las Cimas Parkway </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 100 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Austin, TX
78746 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT FOR THE 2023 ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>April 17, 2023 </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx449732_1">
</A>INFORMATION ABOUT SOLICITATION AND VOTING </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying proxy is solicited on behalf of the board of directors of Aeglea BioTherapeutics, Inc.
(&#147;<B><I>Aeglea</I></B>&#148;) for use at Aeglea&#146;s 2023 Annual Meeting of Stockholders (&#147;<B><I>Annual Meeting</I></B>&#148;) to be held via a virtual meeting. You will be able to participate in the Annual Meeting and vote during the
Annual Meeting via live webcast by visiting <U>www.virtualshareholdermeeting.com/AGLE2023</U> on Tuesday, June&nbsp;6, 2023 at 9:00 a.m. (Central Time), and any adjournment or postponement thereof. You will need the control number included on your
proxy card, voting instruction form or Notice as such number will be required in order for stockholders to gain access to the virtual meeting.</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
Proxy Statement and the accompanying form of proxy were first mailed to stockholders on or about April&nbsp;17, 2023. An annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022 is enclosed with
this Proxy Statement. An electronic copy of this Proxy Statement and annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> are available at <U>www.proxyvote.com</U>. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx449732_2"></A>GENERAL INFORMATION ABOUT THE ANNUAL MEETING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Purpose of the Annual Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Annual Meeting,
stockholders will act upon the proposals described in this Proxy Statement for the 2023 Annual Meeting (&#147;<B><I>Proxy Statement</I></B>&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Record Date; Quorum </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only holders of record of common
stock at the close of business on April&nbsp;10, 2023 (the &#147;<B><I>Record Date</I></B>&#148;) will be entitled to vote at the Annual Meeting. At the close of business on the Record Date, we had 65,395,159 shares of common stock outstanding and
entitled to vote. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of a majority of the voting power of the shares of stock entitled to vote at the Annual Meeting as of the Record Date
must be present at the Annual Meeting in order to hold the Annual Meeting and conduct business. This presence is called a quorum. Your shares are counted as present at the Annual Meeting if you are present and vote in person at the Annual Meeting or
if you have properly submitted a proxy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights; Required Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In deciding all matters at the Annual Meeting, each holder of shares of common stock is entitled to one vote for each share of common stock held as of the
close of business on the Record Date. We do not have cumulative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
voting rights for the election of directors. You may vote all shares owned by you as of the Record Date, including (i)&nbsp;shares held directly in your name as the stockholder of record and
(ii)&nbsp;shares held for you as the beneficial owner in street name through a broker, bank, trustee, or other nominee. There are no dissenter or appraisal rights relating to the matters to be acted upon at the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name.</I> If, on the Record Date, your shares were registered directly in your name with our transfer
agent, American Stock Trust&nbsp;&amp; Transfer Company, then you are considered the stockholder of record with respect to those shares. As a stockholder of record, you may vote at the Annual Meeting or vote by telephone, by Internet, or by filling
out and returning the proxy card. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered in the Name of a Broker or Nominee.</I> If, on the Record Date, your shares were
held in an account with a brokerage firm, bank or other nominee, then you are the beneficial owner of the shares held in street name. As a beneficial owner, you have the right to direct your nominee on how to vote the shares held in your account,
and your nominee has enclosed or provided voting instructions for you to use in directing it on how to vote your shares. However, the organization that holds your shares is considered the stockholder of record for purposes of voting at the Annual
Meeting. Because you are not the stockholder of record, giving you the right to vote the shares at the Annual Meeting, you may not vote your shares at the Annual Meeting unless you request and obtain a valid proxy from the organization that holds
your shares giving you the right to vote the shares at the Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the minimum vote needed to approve each
proposal and the effect of abstentions and broker <FONT STYLE="white-space:nowrap">non-votes:</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Proposal<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Vote Required</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>for Approval</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Effect of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Abstentions</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Effect of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Broker <FONT STYLE="white-space:nowrap">Non-Votes</FONT></B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Election of Class&nbsp;I Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The two nominees receiving the most &#147;FOR&#148; votes (withheld votes will have no effect)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">No effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Majority of the affirmative votes cast</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">No effect; an abstention does not count as a vote cast</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Brokers have discretion to vote</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Advisory vote on the compensation of our named executive officers</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Majority of the affirmative votes cast</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">No effect; an abstention does not count as a vote cast</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">No effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Reverse Stock Split</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Majority of shares of common stock outstanding</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Abstention will have the effect of a vote against such proposal</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have the effect of a vote against the proposal; however brokers have discretion to vote</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment and Restatement of the 2016 Equity Incentive Plan</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Majority of the affirmative votes cast</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">No effect; an abstention does not count as a vote cast</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">No effect</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> occur when a broker, bank or other nominee holding
shares for a beneficial owner does not vote on a particular matter because such broker, bank or other nominee does not have discretionary authority to vote on that matter and has not received voting instructions from the beneficial owner. Brokers,
banks and other nominees typically do not have discretionary authority to vote on <FONT STYLE="white-space:nowrap">non-routine</FONT> matters. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted for purposes of determining whether a
quorum is present, and have no effect on the outcome of the matters voted upon (other than the Reverse Stock Split proposal as described above). Under the rules and interpretations of the New York Stock Exchange,
<FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters are matters that may substantially affect the rights or privileges of stockholders, such as mergers, stockholder proposals, elections of directors, executive compensation and
certain corporate governance proposals, even if management-supported. We have been advised by the New York Stock Exchange that at our Annual Meeting, only the ratification of the appointment of our independent registered public accounting firm
(Proposal No.&nbsp;2) and the Reverse Stock Split (Proposal No.&nbsp;4) are considered &#147;routine&#148; matters. Note that if you are a beneficial holder and do not provide specific voting instructions to your broker, the broker that holds your
shares will not have discretionary authority to vote on the <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> proposals in this Proxy Statement. Accordingly, we encourage you to provide voting instructions to your broker, whether or
not you plan to attend the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, abstentions are voted neither &#147;FOR&#148; nor &#147;AGAINST&#148; a matter, and, therefore, will
have no effect on the outcome of the matters voted upon (other than the Reverse Stock Split proposal as described above), but will be counted for the purpose of establishing a quorum for the Annual Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendations of the Board of Directors on Each of the Proposals Scheduled to be Voted on at the Annual Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The board of directors recommends that you vote: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;FOR&#148; each of the Class&nbsp;I directors named in this Proxy Statement (&#147;<B><I>Proposal
No.</I></B><B><I></I></B><B><I>&nbsp;1</I></B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;FOR&#148; the ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered
public accounting firm for the fiscal year ending December&nbsp;31, 2023 (&#147;<B><I>Proposal No.</I></B><B><I></I></B><B><I>&nbsp;2</I></B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;FOR&#148; the approval, on a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory basis, of the
compensation of our named executive officers, as disclosed in this Proxy Statement (&#147;<B><I>Proposal No.</I></B><B><I></I></B><B><I>&nbsp;3</I></B>&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;FOR&#148; the approval of the Reverse Stock Split (&#147;<B><I>Proposal
No.</I></B><B><I></I></B><B><I>&nbsp;4</I></B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;FOR&#148; the approval of amendment and restatement of the 2016 Equity Incentive Plan (&#147;<B><I>Proposal
No.</I></B><B><I></I></B><B><I>&nbsp;5</I></B>&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the directors or executive officers has any substantial interest in any
matter to be acted upon, other than elections to office with respect to the directors so nominated in Proposal No.&nbsp;1. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Instructions; Voting
of Proxies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record, you may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">vote online at the Annual Meeting&#151;attend the Annual Meeting online and follow the instructions posted at
<U>www.virtualshareholdermeeting.com/AGLE2023</U>. You will need the control number included on your proxy card, voting instruction form or Notice; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">vote via telephone or Internet&#151;in order to do so, please follow the instructions shown on your proxy card;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">vote by mail&#151;complete, sign and date the proxy card enclosed herewith and return it before the Annual
Meeting in the envelope provided. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Votes submitted by telephone or Internet must be received by 11:59 p.m. Eastern Time on June&nbsp;5,
2023. Submitting your proxy, whether via the Internet, by telephone, or by mail, will not affect your right to vote online </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
should you decide to attend the live webcast Annual Meeting. If you are not the stockholder of record, please refer to the voting instructions provided by your nominee to direct it how to vote
your shares. For Proposal No.&nbsp;1, you may vote &#147;FOR ALL&#148; of the nominees, vote &#147;WITHHOLD ALL&#148; with respect to the nominees or vote &#147;FOR ALL EXCEPT&#148; a particular nominee. For Proposal No.&nbsp;2, Proposal No.&nbsp;3,
Proposal No.&nbsp;4 and Proposal No.&nbsp;5, you may vote &#147;FOR&#148; or &#147;AGAINST&#148; or &#147;ABSTAIN&#148; from voting. Your vote is important. Whether or not you plan to attend the Annual Meeting, we urge you to vote by proxy to ensure
that your vote is counted. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All proxies will be voted in accordance with the instructions specified on the proxy card. If you sign a physical proxy
card and return it without instructions as to how your shares should be voted on a particular proposal at the Annual Meeting, your shares will be voted in accordance with the recommendations of our board of directors stated above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you do not vote and you hold your shares in street name, and your broker does not have discretionary power to vote your shares, your shares may constitute
&#147;broker <FONT STYLE="white-space:nowrap">non-votes&#148;</FONT> (as described above) and will not be counted in determining the number of shares necessary for approval of the proposals. However, shares that constitute broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> will be counted for the purpose of establishing a quorum for the Annual Meeting. Additionally, abstentions are voted neither &#147;FOR&#148; nor &#147;AGAINST&#148; a matter, and therefore, will have no
effect on the outcome of the matters voted upon, except as set forth in the table above, but will be counted for the purpose of establishing a quorum for the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you receive more than one proxy card, your shares are registered in more than one name or are registered in different accounts. To make certain all of your
shares are voted, please follow the instructions included on each proxy card and vote each proxy card by telephone, through the Internet or by mail. If you are voting by mail, please complete, sign and return each proxy card to ensure that all of
your shares are voted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expenses of Soliciting Proxies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aeglea will pay the expenses of soliciting proxies. Following the original mailing of the soliciting materials, Aeglea and its agents, including directors,
officers and other employees, without additional compensation, may solicit proxies by mail, electronic mail, telephone, facsimile, by other similar means, or in person. Following the original mailing of the soliciting materials, Aeglea will request
brokers, custodians, nominees and other record holders to forward copies of the soliciting materials to persons for whom they hold shares and to request authority for the exercise of proxies. In such cases, Aeglea, upon the request of the record
holders, will reimburse such holders for their reasonable expenses. If you choose to access the proxy materials and/or vote through the Internet, you are responsible for any Internet access charges you may incur. In addition, Aeglea has retained
Innisfree at a fee estimated to be approximately $15,000, plus certain <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, to act as Aeglea&#146;s proxy solicitor in connection with the proposals
to be acted upon at the Annual Meeting. Pursuant to an agreement, Innisfree has agreed to solicit proxies from Aeglea&#146;s stockholders on Aeglea&#146;s behalf in connection with the Annual Meeting. If you have any questions about submitting your
proxy or require assistance, please contact Aeglea&#146;s proxy solicitor at: </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Innisfree M&amp;A Incorporated </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">501 Madison Avenue, 20th floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders may call toll free: (877) 750-8310 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Banks and
Brokers may call collect: (212) 750-5833 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revocability of Proxies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A stockholder who has given a proxy may revoke it at any time before it is exercised at the Annual Meeting by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delivering to the Corporate Secretary of Aeglea (by any means, including facsimile) a written notice stating that
the proxy is revoked; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">signing and delivering a proxy bearing a later date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting again by telephone or Internet; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attending and voting online at the Annual Meeting by following the instructions posted at
<U>http://www.virtualshareholdermeeting.com/AGLE2023</U> (although attendance at the Annual Meeting will not, by itself, revoke a proxy). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to revoke a proxy, you must contact that broker,
bank, or other nominee to revoke any prior voting instructions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voting results will be tabulated and certified by the inspector of elections appointed for the Annual Meeting. The preliminary voting results will be announced
at the Annual Meeting. The final results will be tallied by the inspector of elections and filed with the Securities and Exchange Commission (&#147;<B><I>SEC</I></B>&#148;) in a current report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT>
within four business days of the Annual Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being a &#147;Smaller Reporting Company&#148; </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a &#147;smaller reporting company&#148; as defined under Rule 405 of the Securities Act of 1933, as amended (the &#147;<B><I>Securities
Act</I></B>&#148;), and, as such, have elected to comply with certain reduced public company reporting requirements. These reduced reporting requirements include reduced disclosure about Aeglea&#146;s executive compensation arrangements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BOARD OF DIRECTORS AND COMMITTEES OF THE BOARD; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE GOVERNANCE STANDARDS AND DIRECTOR INDEPENDENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aeglea is strongly committed to good corporate governance practices. These practices provide an important framework within which our board of directors and
management can pursue our strategic objectives for the benefit of our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Governance Guidelines </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted corporate governance guidelines that set forth the role of the board of directors, director independence standards, board
structure and functions, director selection considerations, and other policies for the governance of Aeglea (&#147;<B><I>Corporate Governance Guidelines</I></B>&#148;). Our Corporate Governance Guidelines are available by clicking on
&#147;Governance Documents&#148; in the Investors&nbsp;&amp; Media section of our website, which is located at <U>https://ir.aeglea.com/governance/governance-documents/default.aspx</U>. Our nominating and corporate governance committee reviews the
Corporate Governance Guidelines periodically, and recommends changes to our board of directors as warranted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Corporate Governance Guidelines provide that our board of directors shall be free to choose its chairperson in any way that it considers in the best
interests of our company, and that the nominating and corporate governance committee shall periodically consider the leadership structure of our board of directors and make such recommendations to the board of directors with respect thereto as the
nominating and corporate governance committee deems appropriate. Our Corporate Governance Guidelines also provide that, when the positions of chairperson and Chief Executive Officer are held by the same person, the independent directors may
designate a &#147;lead independent director.&#148; In cases in which the chairperson and Chief Executive Officer are the same person, the chairperson schedules and sets the agenda for meetings of the board of directors in consultation with the lead
independent director, and the chairperson, or if the chairperson is not present, the lead independent director, chairs such meetings. In addition, the responsibilities of the lead independent director include: presiding over executive sessions of
independent directors; serving as a liaison between the chairperson and the independent directors; being available, under appropriate circumstances, for consultation and direct communication with stockholders; and performing such other functions and
responsibilities as requested by the board of directors from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors believes that Aeglea and our stockholders are best
served by having an independent director serve as our <FONT STYLE="white-space:nowrap">non-executive</FONT> Chair. Since January 2019, Mr.&nbsp;Russell Cox has served as <FONT STYLE="white-space:nowrap">non-executive</FONT> Chair of our board of
directors. Our board of directors believes that the current board leadership structure provides effective independent oversight of management while allowing the board and management to benefit from its members&#146; extensive financial and business
expertise in the biotechnology industry. Our board of directors believes that its independence and oversight of management is maintained effectively through this leadership structure, the composition of the board of directors and sound corporate
governance policies and practices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Board of Directors&#146; Role in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors, as a whole, has responsibility for risk oversight, although the committees of our board of directors oversee and review risk areas that
are particularly relevant to them. The risk oversight responsibility of our board of directors and its committees is supported by our management reporting processes, which are designed to provide visibility to the board of directors and to our
personnel that are responsible for risk assessment and information about the identification, assessment and management of critical risks and management&#146;s risk mitigation strategies. These areas of focus include, but are not limited to,
competitive, economic, operational, financial (accounting, credit, liquidity, and tax), cybersecurity, legal, regulatory, compliance and reputational risks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each committee of the board of directors meets in executive session with key management personnel and
representatives of outside advisors to oversee risks associated with their respective principal areas of focus. The audit committee reviews our major financial risk exposures and the steps management has taken to monitor and control such exposures,
including our risk assessment and risk management policies and guidelines. The compensation committee reviews risks and exposures associated with compensation programs and arrangements, including incentive plans. The nominating and corporate
governance committee, together with the audit committee, reviews our major legal compliance risk exposures and monitors the processes put in place by management to mitigate these exposures, including our legal risk assessment and legal risk
management policies and guidelines. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors determines the independence of our directors by applying the applicable rules, regulations and listing standards of The Nasdaq Global
Market (&#147;<B><I>Nasdaq</I></B>&#148;). These provide that a director is independent only if the board affirmatively determines that the director does not have a relationship with the company which, in the opinion of the board of directors, would
interfere with the exercise of his or her independent judgment in carrying out the responsibilities of a director. They also specify various relationships that preclude a determination of director independence. Such relationships may include
employment, commercial, accounting, family and other business, professional and personal relationships. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applying these standards, the board annually
reviews the independence of our directors, taking into account all relevant facts and circumstances. In its most recent review, our board of directors considered, among other things, the relationships that each non- employee director has with our
company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon this review, our board of directors has determined that the following members of our board are currently independent as determined under
applicable rules, regulations and listing standards of Nasdaq: Mr.&nbsp;Russell Cox, Dr.&nbsp;Armen Shanafelt, Dr.&nbsp;Ivana Magovcevic-Liebisch, Dr.&nbsp;Bryan Lawlis, Ms.&nbsp;Alison Lawton, Mr.&nbsp;Marcio Souza and Mr.&nbsp;Hunter
Smith.&nbsp;All members of our audit committee, compensation committee and nominating and corporate governance committee must be independent directors under the applicable rules, regulations and listing standards of Nasdaq. Members of the audit
committee also must satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Securities Exchange Act of 1934, as amended (the &#147;<B><I>Exchange Act</I></B>&#148;). Members of the compensation
committee also must satisfy the independence criteria set forth in Rule 10C under the Exchange Act, and related Nasdaq listing standards with respect to their affiliation with Aeglea and any consulting, advisory or other fees they may have received
from Aeglea. Our board of directors has determined that all members of our audit committee, compensation committee and nominating and corporate governance committee are independent and satisfy the relevant SEC, Exchange Act and Nasdaq independence
requirements for such committees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee. The composition and
responsibilities of each committee are described below. Each of these committees has a written charter approved by our board of directors. Copies of the charters for the audit committee, compensation committee and nominating and corporate governance
committee are available, without charge, upon request in writing to Aeglea BioTherapeutics, Inc., 805 Las Cimas Parkway, Suite 100, Austin, Texas 78746, Attn: Corporate Secretary or by clicking on &#147;Governance Documents&#148; in the
Investors&nbsp;&amp; Media section of our website at <U>https://ir.aeglea.com/governance/governance-documents/default.aspx</U>. Members serve on these committees until their resignations or until otherwise determined by our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit committee is comprised of Mr.&nbsp;Smith, who serves as the chair, Dr.&nbsp;Magovcevic-Liebisch and Dr.&nbsp;Lawlis. The members of our audit
committee meet the requirements for independence under current Nasdaq, Exchange Act and SEC rules, regulations and listing standards. Each member of our audit committee is financially literate as required by Nasdaq listing standards. In addition,
our board of directors has determined that Mr.&nbsp;Smith is an audit committee financial expert within the meaning of Item&nbsp;407(d) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> under the Securities Act. This designation does
not impose on him any duties, obligations or liabilities that are greater than those that are generally imposed on members of our audit committee and our board of directors. Our audit committee is directly responsible for, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selecting a firm to serve as the independent registered public accounting firm to audit our consolidated
financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensuring the independence of the independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the scope and results of the audit with the independent registered public accounting firm, and
reviewing, with management and that firm, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT> operating results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for employees to anonymously submit concerns about questionable accounting or audit
matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering the adequacy of our internal controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing our compliance with legal and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assisting the board of directors with risk assessment and management, including cybersecurity risk management;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing material related party transactions or those that require disclosure; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving</FONT> all audit and <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting firm. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation committee
is comprised of Mr.&nbsp;Cox, who serves as the chair, Dr.&nbsp;Magovcevic-Liebisch and Mr.&nbsp;Souza. The composition of our compensation committee meets the requirements for independence under current Nasdaq and SEC rules, regulations and listing
standards. Each member of this committee is also a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, as defined pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3</FONT> promulgated under the Exchange Act and is
&#147;independent&#148; as defined in Section&nbsp;5605(a)(2) of the Nasdaq rules and Rule <FONT STYLE="white-space:nowrap">10C-1</FONT> promulgated under the Exchange Act. The purpose of our compensation committee is to discharge the
responsibilities of our board of directors relating to compensation of our executive officers. Our compensation committee is responsible for, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving, or recommending that our board of directors approve, the compensation of our executive
officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our board of directors the compensation of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our board of directors the terms of any compensatory agreements with our executive
officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our stock and equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving, or making recommendations to our board of directors with respect to, incentive
compensation and equity plans; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our overall compensation philosophy. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation committee has the sole authority and responsibility, subject to any approval by the board
of directors which the compensation committee or legal counsel determines to be desirable or required by applicable law or the Nasdaq rules, to determine all aspects of executive compensation packages for the Chief Executive Officer and other
executive officers. The compensation committee also makes recommendations to our board of directors regarding the form and amount of compensation of <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. The compensation committee may take
into account the recommendations of the Chief Executive Officer with respect to compensation of the other executive officers, and the recommendations of the board of directors or any member thereof with respect to compensation of the Chief Executive
Officer and other executive officers. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation committee engaged Compensia, Inc., a national compensation consulting firm
(&#147;<B><I>Compensia</I></B>&#148;), to evaluate our executive and <FONT STYLE="white-space:nowrap">non-executive</FONT> compensation programs, policies, and practices and provide advice and ongoing assistance on executive compensation matters for
fiscal year 2022. Specifically, Compensia was engaged to: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluate and analyze executive compensation-related data for a peer group of companies to serve as a basis for
assessing competitive compensation practices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review and evaluate our current compensation program, policies and practices for our Chief Executive Officer,
other executive officers relative to competitive market practices and identify any potential changes or enhancements to be brought to the attention of the compensation committee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review and evaluate our current compensation program, policies, and practices for the <FONT
STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors relative to competitive market practices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review market practices on employee stock purchase plans and other equity compensation programs; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review key trends&nbsp;&amp; developments in executive and board compensation programs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Representatives of Compensia met informally with the chair of the compensation committee and attended the regular meetings of the compensation committee,
including executive sessions from time to time without any members of management present. During fiscal year 2022, Compensia worked directly with the compensation committee (and not on behalf of management) to assist the committee in satisfying its
responsibilities and undertook no projects for management without the committee&#146;s prior approval. After reviewing the rules of the SEC and the applicable Nasdaq listing standards, the compensation committee has determined that its relationship
with Compensia and the work performed by Compensia during fiscal year 2022 on behalf of the compensation committee did not raise any conflict of interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
nominating and corporate governance committee is comprised of Ms.&nbsp;Lawton, who serves as the chair, Dr.&nbsp;Shanafelt and Mr.&nbsp;Souza. The composition of our nominating and corporate governance committee meets the requirements for
independence under current Nasdaq and SEC rules, regulations and listing standards. Our nominating and corporate governance committee is responsible for, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying and recommending candidates for membership on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending directors to serve on board committees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending our Corporate Governance Guidelines and policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing proposed waivers of the code of conduct for directors and executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating, and overseeing the process of evaluating, the performance of our board of directors and individual
directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assisting our board of directors on corporate governance matters. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2022, Mr.&nbsp;Cox, Dr.&nbsp;Magovcevic-Liebisch and Mr.&nbsp;Souza served on our Compensation Committee. Mr.&nbsp;Sandesh Mahatme served on our
Compensation Committee until July 2022. No member of our compensation committee in 2022 was at any time during 2022 or previously an officer or employee of Aeglea or any of its subsidiaries, and none had or have any relationships with Aeglea that
are required to be disclosed under Item&nbsp;404 of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> None of our executive officers has served as a member of the board of directors, or as a member of the compensation or similar
committee, of any entity that has one or more executive officers who served on our board of directors or compensation committee during fiscal year 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Conduct and Ethics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a Code of
Conduct and Ethics that applies to all of our employees, officers and directors, including our Chief Executive Officer and other executive officers. The full text of our Code of Conduct and Ethics is available on the Investors&nbsp;&amp; Media
section of our website located at <U>https://ir.aeglea.com/governance/governance-documents/default.aspx</U> by clicking on &#147;Governance Documents.&#148; Any amendments or waivers of our Code of Conduct and Ethics pertaining to a member of our
board of directors or one of our executive officers will be disclosed on our website at the above-referenced address. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-hedging </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted an Insider Trading Policy that applies to all of our employees, officers and directors, including our Chief Executive Officer and other
executive officers, which prohibits such individuals from purchasing financial instruments, or otherwise engaging in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in market value of our common stock, such as
prepaid variable forward contracts, equity swaps, collars, forward sale contracts and exchange funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board and Committee Meetings and Attendance
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors and its committees meet throughout the year on a set schedule, and also hold special meetings and act by written consent from
time to time. During fiscal year 2022, our board of directors met 12 times, including telephonic meetings, the audit committee held four meetings, the compensation committee held eight meetings and the nominating and corporate governance committee
held six meetings. None of the directors attended fewer than 75% of the aggregate of the total number of meetings held by the board of directors and the total number of meetings held by all committees of the board of directors on which such director
served (during the period that such director served on the board of directors and any committee). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Attendance at Annual Stockholders&#146;
Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our policy is to invite and encourage each member of our board of directors to be present at our annual meetings of stockholders.
Dr.&nbsp;Shanafelt, Mr.&nbsp;Cox, Dr.&nbsp;Magovcevic-Liebisch, Ms.&nbsp;Lawton, Mr.&nbsp;Smith, Mr.&nbsp;Souza and former director Dr.&nbsp;Anthony Quinn attended the 2022 annual meeting of stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presiding Director of <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Meetings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">non-employee</FONT> directors meet in regularly scheduled executive sessions without management to promote open and honest
discussion, led by our <FONT STYLE="white-space:nowrap">non-executive</FONT> Chair, Mr. Cox. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Communication with Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders and interested parties who wish to communicate with our board of directors, <FONT STYLE="white-space:nowrap">non-management</FONT> members of our
board of directors as a group, a committee of the board of directors or a specific member of our board of directors (including our Chair or lead independent director, if any) may do so by letters addressed to the attention of our Compliance Officer.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All communications are reviewed by the Compliance Officer and provided to the members of the board of
directors consistent with a screening policy providing that unsolicited items, sales materials, abusive, threatening or otherwise inappropriate materials and other routine items and items unrelated to the duties and responsibilities of the board of
directors not be relayed on to directors. Any communication that is not relayed is recorded in a log and made available to our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
address for these communications is: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Aeglea BioTherapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>c/o Compliance Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>805 Las Cimas Parkway </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 100 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Austin, TX
78746 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx449732_3"></A>NOMINATIONS PROCESS AND DIRECTOR QUALIFICATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nomination to the Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Candidates for
nomination to our board of directors are selected by our board of directors based on the recommendation of the nominating and corporate governance committee in accordance with the committee&#146;s charter, our Restated Certificate of Incorporation
and amended and restated bylaws (&#147;<B><I>Bylaws</I></B>&#148;), our Corporate Governance Guidelines, and the criteria adopted by the board of directors regarding director candidate qualifications. In recommending candidates for nomination, the
nominating and corporate governance committee considers candidates recommended by directors, officers, employees, stockholders and others, using the same criteria to evaluate all candidates. Evaluations of candidates generally involve a review of
background materials, internal discussions and interviews with selected candidates as appropriate and, in addition, the committee may engage consultants or third-party search firms to assist in identifying and evaluating potential nominees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee will consider properly submitted stockholder recommendations for candidates for our board of directors who
meet the qualifications as described above. The nominating and corporate governance committee does not intend to alter the manner in which it evaluates candidates, including the criteria set forth below, based on whether or not the candidate was
recommended by a stockholder. A stockholder of record can nominate a candidate for election to the board of directors by complying with the procedures in Article I, Section&nbsp;1.12 of our Bylaws. Submissions must include the full name of the
proposed nominee, complete biographical information, a description of the proposed nominee&#146;s qualifications as a director, other information specified in our Bylaws, and a representation that the nominating stockholder is a beneficial or record
holder of our stock. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected. These candidates are evaluated at meetings of the nominating and corporate
governance committee, and may be considered at any point during the year. If any materials are provided by a stockholder in connection with the recommendation of a director candidate, such materials are forwarded to the nominating and corporate
governance committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional information regarding the process for properly submitting stockholder nominations for candidates for membership on our
board of directors is set forth below under &#147;Stockholder Proposals to Be Presented at Next Annual Meeting.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Qualifications </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With the goal of developing a diverse, experienced and highly qualified board of directors, the nominating and corporate governance committee is responsible
for developing and recommending to the board of directors the desired qualifications, expertise and characteristics of members of our board of directors, including any specific minimum qualifications that the committee believes must be met by a
committee-recommended nominee for membership on the board of directors and any specific qualities or skills that the committee believes are necessary for one or more of the members of the board of directors to possess. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the identification, evaluation and selection of qualified directors is a complex and subjective process that requires consideration of many intangible
factors, and will be significantly influenced by the particular needs of the board of directors from time to time, our board of directors has not adopted a specific set of minimum qualifications, qualities or skills that are necessary for a nominee
to possess, other than those that are necessary to meet U.S. legal, regulatory and Nasdaq listing requirements and the provisions of our Restated Certificate of Incorporation, Bylaws, Corporate Governance Guidelines, and charters of the board
committees. In addition, neither the board of directors nor the nominating and corporate governance committee has a formal policy with regard to the consideration of diversity in identifying nominees. When considering nominees, the nominating and
corporate governance committee may take into consideration many factors including, among other things, a candidate&#146;s independence, integrity, skills, financial and other expertise, breadth of experience, knowledge about
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our business or industry and ability to devote adequate time and effort to responsibilities of the board of directors in the context of its existing composition. Through the nomination process,
the nominating and corporate governance committee seeks to promote board membership that reflects a diversity of business experience, expertise, viewpoints, personal backgrounds and other characteristics that are expected to contribute to the board
of directors&#146; overall effectiveness. A nominee&#146;s self-identified diversity characteristics will also be considered by the board of directors in accordance with the factors described above. The brief biographical description of each
director set forth in Proposal No.&nbsp;1 below includes the primary individual experience, qualifications, attributes and skills of each of our directors that led to the conclusion that each director should serve as a member of our board of
directors at this time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx449732_4"></A>PROPOSAL NO. 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION OF DIRECTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of
directors currently consists of eight directors and is divided into three classes. Each class serves for three years, with the terms of office of the respective classes expiring in successive years. Directors in Class&nbsp;I will stand for election
at our Annual Meeting to be held on June&nbsp;6, 2023. The terms of office of directors in Class&nbsp;II and Class&nbsp;III do not expire until the annual meetings of stockholders held in 2024 and 2025, respectively. At the recommendation of our
nominating and corporate governance committee, our board of directors proposes that each of the two Class&nbsp;I nominees named below, each of whom is currently serving as a director in Class&nbsp;I, be elected as a Class&nbsp;I director for a
three-year term expiring at the 2026 annual meeting of stockholders and until such director&#146;s successor is duly elected and qualified or until such director&#146;s earlier resignation or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares represented by proxies will be voted &#147;FOR&#148; the election of each of the two nominees named below, unless the proxy is marked to withhold
authority to so vote. If any nominee for any reason is unable to serve or for good cause will not serve, the proxies may be voted for such substitute nominee as the proxy holder might determine. Each nominee has consented to being named in this
Proxy Statement and to serve if elected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nominees to the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nominees, and their ages, occupations and length of board service as of March&nbsp;31, 2023, are provided in the table below. Additional biographical
descriptions of each nominee are set forth in the text below the table. These descriptions include the primary individual experience, qualifications, qualities and skills of each of our nominees that led to the conclusion that each director should
serve as a member of our board of directors at this time. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="11%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name of Director/Nominee</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Principal Occupation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Director&nbsp;Since</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;I Director Nominees:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alison Lawton <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">61</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director, ProQR Therapeutics N.V; Director, Magenta Therapeutics, Inc; Director X4 Pharmaceuticals Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hunter C. Smith, M.B.A. <SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer and Treasurer of Rhythm Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2021</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Alison Lawton.</I> Ms.&nbsp;Lawton has served as a director since December 2020. Ms.&nbsp;Lawton served as a special advisor at Kaleido Biosciences, Inc.
from June 2020 to December 2020. Ms.&nbsp;Lawton previously served as President and Chief Executive Officer of Kaleido Biosciences, Inc. from August 2018 to June 2020, and served as President and Chief Operating Officer from December 2017 to August
2018. Prior to joining Kaleido Biosciences, Inc., Ms.&nbsp;Lawton served as Chief Operating Officer at Aura Biosciences, Inc., an oncology therapeutics company, from January 2015 until December 2017, and, prior to joining Aura, served as a
consultant to Aura from March 2014 to December 2014. From January 2013 to January 2014, Ms.&nbsp;Lawton served as Chief Operating Officer at OvaScience Inc., a life sciences company. From 2014 to 2017, Ms.&nbsp;Lawton served as a biotech consultant
for various companies, including as Chief Operating Officer consultant at X4 Pharmaceuticals Inc. Prior to that, Ms.&nbsp;Lawton spent more than 20 years in various positions of increasing responsibility including Senior VP and General Manager of
Biosurgery and prior to that, Senior VP of Market Access at Genzyme Corporation, a global biopharmaceutical company, and subsequently at Sanofi S.A., also a global biopharmaceutical company, following the acquisition of Genzyme by Sanofi in 2011.
Additionally, Ms.&nbsp;Lawton previously served two terms as the industry representative on the U.S. Food&nbsp;&amp; Drug Administration&#146;s Cell&nbsp;&amp; Gene Therapy Advisory Committee and as Chair of the Board of the Regulatory Affairs
Professional Society. Ms.&nbsp;Lawton currently serves on the boards of directors of ProQR Therapeutics N.V., Magenta Therapeutics, Inc., </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
X4 Pharmaceuticals and three other private companies. Ms.&nbsp;Lawton previously served on the boards of directors of Kaleido Biosciences, Verastem, Inc., CoLucid Pharmaceuticals, Inc., Cubist
Pharmaceuticals, Inc. Ms.&nbsp;Lawton received a B.Sc. in pharmacology from Kings College, University of London. We believe that Ms.&nbsp;Lawton is qualified to serve on our board of directors due to her extensive commercial and operating experience
in the biopharmaceutical industry. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hunter C. Smith, M.B.A. </I>Mr.&nbsp;Smith has served as a director since November 2021. Mr.&nbsp;Smith has
served as Chief Financial Officer of Rhythm Pharmaceuticals, Inc. since July 2017 and Treasurer since August 2017. He has more than 25 years of global finance and management experience across multiple industries and financial disciplines, including
expertise in business analysis and planning, mergers and acquisitions, capital raising and investor relations. Previously, he was Vice President, Finance and Chief Financial Officer of the Inflammation and Immunology Business Unit at Celgene
Corporation from 2013 to July 2017. Before joining Celgene, Mr.&nbsp;Smith worked in roles of increasing responsibility at Bunge Limited from 1999 to 2013, including Director of Investor Relations, Chief Financial Officer-Asia, Corporate Treasurer,
and Chief Financial Officer of Bunge&#146;s Sugar and Bioenergy Segment. Mr.&nbsp;Smith served previously as an independent director of Genessee&nbsp;&amp; Wyoming Inc. and was a member of its compensation and nominating and governance committees.
Mr.&nbsp;Smith holds an MBA in Finance from New York University&#146;s Stern School of Business and a B.A. in History, with honors, from Northwestern University.&nbsp;We believe Mr.&nbsp;Smith is qualified to serve on our board of directors because
of his business and leadership experience in the life sciences industry. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Continuing Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The directors who are serving for terms that end following the Annual Meeting, and their ages, occupations and length of board service as of March&nbsp;31,
2023, are provided in the table below. Additional biographical descriptions of each such director are set forth in the text below the table. These descriptions include the primary individual experience, qualifications, qualities and skills of each
of our nominees that led to the conclusion that each director should serve as a member of our board of directors at this time. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name of Director</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Principal Occupation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Director&nbsp;Since</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Class&nbsp;II Directors:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Russell J. Cox <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer, Epirium Bio, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2015</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ivana Magovcevic-Liebisch, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top"> (1)(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer, Vigil Neuroscience, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Marcio Souza<SUP STYLE="font-size:75%; vertical-align:top"> (1)(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">44</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President, Chief Executive Officer and Director of Praxis Precision Medicines, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Class&nbsp;III Directors:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jeffrey M. Goldberg</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer, Aeglea</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2022</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Armen Shanafelt, Ph.D. <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">63</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director, Surface Oncology, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2013</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">V. Bryan Lawlis, Ph.D. <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">71</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director, Biomarin Pharmaceutical, , Inc; Director, Geron Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2018</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Russell J. Cox. </I>Mr.&nbsp;Cox has served as a director since June 2015 and has served as Chair of our board since January 2019. Mr.&nbsp;Cox has served
as President and Chief Executive Officer of Epirium Bio, Inc. since July 2019. Mr.&nbsp;Cox previously served as Chief Executive Officer at Vital Therapies, Inc. from January 2018 to January 2019. Additionally, Mr.&nbsp;Cox served as Executive Vice
President and Chief Operating Officer at Jazz </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Pharmaceuticals plc, a publicly traded biopharmaceutical company, from May 2014 to January 2018, where he also served as Executive Vice President and Chief Commercial Officer from March 2012 to
May 2014 and as Senior Vice President, Sales and Marketing from July 2010 until February 2012. Prior to that, Mr.&nbsp;Cox served in a variety of senior management roles since joining Jazz Pharmaceuticals, Inc. (the predecessor to Jazz
Pharmaceutical plc) in July 2010. From January 2009 to January 2010, he served as Senior Vice President and Chief Commercial Officer of Ipsen Group, a publicly traded pharmaceutical company, and from 2007 until December 2008, he served as Vice
President of Marketing at Tercica, Inc. (acquired by Ipsen Group), a biotechnology company. From 2003 to 2007, Mr.&nbsp;Cox was with Scios Inc. (acquired by Johnson and Johnson in 2003), where he also served as Vice President, Marketing. Prior to
2003, Mr.&nbsp;Cox was with Genentech, Inc. for 12 years, where he was a Product Team Leader responsible for the Growth Hormone franchise and led numerous product launches as a Group Product Manager. Mr.&nbsp;Cox currently serves on the boards of
directors of Epirium Bio, Inc. and Gossamer Bio, Inc. Mr.&nbsp;Cox received a B.S. in Biomedical Science from Texas A&amp;M University. We believe Mr.&nbsp;Cox is qualified to serve on our board of directors due to his commercial and operating
experience in the biopharmaceutical industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Ivana Magovcevic-Liebisch, Ph.D. </I>Dr.&nbsp;Magovcevic-Liebisch has served as a director since March
2018 and has served as President and Chief Executive Officer of Vigil Neuroscience since July 2020. Dr.&nbsp;Magovcevic-Liebisch previously served as Executive Vice President, Chief Business Officer for Ipsen from March 2018 to March 2020. From May
2017 through March 2018, Dr.&nbsp;Magovcevic-Liebisch served as Executive Vice President, Chief Strategy and Corporate Development Officer for Axcella Health Inc. From April 2013 through May 2017, Dr.&nbsp;Magovcevic-Liebisch served as Senior Vice
President, Head of Global Business Development for Teva Pharmaceutical Industries Ltd. Prior to joining Teva, Dr.&nbsp;Magovcevic-Liebisch held several senior positions within Dyax Corp. from April 2001 through March 2013, most recently serving as
Executive Vice President and Chief Operating Officer. Dr.&nbsp;Magovcevic-Liebisch currently serves on the board of directors of Applied Genetic Technologies Corporation, a biotechnology company, as well as several other private companies.
Dr.&nbsp;Magovcevic-Liebisch received her J.D. from Suffolk University Law School and her Ph.D. in genetics from Harvard University. We believe that Dr.&nbsp;Magovcevic-Liebisch is qualified to serve on our board of directors due to her extensive
experience in biopharmaceutical business development and operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marcio Souza</I>. Mr.&nbsp;Souza has served as a director since June 2021.
Mr.&nbsp;Souza has served as a director and President and Chief Executive Officer of Praxis Precision Medicines, Inc. since April 2020. From May 2017 to April 2020, Mr.&nbsp;Souza served as Chief Operating Officer, and from July 2016 to May 2017, as
Senior Vice President and Head of Product Strategy of PTC Therapeutics, Inc. Prior to joining PTC, Mr.&nbsp;Souza served in positions of increasing responsibility at NPS Pharmaceuticals, Inc., Shire Human Genetic Therapies Inc. and Sanofi Genzyme
Corporation. Mr.&nbsp;Souza previously served on the board of directors of Clearpoint Neuro, Inc. (previously MRI Interventions, Inc.). Mr.&nbsp;Souza received a degree in pharmacy and biochemistry with a specialization in toxicology and clinical
analysis from the University of S&atilde;o Paulo and an M.B.A. from Funda&ccedil;&atilde;o Dom Cabral. We believe Mr.&nbsp;Souza is qualified to serve on our board of directors because of his business and leadership experience in the life sciences
industry and his scientific background. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jeffrey M. Goldberg.</I><I></I>&nbsp;Mr.&nbsp;Goldberg has served as our President and Chief Executive Officer
and as a member of our board of directors since November 2022.&nbsp;Prior to joining Aeglea, Mr.&nbsp;Goldberg served as president and chief executive officer at Immunitas Therapeutics, Inc. from 2019 to 2021. Prior to Immunitas, Mr.&nbsp;Goldberg
served as the founding chief operating officer at Akcea Therapeutics, Inc. Earlier in his career, Mr.&nbsp;Goldberg was the vice president of business operations at Proteostasis Therapeutics, Inc., a rare disease company, and also held roles of
increasing responsibility at Genzyme Corporation, where he led teams through product development and global launches across multiple therapeutic areas. Mr.&nbsp;Goldberg has an M.B.A. and a M.S. in Chemical Engineering from the Massachusetts
Institute of Technology, and a B.S. in Chemical Engineering from Cornell University. We believe Mr.&nbsp;Goldberg is qualified to serve on our board of directors due to his executive leadership experience in the biopharmaceutical industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Armen Shanafelt, Ph.D.</I><I></I>&nbsp;Dr.&nbsp;Shanafelt has served as a director since December 2013 and served as Chair of our board of directors from
2014 to 2019. From 2009 to 2020, Dr.&nbsp;Shanafelt served as venture partner, then general </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
partner, of Lilly Ventures, a venture capital firm. Prior to joining Lilly Ventures, Dr.&nbsp;Shanafelt was one of several Chief Science Officers at Eli Lilly and Company, a pharmaceutical
research company, specifically responsible for the generation of the early biotherapeutic pipeline which spanned the therapeutic areas of oncology, endocrine and neuroscience. Dr.&nbsp;Shanafelt&nbsp;also serves on the board of directors of Surface
Oncology, Inc. Dr.&nbsp;Shanafelt&nbsp;previously served on the boards of directors of Aileron Therapeutics, Inc., Protagonist Therapeutics, Inc.,&nbsp;Sutro&nbsp;Biopharma, Inc., and&nbsp;Symic&nbsp;Bio. Dr.&nbsp;Shanafelt&nbsp;received his B.S. in
Chemistry and Physics from Pacific Lutheran University and his Ph.D. in Chemistry from the University of California, Berkeley. Dr.&nbsp;Shanafelt&nbsp;completed his postdoctoral work at DNAX Research Institute. Dr.&nbsp;Shanafelt&nbsp;is a Kauffman
Fellow (Class 14). We believe that Dr.&nbsp;Shanafelt&nbsp;is qualified to serve on our board of directors due to his experience in the pharmaceutical and biotechnology businesses, including his expertise with respect to the generation of early
biotherapeutic pipelines and his investment and board experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>V. Bryan Lawlis, Ph.D</I>. Dr.&nbsp;Lawlis has served as a director since July 2018.
Dr.&nbsp;Lawlis served as the President and Chief Executive Officer of Itero Holdings, LLC from 2011 to 2017 and of the predecessor company, Itero Biopharmaceuticals, Inc. from 2007 to 2011, a pharmaceutical company focused on protein therapeutics.
Previously, Dr.&nbsp;Lawlis served in various senior management positions at Aradigm Corporation, Covance Biotechnology Services, Inc. and Genentech, Inc. Dr.&nbsp;Lawlis is also an advisor for Phoenix Venture Partners, a venture capital firm that
invests in material science and manufacturing technology. Dr.&nbsp;Lawlis currently serves on the boards of directors at BioMarin Pharmaceutical Inc. and Geron, Inc., as well as on the boards of directors of several private companies.
Dr.&nbsp;Lawlis previously served on the boards of directors of Sutro Biopharma, Inc. and Kalobios, Inc. Dr.&nbsp;Lawlis received a B.A. in Microbiology from the University of Texas at Austin and a Ph.D. in Biochemistry from Washington State
University. We believe that Dr.&nbsp;Lawlis is qualified to serve on our board of directors due to his longtime involvement in the biotechnology industry and extensive service as a director or officer of other life sciences companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships
among our directors and executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Diversity Matrix </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the standing committees of our board of directors has diverse representation. In addition, on our board of directors there are three directors who hold
doctorates in scientific fields, one director who holds a law degree and three directors who hold a master of business administration. The table below provides certain highlights of the composition of our board of directors as of the date of this
Proxy Statement. Each of the categories listed in the table below has the meaning set forth in Nasdaq Rule 5605(f). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="12" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Board Diversity Matrix</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total Number of Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">8</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Female</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Male</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Binary</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Did&nbsp;Not&nbsp;Disclose<BR>Gender</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Part I: Gender Identity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Part II: Demographics Background</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">African American or Black</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alaskan Native or Native American</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Asian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hispanic or Latino</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Native Hawaiian or Pacific Islander</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">White</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Two or More Races or Ethnicities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LGBTQ+</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Did Not Disclose Demographic Background</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information for the fiscal year ended December&nbsp;31, 2022 regarding all compensation awarded to, earned by or paid to each
person who served as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director for some portion of 2022. Mr.&nbsp;Goldberg, our President and Chief Executive Officer, received compensation solely as an employee of Aeglea in 2022. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned</B><br><B>or Paid&nbsp;in<BR>Cash ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Awards&nbsp;($)&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alison Lawton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Armen Shanafelt, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hunter C. Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ivana Magovcevic-Liebisch, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marcio Souza</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russell J. Cox</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">V. Bryan Lawlis, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sandesh Mahatme <SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sarah Brownstein <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported in this column represent the aggregate grant date fair value of the awards granted to our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors during the year ended December&nbsp;31, 2022, as computed in accordance with Accounting Standards Codification Topic 718 (&#147;<B><I>ASC 718</I></B>&#148;). The assumptions used in
calculating the grant date fair value of the awards reported in the Option Awards column are set forth in Note&nbsp;10 to our consolidated financial statements included in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for
the year ended December&nbsp;31, 2022. Note that the amounts reported in this column reflect the aggregate accounting cost for these awards, and do not necessarily correspond to the actual economic value that may be received by the <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors from the awards. For information regarding the number of stock options and restricted common stock held by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director as of
December&nbsp;31, 2022, see the table below. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Mahatme resigned from our board of directors in July 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Brownstein resigned from our board of directors in February 2022. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors held the following number of outstanding stock options. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alison Lawton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Armen Shanafelt, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">195,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hunter C. Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ivana Magovcevic-Liebisch, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marcio Souza</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russell J. Cox</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">V. Bryan Lawlis, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors received the following compensation pursuant to a program adopted by our board of directors:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Compensation.</I>&nbsp;The program provides an annual cash retainer of $40,000 to each of our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors and an additional $35,000 to the chair of the board. The chair of our audit committee, compensation committee and nominating and corporate governance committee receives annual retainers of $20,000, $15,000 and $10,000, respectively. Each <FONT
STYLE="white-space:nowrap">non-chairperson</FONT> member of our audit committee, compensation committee and nominating and corporate governance committee receives an annual cash retainer of $10,000, $7,500 and $5,000, respectively. We do not pay
fees to directors for attendance at meetings of our board of directors and its committees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Compensation.</I> Each new, <FONT STYLE="white-space:nowrap">non-employee</FONT> director who
joins our board of directors will receive an initial option grant for the purchase of 65,000 shares of our common stock upon election to our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the date of each annual meeting of stockholders, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who continues to serve on our board of
directors immediately following such meeting will receive an option grant for the purchase of 43,000 shares of our common stock, or such other amount as determined by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equity awards for new directors will vest in equal monthly installments for three years after the grant date if the director has served continuously as a
member of our board of directors through the applicable vesting date. Annual equity grants for directors will vest in equal monthly installments for one year after the grant date if the director has served continuously as a member of our board of
directors through the applicable vesting date. In addition, equity awards for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will vest in full in the event that we are subject to a change in control or upon certain other events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors receive no other form of remuneration, perquisites or benefits, but are reimbursed for their
reasonable travel expenses incurred in attending board and committee meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUR BOARD OF DIRECTORS RECOMMENDS A VOTE</B><B><I>
&#147;</I></B><B>FOR</B><B><I>&#148;</I></B><B> ELECTION OF EACH OF THE TWO NOMINATED DIRECTORS </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx449732_5"></A>PROPOSAL NO. 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit committee has selected PricewaterhouseCoopers LLP as Aeglea&#146;s independent registered public accounting firm to perform the audit of
Aeglea&#146;s financial statements for the fiscal year ending December&nbsp;31, 2023 and recommends that stockholders vote for ratification of such selection. Although ratification by stockholders is not required by law, Aeglea has determined that
it is good practice to request ratification of this selection by the stockholders. In the event that PricewaterhouseCoopers LLP is not ratified by our stockholders, the audit committee will review its future selection of PricewaterhouseCoopers LLP
as Aeglea&#146;s independent registered public accounting firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PricewaterhouseCoopers LLP audited Aeglea&#146;s financial statements for Aeglea&#146;s
fiscal year ended December&nbsp;31, 2022. Representatives of PricewaterhouseCoopers LLP are expected to be present at the Annual Meeting, in which case they will be given an opportunity to make a statement at the Annual Meeting if they desire to do
so, and will be available to respond to appropriate questions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Independent Registered Public Accounting Firm Fees and Services </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We regularly review the services and fees from our independent registered public accounting firm. These services and fees are also reviewed with our audit
committee annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information regarding fees billed by PricewaterhouseCoopers LLP during the years ended December&nbsp;31,
2022 and 2021:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">512,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">460,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-related fees <SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax fees <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other fees <SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">548,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">493,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>&#147;Audit fees&#148;</I> include fees billed for professional services primarily related to the audits of
our 2022 and 2021 annual financial statements, the review of our quarterly financial statements, and related services that are normally provided in connection with registration statements. Included in our 2022 audit fees are fees of $53,000 for
financing attempts in the first quarter of 2022, $52,000 related to comfort letter fees incurred to maintain availability of our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> offering program, and
$40,000 related to our completed registered direct offering in May 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There were no &#147;<I>Audit-related fees&#148;</I> incurred in 2022 or 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>&#147;Tax fees&#148;</I> include fees for tax compliance and advice. Tax advice fees encompass a variety of
permissible tax services, including technical tax advice related to federal and state income tax matters; assistance with international tax planning; and assistance with the computation of eligible amounts of federal and state research tax credits
and the federal orphan drug credit. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>&#147;All Other fees&#148;</I> includes database subscription fees paid to PricewaterhouseCoopers LLP.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit committee has considered whether the provision of <FONT STYLE="white-space:nowrap">non-audit</FONT> services is compatible
with maintaining the independence of PricewaterhouseCoopers LLP and has concluded that the provision of such services is compatible with maintaining such independence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policy on Audit Committee <FONT STYLE="white-space:nowrap">Pre-Approval</FONT> of Audit and Permissible <FONT
STYLE="white-space:nowrap">Non-Audit</FONT> Services of Independent Registered Public Accounting Firm </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit committee&#146;s policy is to <FONT
STYLE="white-space:nowrap">pre-approve</FONT> all audit and permissible <FONT STYLE="white-space:nowrap">non-audit</FONT> services provided by the independent registered public accounting firm. These services may include audit services,
audit-related services, tax services and other services. <FONT STYLE="white-space:nowrap">Pre-approval</FONT> is detailed as to the particular service or category of services and is generally subject to a specific budget. The independent registered
public accounting firm and management are required to report periodically to the audit committee regarding the extent of services provided by the independent registered public accounting firm in accordance with this
<FONT STYLE="white-space:nowrap">pre-approval,</FONT> and the fees for the services performed to date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the services relating to the fees described
in the table above were approved by our audit committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUR BOARD OF DIRECTORS RECOMMENDS A VOTE</B><B><I>
&#147;</I></B><B>FOR</B><B><I>&#148;</I></B><B> THE RATIFICATION OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER&nbsp;31, 2023 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx449732_6"></A>PROPOSAL NO. 3 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-BINDING</FONT> ADVISORY VOTE ON NAMED EXECUTIVE OFFICER COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the rules of the SEC, we are providing stockholders with an opportunity to make a <FONT STYLE="white-space:nowrap">non-binding,</FONT>
advisory vote on the compensation of our named executive officers. This <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote is commonly referred to as a &#147;say on pay&#148; vote. The
<FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on the compensation of our named executive officers, as disclosed in this Proxy Statement, will be determined by if the number of votes cast &#147;FOR&#148; the proposal exceeds the
number of votes &#147;AGAINST&#148; the proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders are urged to read the &#147;Executive Compensation&#148; section of the Proxy Statement,
which discusses how our executive compensation policies and procedures implement our compensation philosophy and contains tabular information and narrative discussion about the compensation of our named executive officers. Our compensation committee
and board of directors believe that these policies and procedures are effective in implementing our compensation philosophy and in achieving our goals. Accordingly, we ask our stockholders to vote &#147;FOR&#148; the following resolution at the
Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, that our stockholders approve, on a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory basis,
the compensation of the named executive officers, as disclosed in the proxy statement pursuant to Item 402&nbsp;of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> including the compensation tables and narrative discussion and the other
related disclosures.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an advisory vote, this proposal is not binding. However, our board of directors and compensation committee, which is
responsible for designing and administering our executive compensation program, value the opinions expressed by stockholders in their vote on this proposal and will consider the outcome of the vote when making future compensation decisions for our
named executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUR BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;FOR&#148; APPROVAL OF PROPOSAL NO. 3, APPROVING THE
COMPENSATION PAID BY US TO OUR NAMED EXECUTIVE OFFICERS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx449732_7"></A>PROPOSAL NO. 4 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPROVAL AND ADOPTION OF THE REVERSE STOCK SPLIT AMENDMENT</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;13, 2023, Aeglea received notification from The Nasdaq Stock Market LLC that Aeglea was not in compliance with the requirement to maintain a
minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of Aeglea&#146;s common stock was below $1.00 per share for 30 consecutive business days. In accordance with Nasdaq Listing
Rule 5810(c)(3)(A), Aeglea has a period of 180 calendar days from the date of notification, or until July&nbsp;12, 2023 (&#147;<B><I>Compliance Date</I></B>&#148;), to regain compliance with the minimum bid price requirement to maintain a minimum
bid price of $1.00 per share for continued listing on The Nasdaq Global Market (the &#147;<B><I>Minimum Bid Price Requirement</I></B>&#148;). In the event Aeglea does not regain compliance by the Compliance Date, Aeglea may be eligible for an
additional 180 calendar day compliance period to demonstrate compliance with the bid price requirement. To qualify for the additional <FONT STYLE="white-space:nowrap">180-day</FONT> period, Aeglea will be required to meet the continued listing
requirements for market value of publicly held shares and all other initial listing standards (with the exception of the bid price requirement) and transfer its listing to the Nasdaq Capital Market. In addition, Aeglea will need to provide written
notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board
of directors has unanimously approved and declared advisable the proposed amendment to our Restated Certificate of Incorporation to effect the Reverse Stock Split, and recommends that our stockholders adopt and approve the proposed amendment. The
description of the proposed amendment contained in this Proposal No.&nbsp;4 is a summary and is subject to the full text of the proposed certificate of amendment to our Restated Certificate of Incorporation (the &#147;<B><I>Certificate of
Amendment</I></B>&#148;), which is attached to this Proxy Statement as <U>Annex A</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If stockholders approve this proposal, our board of directors will
cause the Certificate of Amendment to be filed with the Delaware Secretary of State and effect the Reverse Stock Split only if our board of directors determines that the Reverse Stock Split would be in the best interests of Aeglea and its
stockholders to regain compliance with the Nasdaq continued listing rules by the deadline set forth by Nasdaq (as further described below). Our board of directors may determine in its discretion not to effect the Reverse Stock Split and not to file
the Certificate of Amendment. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Reverse Stock Split Amendment, if filed, will effect a reverse stock split of the issued and outstanding shares of
Aeglea&#146;s common stock, and a corresponding and proportionate reduction in the number of authorized shares of common stock at a ratio ranging from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-10</FONT></FONT> shares up
to a ratio of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-25</FONT></FONT> shares, which ratio will be selected by our board of directors and set forth in a public announcement. As of the Record Date, 500,000,000 shares
of our common stock were authorized and 65,395,159 shares of our common stock were issued and outstanding. Based on such number of shares of our common stock authorized, issued and outstanding, immediately following the effectiveness of the Reverse
Stock Split (and without giving any effect to the payment of cash in lieu of fractional shares), we will have, depending on the reverse stock split ratio selected by our board of directors, authorized, issued and outstanding shares of stock as
illustrated in the table under the caption &#147;&#151;Effects of the Reverse Stock Split&#151;Effect on Shares of Common Stock.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Reverse
Stock Split will not change the number of authorized shares of preferred stock or the relative voting power of holders of our outstanding common stock and preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All holders of Aeglea&#146;s common stock will be affected proportionately by the Reverse Stock Split. No fractional shares of common stock will be issued as
a result of the Reverse Stock Split. Instead, the transfer agent will aggregate all fractional shares and sell them as soon as practicable after the Effective Time at the then-prevailing prices on the open market, on behalf of those stockholders who
would otherwise be entitled to receive a fractional share as a result of the Reverse Stock Split. See &#147;Fractional Shares&#148; for more information regarding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cash payments in lieu of fractional shares. Each common stockholder will hold the same percentage of the outstanding common stock immediately following the Reverse Stock Split as that stockholder
did immediately prior to the Reverse Stock Split, except to the extent that the Reverse Stock Split results in stockholders receiving cash in lieu of fractional shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reasons for the Reverse Stock Split</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meet Nasdaq
Continued Listing Requirements</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is currently listed on the Nasdaq Global Market under the symbol &#147;AGLE.&#148; As described in
Aeglea&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on January&nbsp;18, 2023, Aeglea received written notice from the Listing Qualifications Department of Nasdaq on January&nbsp;13, 2023 notifying
Aeglea that, based on the closing bid price of Aeglea&#146;s common stock for the last 30 consecutive business days, Aeglea no longer complied with the Minimum Bid Price Requirement. Nasdaq Listing Rule 5450(a)(1) requires listed securities to
maintain the Minimum Bid Price Requirement, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive trading days. In accordance with
Nasdaq Listing Rule 5810(c)(3)(A), we were given 180 calendar days, or until the Compliance Date of July&nbsp;12, 2023, to regain compliance with the Minimum Bid Price Requirement. As of the date of this Proxy Statement, we were not in compliance
with the Minimum Bid Price Requirement. In the event Aeglea does not regain compliance by the Compliance Date, Aeglea may be eligible for an additional 180 calendar day compliance period to demonstrate compliance with the Minimum Bid Price
Requirement. To qualify for the additional <FONT STYLE="white-space:nowrap">180-day</FONT> period, Aeglea will be required to meet the continued listing requirements for market value of publicly held shares and all other initial listing standards
(with the exception of the Minimum Bid Price Requirement) and transfer its listing to the Nasdaq Capital Market. In addition, Aeglea will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance
period by effecting a reverse stock split, if necessary. If Aeglea does not qualify for the second compliance period or fails to regain compliance during the second <FONT STYLE="white-space:nowrap">180-day</FONT> period, then Nasdaq will notify
Aeglea that our common stock is subject to delisting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has considered the potential harm to us and our stockholders should Nasdaq
delist our common stock from the Nasdaq Capital Market following a transfer from the Nasdaq Global Market. Delisting may adversely affect our ability to raise additional financing through the public or private sale of equity securities, may
significantly affect the ability of investors to trade our securities and may negatively affect the value and liquidity of our common stock. Delisting also could have other negative results, including the potential loss of employee confidence, the
loss of institutional investors or interest in business development opportunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors believes that the proposed Reverse Stock Split
is a potentially effective means for us to maintain compliance with the Minimum Bid Price Requirement and to avoid, or at least mitigate, the likely adverse consequences of our common stock being delisted from the Nasdaq Global Market by producing
the immediate effect of increasing the bid price of our common stock. Although we believe that implementing the Reverse Stock Split is likely to lead to compliance with Rule 5550(a)(2), there can be no assurance that the closing share price after
implementation of the Reverse Stock Split will succeed in restoring such compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the foregoing, our board of directors also believes
that an increased bid price could encourage investor interest and improve the marketability of our common stock to a broader range of investors, and thus enhance our liquidity. Because of the trading volatility often associated with <FONT
STYLE="white-space:nowrap">low-priced</FONT> stocks, many brokerage firms and institutional investors have internal policies and practices that either prohibit them from investing in <FONT STYLE="white-space:nowrap">low-priced</FONT> stocks or tend
to discourage individual brokers from recommending <FONT STYLE="white-space:nowrap">low-priced</FONT> stocks to their customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the above reasons,
we believe that providing our board of directors with the ability to effect the Reverse Stock Split, in the event that it determines, in its sole discretion, that implementing the Reverse Stock Split will
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
help us regain and maintain compliance with the Nasdaq listing requirements and, as a result, could also improve the marketability and liquidity of our common stock, is in the best interests of
Aeglea and our stockholders. However, although we expect that the Reverse Stock Split will result in an increase in the bid price of our common stock, the Reverse Stock Split may not result in a permanent increase in the bid price of our common
stock, which would be dependent on many factors, including general economic, market and industry conditions as well as factors specific to Aeglea, including our financial results and outlook, and other factors detailed from time to time in the
reports we file with the SEC. Regardless of whether or not our board of directors believes that implementing the Reverse Stock Split could help us regain and maintain compliance with the Nasdaq listing requirements, our board of directors reserves
the right not to implement the Reverse Stock Split if it determines, in its sole discretion, that it otherwise would not be in our and our stockholders&#146; best interests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Criteria to be Used for Decision to Apply the Reverse Stock Split</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our stockholders approve the Reverse Stock Split Amendment, our board of directors will be authorized to proceed with the Reverse Stock Split. The exact
ratio of the Reverse Stock Split, within the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-10</FONT></FONT> to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-25</FONT></FONT> range, would be
determined by our board of directors and publicly announced by us prior to the effective time of the Reverse Stock Split. In determining whether to proceed with the Reverse Stock Split and setting the appropriate ratio for the Reverse Stock Split,
our board of directors will consider, among other things, factors such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Aeglea&#146;s compliance with Nasdaq&#146;s continued listing rules; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of our common stock that would be outstanding following the Reverse Stock Split;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the then-prevailing and expected trading prices and trading volume of our common stock and the anticipated impact
of the Reverse Stock Split on the trading market for our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business developments affecting us; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevailing general market and economic conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Risks Associated with the Reverse Stock Split</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>We cannot assure you that the proposed Reverse Stock Split will increase our stock price.</I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that the Reverse Stock Split will increase the per share trading price of our common stock. However, the effect of the Reverse Stock Split on the per
share trading price of our common stock cannot be predicted with any certainty, and the history of reverse stock splits for other companies is varied, particularly since some investors may view a reverse stock split negatively. It is possible that
the per share trading price of our common stock after the Reverse Stock Split will not increase in the same proportion as the reduction in the number of our outstanding shares of common stock following the Reverse Stock Split, and the Reverse Stock
Split may not result in a per share trading price that would attract investors who do not trade in lower priced stocks. In addition, although we believe the Reverse Stock Split may enhance the marketability of our common stock to certain potential
investors, we cannot assure you that, if implemented, our common stock will be more attractive to investors. Even if we implement the Reverse Stock Split, the per share trading price of our common stock may decrease due to factors unrelated to the
Reverse Stock Split, including our future performance. If the Reverse Stock Split is consummated and the per share trading price of the common stock declines, the percentage decline as an absolute number and as a percentage of our overall market
capitalization may be greater than would occur in the absence of the Reverse Stock Split. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The proposed Reverse Stock Split may decrease the liquidity
of our common stock and result in higher transaction costs.</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The liquidity of our common stock may be negatively impacted by the Reverse Stock Split,
given the reduced number of shares that would be outstanding after the Reverse Stock Split, particularly if the per share trading price does not increase as a result of the Reverse Stock Split. In addition, if the Reverse Stock Split is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
implemented, it will increase the number of our stockholders who own &#147;odd lots&#148; of fewer than 100 shares of common stock. Brokerage commission and other costs of transactions in odd
lots are generally higher than the costs of transactions of more than 100 shares of common stock. Accordingly, the Reverse Stock Split may not achieve the desired results of increasing marketability of our common stock as described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effective Time</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effective time of the Reverse Stock
Split (the &#147;<B><I>Effective Time</I></B>&#148;), if approved by stockholders and implemented by Aeglea, will be the date and time set forth in the Certificate of Amendment that will be filed with the Delaware Secretary of State. The exact
timing of the filing of the Certificate of Amendment (if in fact it is filed) will be determined by our board of directors based on its evaluation as to when such action will be the most advantageous to Aeglea and our stockholders taking into
consideration the factors noted above, among other matters that may be relevant at the time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, at any time prior to the filing of the Certificate of
Amendment with the Delaware Secretary of State, notwithstanding stockholder approval, and without further action by the stockholders, our board of directors, in its sole discretion, determines that it is in Aeglea&#146;s best interests and the best
interests of our stockholders to delay the filing of the Certificate of Amendment or abandon the Reverse Stock Split, the Reverse Stock Split may be delayed or abandoned. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fractional Shares</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders will not receive
fractional shares of common stock in connection with the Reverse Stock Split. Instead, the transfer agent will aggregate all fractional shares and sell them as soon as practicable after the Effective Time at the then-prevailing prices on the open
market, on behalf of those stockholders who would otherwise be entitled to receive a fractional share as a result of the Reverse Stock Split. We expect that the transfer agent will conduct the sale in an orderly fashion at a reasonable pace and that
it may take several days to sell all of the aggregated fractional shares of our common stock. After the transfer agent&#146;s completion of such sale, stockholders who would have been entitled to a fractional share will instead receive a cash
payment from the transfer agent in an amount equal to their respective pro rata share of the total proceeds of that sale, net of any brokerage costs incurred by the transfer agent to sell such stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders will not be entitled to receive interest for the period of time between the Effective Time and the date payment is made for their fractional
share interest. You should also be aware that, under the escheat laws of certain jurisdictions, sums due for fractional interests that are not timely claimed after the funds are made available may be required to be paid to the designated agent for
each such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds may have to obtain the funds directly from the state to which they were paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you believe that you may not hold sufficient shares of common stock at the Effective Time to receive at least one share in the Reverse Stock Split and you
want to continue to hold Aeglea&#146;s common stock after the Reverse Stock Split, you may do so by either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchasing a sufficient number of shares of Aeglea&#146;s common stock; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if you have shares of common stock in more than one account, consolidating your accounts, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in each case, so that you hold a number of shares of our common stock in your account prior to the Reverse Stock Split that would entitle you to receive at
least one share of common stock in the Reverse Stock Split. Shares of our common stock held in registered form and shares of our common stock held in &#147;street name&#148; (that is, through a broker, bank or other holder of record) for the same
stockholder will be considered held in separate accounts and will not be aggregated when effecting the Reverse Stock Split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effects of the Reverse Stock Split</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Reverse Stock Split is implemented by our
board of directors, after the Effective Time, each stockholder will own a reduced number of shares of common stock. The principal effect of the Reverse Stock Split will be to proportionately decrease the number of authorized, issued and outstanding
shares of our common stock based on the reverse stock split ratio selected by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voting rights and other rights of the holders of
our common stock will not be affected by the Reverse Stock Split, other than as a result of the treatment of fractional shares as described above. For example, a holder of 2% of the voting power of the outstanding shares of our common stock
immediately prior to the effectiveness of the Reverse Stock Split will generally continue to hold 2% (assuming there is no impact as a result of the payment of cash in lieu of issuing fractional shares) of the voting power of the outstanding shares
of our common stock after the Reverse Stock Split. The number of stockholders of record will not be affected by the Reverse Stock Split (except to the extent any are cashed out as a result of holding fractional shares). If approved and implemented,
the Reverse Stock Split may result in some stockholders owning &#147;odd lots&#148; of less than 100 shares of our common stock. Odd lot shares may be more difficult to sell, and brokerage commissions and other costs of transactions in odd lots are
generally somewhat higher than the costs of transactions in &#147;round lots&#148; of even multiples of 100 shares. Our board of directors believes, however, that these potential effects are outweighed by the benefits of the Reverse Stock Split.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Effects on Shares of Common Stock</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
table contains approximate information, based on share information as of March&nbsp;31, 2023 relating to our outstanding common stock based on the proposed reverse stock split ratios assuming that the proposal is approved and the Reverse Stock Split
is implemented. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Common&nbsp;Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Common&nbsp;Stock<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Common&nbsp;Stock<BR>Authorized but<BR>Not&nbsp;Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pre-Reverse</FONT> Stock Split</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,395,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">434,604,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Reverse Stock Split 1:10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,539,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,460,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Reverse Stock Split 1:15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,359,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,973,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Reverse Stock Split 1:20</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,269,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,730,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Reverse Stock Split 1:25</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,615,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,384,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the effective date of the Reverse Stock Split that our board of directors elects to implement, our common stock would
have a new committee on uniform securities identification procedures, or CUSIP number, a number used to identify our common stock. Our common stock is currently registered under Section&nbsp;12(b) of the Exchange Act and we are subject to the
periodic reporting and other requirements of the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Effect on Preferred Stock</I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our Restated Certificate of Incorporation, our capital stock consists of 10,000,000 shares of Preferred Stock, par value $0.0001 per share. The
proposed amendment to our Restated Certificate of Incorporation to effect the Reverse Stock Split would not impact the total authorized number of shares of preferred stock or the par value of the preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Effect on Par Value</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proposed amendments to our
Restated Certificate of Incorporation will not affect the par value of our common stock, which will remain at $0.0001. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Reduction In Stated Capital</I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the Reverse Stock Split, upon the Effective Time, the stated capital on our balance sheet attributable to our common stock, which consists of
the par value per share of our common stock multiplied by the aggregate number of shares of our common stock issued and outstanding, will be reduced in proportion to the size of the Reverse Stock Split, subject to a minor adjustment in respect of
the treatment of fractional shares, and the additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital account will be credited with the amount by which the stated capital is reduced. Our stockholders&#146; equity, in the aggregate, will
remain unchanged. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Effect on Aeglea&#146;s Equity Plans</I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our 2015 Equity Incentive Plan, 2016 Equity Incentive Plan and 2018 Equity Inducement Plan (together, the &#147;<B><I>Stock Plans</I></B>&#148;), our
board of directors has discretion to determine the appropriate adjustment to the awards granted under our Stock Plans in the event of a reverse stock split. Accordingly, if the Reverse Stock Split is effected, the number of shares available for
issuance under the Stock Plans, as well as the number of shares subject to any outstanding award under the Stock Plans, and the exercise price, grant price or purchase price relating to any such award under the Stock Plans, are expected to be
proportionately adjusted by our board of directors to reflect the Reverse Stock Split. Our board of directors will also determine the treatment of fractional shares subject to stock options and other outstanding awards under the Stock Plans. In
addition, pursuant to the authority provided under the Stock Plans, our board of directors is expected to authorize Aeglea to effect any other changes necessary, desirable or appropriate to give effect to the Reverse Stock Split, including any
applicable technical, conforming changes to our Stock Plans. Our board of directors will also determine the appropriate adjustments to our 2016 Employee Stock Purchase Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>No Going Private Transaction</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the decrease
in the number of outstanding shares following the proposed Reverse Stock Split, our board of directors does not intend for this transaction to be the first step in a &#147;going private transaction&#148; within the meaning of Rule <FONT
STYLE="white-space:nowrap">13e-3</FONT> of the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shares Held in Book-Entry and Through a Broker, Bank or Other Holder of Record</I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold registered shares of our common stock in book-entry form, you do not need to take any action to receive your post-Reverse Stock Split shares of our
common stock in registered book-entry form or your cash payment in lieu of fractional shares, if applicable. If you are entitled to post-Reverse Stock Split shares of our common stock, a transaction statement will automatically be sent to your
address of record as soon as practicable after the Effective Time indicating the number of shares of our common stock you hold. In addition, if you are entitled to a payment of cash in lieu of fractional shares, a check will be mailed to you at your
registered address as soon as practicable after the Effective Time. By signing and cashing this check, you will warrant that you owned the shares of Aeglea&#146;s common stock for which you received a cash payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Effective Time, we intend to treat stockholders holding shares of our common stock in &#147;street name&#148; (that is, through a broker, bank or other
holder of record) in the same manner as registered stockholders whose shares of our common stock are registered in their names. Brokers, banks or other holders of record will be instructed to effect the Reverse Stock Split for their beneficial
holders holding shares of our common stock in &#147;street name&#148;; however, these brokers, banks or other holders of record may apply their own specific procedures for processing the Reverse Stock Split. If you hold your shares of our common
stock with a broker, bank or other holder of record, and you have any questions in this regard, we encourage you to contact your holder of record. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No
Appraisal Rights</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Delaware General Corporation Law, our stockholders are not entitled to dissenter&#146;s rights or appraisal rights with
respect to the Reverse Stock Split described in this proposal and we will not independently provide our stockholders with any such rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest of Certain Persons in Matters to be Acted Upon</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No officer or director has any substantial interest, direct or indirect, by security holdings or otherwise, in the Reverse Stock Split that is not shared by
all of our other stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Material U.S. Federal Income Tax Consequences of the Reverse Stock Split&nbsp;to U.S. Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion is a general summary of certain material U.S. federal income tax consequences of the Reverse Stock Split that generally are expected
to be applicable to U.S. Holders (as defined below) of our common stock that hold such stock as a capital asset for U.S. federal income tax purposes (generally, property held for investment), but does not purport to be a complete discussion of all
of the potential tax considerations relating thereto. This summary is based upon the provisions of the Internal Revenue Code of 1986, as amended (the &#147;<B><I>Code</I></B>&#148;), applicable Treasury regulations promulgated thereunder, judicial
authorities and administrative rulings and practices in effect as of the date of this Proxy Statement, all of which may change, possibly with retroactive effect, resulting in U.S. federal income tax consequences that may differ from those discussed
below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion does not address all aspects of U.S. federal income taxation that may be relevant to U.S. Holders in light of their particular
circumstances or to holders that may be subject to special tax rules, including: (i)&nbsp;holders subject to the alternative minimum tax; (ii)&nbsp;banks, insurance companies, or other financial institutions;
<FONT STYLE="white-space:nowrap">(iii)&nbsp;tax-exempt</FONT> organizations; (iv)&nbsp;dealers in securities or commodities; (v)&nbsp;mutual funds, regulated investment companies or real estate investment trusts; (vi)&nbsp;partnerships, limited
liability companies that are not treated as corporations for U.S. federal income tax purposes, S corporations, or other flow-through entities for U.S. federal income tax purposes and their partners or owners; (vii)&nbsp;traders in securities that
elect to use a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting for their securities holdings; (viii)&nbsp;U.S. Holders (as defined below) whose &#147;functional currency&#148; is
not the U.S. dollar; (ix)&nbsp;persons holding our common stock as a position in a hedging transaction, &#147;straddle,&#148; &#147;conversion transaction&#148; or other integrated risk reduction transaction; (x)&nbsp;persons who acquire shares of
our common stock in connection with the exercise of employee stock options, employment or other performance of services; (xi)&nbsp;personal holding companies, foreign entities, nonresident alien individuals or U.S. expatriates; (xii)&nbsp;holders
whose common stock constitutes qualified small business stock within the meaning of Section&nbsp;1202 of the Code; (xiii)&nbsp;holders who hold their common stock through individual retirement or other
<FONT STYLE="white-space:nowrap">tax-deferred</FONT> accounts; or (xiv)&nbsp;holders who acquired their common stock in a transaction subject to the gain rollover provisions of Section&nbsp;1045 of the Code. If a partnership (including any entity or
arrangement treated as a partnership for U.S. federal income tax purposes) holds shares of our common stock, the tax treatment of a holder that is a partner in the partnership generally will depend upon the status of the partner and the activities
of the partnership. The following summary also does not address the tax consequences of transactions effectuated prior or subsequent to, or concurrently with, the Reverse Stock Split (whether or not any such transactions are consummated in
connection with the Reverse Stock Split), the tax consequences to holders of options, warrants or similar rights to acquire common stock, or any U.S. state or local or any foreign tax consequences, any estate, gift or other <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> federal income tax consequences, or the Medicare tax on net investment income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not sought, and will
not seek, an opinion of counsel or a ruling from the Internal Revenue Service (&#147;<B><I>IRS</I></B>&#148;) regarding the U.S. federal income tax consequences of the Reverse Stock Split and there can be no assurance that the IRS will not challenge
the statements and conclusions set forth below or a court would not sustain any such challenge. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS SUMMARY OF CERTAIN MATERIAL U.S. FEDERAL INCOME
TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT IS FOR GENERAL INFORMATION ONLY AND IS NOT TAX ADVICE. EACH HOLDER OF COMMON STOCK SHOULD CONSULT SUCH HOLDER&#146;S TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT
TO SUCH HOLDER.</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the discussion below, a &#147;U.S. Holder&#148; is a beneficial owner of shares of our common stock that for U.S.
federal income tax purposes is: (1)&nbsp;an individual citizen or resident of the United States; (2)&nbsp;a corporation (including any entity taxable as a corporation for U.S. federal income tax purposes) created or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
organized in or under the laws of the United States, any state or political subdivision thereof, or the District of Columbia; (3)&nbsp;an estate the income of which is subject to U.S. federal
income taxation regardless of its source; or (4)&nbsp;a trust, if (i)&nbsp;a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority to control all
substantial decisions of the trust, or (ii)&nbsp;the trust has a valid election in effect to be treated as a U.S. person. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tax Consequences of the
Reverse Stock Split </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Reverse Stock Split should constitute a &#147;recapitalization&#148; for U.S. federal income tax purposes, and the remainder
of this discussion assumes the Reverse Stock Split so qualifies. As a result, a U.S. Holder that receives solely a reduced number of shares of common stock generally should not recognize gain or loss upon the Reverse Stock Split. A U.S.
Holder&#146;s aggregate tax basis in the reduced number of shares of our common stock should equal the aggregate tax basis of its <FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split shares of our common stock, and such U.S. Holder&#146;s
holding period in the reduced number of shares of our common stock should include the holding period in the shares of our <FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split common stock surrendered. Treasury regulations promulgated
under the Code provide detailed rules for allocating the tax basis and holding period of the shares of our common stock surrendered to the shares of our common stock received pursuant to the Reverse Stock Split. U.S. Holders of shares of our common
stock acquired on different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No gain or loss will be recognized by Aeglea as a result of the proposed Reverse Stock Split. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash in Lieu of Fractional Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. Holder that
receives cash in lieu of a fractional share of our common stock pursuant to the Reverse Stock Split should be treated as having received the fractional shares pursuant to the Reverse Stock Split and then as having exchanged the fractional shares for
cash in a redemption by Aeglea, and generally should recognize capital gain or loss in an amount equal to the difference, if any, between the amount of cash received and the U.S. Holder&#146;s tax basis in the shares of our common stock surrendered
that is allocated to such fractional share. Such capital gain or loss should be long term capital gain or loss if the U.S. Holder&#146;s holding period for our <FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split common stock exceeded one
year at the Effective Time. Long-term capital gains of individuals are generally subject to tax at reduced rates. There are limitations on the deductibility of capital losses under the Code. A U.S. Holder&#146;s aggregate tax basis in the reduced
number of shares of common stock, if any, should equal the U.S. Holder&#146;s aggregate tax basis in its <FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split shares of common stock decreased by the tax basis allocated to the fractional
share for which such U.S. Holder is entitled to receive cash, and the holding period of the reduced number of shares of common stock received, if any, should include the holding period of the <FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock
Split shares of common stock exchanged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE PRECEDING DISCUSSION IS INTENDED ONLY AS A SUMMARY OF CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES
OF THE REVERSE STOCK SPLIT TO U.S. HOLDERS. IT IS NOT A COMPLETE ANALYSIS OR DISCUSSION OF ALL POTENTIAL TAX EFFECTS THAT MAY BE IMPORTANT TO A PARTICULAR HOLDER. ALL HOLDERS OF OUR COMMON STOCK SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE
SPECIFIC TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT TO THEM, INCLUDING RECORD RETENTION AND TAX REPORTING REQUIREMENTS, AND THE APPLICABILITY AND EFFECT OF ANY U.S. FEDERAL, STATE, LOCAL AND <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX
LAWS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required for Approval of this Proposal</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, the affirmative vote of the holders of a majority of the shares outstanding and entitled to vote at the Annual Meeting is required to adopt
and approve the amendment to our Restated Certificate of Incorporation to effect the Reverse Stock Split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUR BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;FOR&#148; APPROVAL OF PROPOSAL NO. 4,
APPROVING THE REVERSE STOCK SPLIT AMENDMENT. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx449732_8"></A>PROPOSAL NO. 5 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPROVAL OF AMENDMENT AND RESTATEMENT OF THE 2016 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our 2016 Equity Incentive Plan was originally
adopted by our board of directors in December 2015 and subsequently approved by our stockholders in December 2015. Our 2016 Equity Incentive Plan became effective in April 2016 as the successor to our 2015 Equity Incentive Plan (the &#147;<B><I>2015
Plan</I></B>&#148;) in connection with our initial public offering. The material terms of our 2016 Equity Incentive Plan were reapproved by our stockholders on June&nbsp;7, 2017. On October&nbsp;8, 2018, our stockholders approved an amendment and
restatement of our 2016 Equity Incentive Plan. For purposes of this Proposal No.&nbsp;5, we refer to the 2016 Equity Incentive Plan, as amended on October&nbsp;8, 2018, which is Aeglea&#146;s current equity incentive plan, as the &#147;<B><I>2016
Plan</I></B>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2016 Plan currently provides that the number of shares reserved for issuance thereunder automatically increases on each
January&nbsp;1 by 4% of the number of issued and outstanding shares of our common stock on December&nbsp;31 of the preceding calendar year, through 2028 (the &#147;<B><I>Evergreen Provision</I></B>&#148;), unless our board of directors determines to
increase the share pool by a smaller number of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has determined that it is in the best interests of Aeglea and its
stockholders to seek stockholder approval of an amendment and restatement our 2016 Plan. The following is a summary of the key changes to the 2016 Plan, as proposed to be amended and restated hereby. This summary, however, does not purport to be a
complete description of all of the provisions of or proposed changes to the 2016 Plan and is qualified in its entirety by reference to the full text of the amended and restated 2016 Plan which is attached as <U>Annex B</U> to this Proxy Statement:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Provide for an increase in the number of shares of common stock reserved for issuance thereunder by 5,000,000
shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Provide for the following changes to the Evergreen Provision: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An increase to the number of shares of common stock subject to the Evergreen Provision, from 4% to 5% of the
number of such shares outstanding on December&nbsp;31 of the preceding year (or such lesser number of shares as the board may determine); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The inclusion of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in the calculation of the number of
shares outstanding as of December 31; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An extension of the term of the Evergreen Provision, such that the share reserve will automatically increase by
the stated amount on January&nbsp;1 of each year from 2024 through 2033. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Revise the annual limit on <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation from
100,000 shares to (a) $750,000 in total value or (b) $1,000,000 in the year of the director&#146;s initial services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, in either case, applicable to fees paid in both cash and equity.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Eliminate <FONT STYLE="white-space:nowrap">per-participant</FONT> annual award limits and other provisions
originally intended to comply with the qualified performance-based compensation exception set forth in Section&nbsp;162(m) of the Code, in light of the repeal of such exception pursuant to the Tax Cuts and Jobs Act of 2017. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Remove the fixed termination date of the 2016 Plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors adopted the amendment and restatement of the 2016 Plan, subject to approval by our stockholders. If the proposed amendment and
restatement of the 2016 Plan is not approved, our current 2016 Plan will remain <FONT STYLE="white-space:nowrap">as-is.</FONT> </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing price of
our common stock as reported on Nasdaq as of April 14, 2023, the latest practicable date prior to the filing of this proxy statement, was $0.15. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reasons for the Amendment and Restatement of the 2016 Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are asking our stockholders to approve the amendment and restatement of the 2016 Plan because, among other things, we believe that the amendment and
restatement of the 2016 Plan is in the best interests of Aeglea and its stockholders because of the continuing need to provide stock options, restricted stock units and other equity-based incentives to attract and retain qualified personnel and to
respond to relevant market changes in equity compensation practices. If our stockholders do not approve the amendment and restatement of the 2016 Plan, we will be limited in our ability to continue to issue awards under the 2016 Plan in numbers
sufficient to attract and motivate the highly skilled employees we need to recruit and retain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equity compensation is a critical element of our
compensation program. Offering a broad-based equity compensation program is vital to attracting and retaining highly skilled people in the highly competitive life sciences industry. We use equity awards to increase incentives on the part of eligible
employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants who provide significant services to us and our affiliates. We believe that providing an equity stake in the future success of our business encourages our
employees to be highly motivated to achieve our long-term business goals and to increase stockholder value. Their innovation and productivity are critical to our success. Accordingly, approving the amendment and restatement of the 2016 Plan is in
the best interest of our stockholders because equity awards help us to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract, motivate and retain talented employees, directors and consultants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">align employee and stockholder interests; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">link employee compensation with Company performance. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We strongly believe that approval by stockholders of the amendment and restatement of the 2016 Plan will enable us to achieve our goals in attracting and
retaining our most valuable asset: our employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Without stock options, restricted stock units or other forms of equity incentives, we would be forced
to consider cash replacement alternatives to provide a market-competitive total compensation package necessary to attract, retain and motivate the employee talent critical to our future successes. These cash replacement alternatives could, among
other things, reduce the cash available for investment in growth and development and cause a loss of motivation by employees to achieve superior performance over a longer period of time. Equity-based awards also directly align a portion of the
compensation of our employees with the economic interests of our stockholders. If this Proposal No.&nbsp;5 is not approved by our stockholders, we believe our ability to attract and retain the talent we need to compete in our industry would be
adversely impacted, and this could affect our long-term success. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of the Amendment and Restatement of the 2016 Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of the principal provisions of the 2016 Plan, as proposed to be amended and restated hereby. This summary, however, does not purport
to be a complete description of all of the provisions of the amended and restated 2016 Plan and is qualified in its entirety by reference to the full text of the amended and restated 2016 Plan which is attached as <U>Annex B</U> to this Proxy
Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share Reserve. </I>As of March&nbsp;31, 2023, the number of shares of our common stock reserved and available for grant and issuance under
the 2016 Plan was 797,690. The 2016 Plan&#146;s Evergreen Provision currently provides that the number of shares reserved for issuance under the 2016 Plan automatically increases on each January&nbsp;1 by 4% of the number of issued and outstanding
shares of our common stock on December&nbsp;31 of the preceding calendar year, through 2028, unless our board of directors determines to increase the share pool by a smaller number of shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As proposed to be amended and restated, the following shares will be available for grant and issuance under the 2016 Plan: the sum of (a) 5,797,690 shares,
inclusive of shares initially reserved under the 2016 Plan in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with Aeglea&#146;s initial public offering, shares added to the 2016 Plan share reserve between the time of Aeglea&#146;s initial public offering and the Annual Meeting as a result of
our 2018 amendment and restatement and the Evergreen Provision, (b)&nbsp;an additional 5,000,000 shares to be added to the reserve on the date of the Annual Meeting, provided stockholder approval of the 2016 Plan amendment and restatement is
obtained, and (c)&nbsp;any shares subject to awards or issued under the 2015 Plan that return to the share reserve due to forfeitures, repurchases, or that are used or withheld to pay the exercise price of an option or to satisfy tax withholding
obligations, less any shares that are issued under the 2016 Plan on or prior to, or subject to outstanding awards as of, the date of the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Evergreen Provision under the amended and restated 2016 Plan provides for an automatic increase in the number of shares reserved for issuance thereunder
on January&nbsp;1 of each year from 2024 through 2033 equal to (a) 5.0% of the aggregate number of issued and outstanding shares of common stock, including common stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants, if any, on December&nbsp;31 of the immediately preceding year, or (b)&nbsp;a lesser amount as approved by the board each year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the
following shares are available for grant and issuance under the 2016 Plan: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares subject to options or stock appreciation rights granted under the 2016 Plan that cease to be subject to
the option or stock appreciation right for any reason other than exercise of the option or stock appreciation right; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares subject to awards granted under the 2016 Plan that are subsequently forfeited or repurchased by us at the
original issue price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares subject to awards granted under the 2016 Plan that otherwise terminate without shares being issued;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares surrendered pursuant to an exchange program as defined in the 2016 Plan; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares subject to awards under the 2016 Plan that are used to pay the exercise price of an option or withheld to
satisfy the tax withholding obligations related to any award. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Awards under the 2016 Plan settled in cash or other property rather than
shares do not reduce the amount of shares available under the 2016 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Award Types.</I> The 2016 Plan provides for the grant of awards in the form
of stock options, restricted stock awards (&#147;<B><I>RSAs</I></B>&#148;), stock bonus awards (&#147;<B><I>Stock Bonus Awards</I></B>&#148;), stock appreciation rights (&#147;<B><I>SARs</I></B>&#148;), restricted stock units
(&#147;<B><I>RSUs</I></B>&#148;) and performance awards (&#147;<B><I>Performance Awards</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Limits. </I>No more than 17,400,000
shares will be issued pursuant to the exercise of incentive stock options (&#147;<B><I>ISOs</I></B>&#148;). Further, the aggregate value of all compensation (cash and equity-based) to be granted or paid in each fiscal year to each <FONT
STYLE="white-space:nowrap">non-employee</FONT> member of our board for service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director will not exceed (x) $750,000 in total value or (y) $1,000,000 in the fiscal year in which an individual
first begins providing services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, calculating the value of any equity awards based on the grant date fair value of such awards for financial reporting purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration. </I>Our 2016 Plan is administered by our compensation committee, all of the members of which are
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors, or by our board of directors acting in place of our compensation committee. The compensation committee has, among others, the authority to construe and interpret our 2016 Plan, grant
awards and make all other determinations necessary or advisable for the administration of the 2016 Plan, and has full power to implement and carry out the 2016 Plan, except that our board of directors will establish the terms of the grant of any
awards to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility.</I> Our 2016 Plan provides for the grant of awards to eligible
employees, directors, consultants, independent contractors and advisors, provided the consultants, independent contractors, directors and advisors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
render bona fide services not in connection with the offer and sale of securities in a capital-raising transaction. ISOs may be granted only to employees. As of March&nbsp;31, 2023, approximately
62 employees, seven <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, and 18 consultants and advisors were eligible to participate in the 2016 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options.</I> A stock option is a right to purchase a share of our common stock, subject to certain conditions, if applicable. The exercise price of
stock options must be at least equal to the fair market value of our common stock on the date of grant. Stock options may vest based on time or achievement of performance conditions, or a combination of both. Stock options may be vested and
exercisable within the times or upon the conditions as set forth in the award agreement and our compensation committee may provide for stock options to become exercisable at one time or from time to time, periodically or otherwise, in such number of
shares or percentage of shares as it determines. The maximum term of options granted under our 2016 Plan is ten years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards.</I> An
RSA is a grant by us of shares of our common stock subject to restrictions, which may vest based on time or achievement of performance conditions. The price, if any, of an RSA will be determined by the compensation committee and may be less than the
fair market value of our common stock on the date of grant. Unless otherwise determined by the compensation committee at the time of award, vesting will cease on the date the participant no longer provides services to us and unvested shares will be
forfeited to or repurchased by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights.</I> SARs provide for a payment, or payments, in cash or shares of our common stock, to
the holder based upon the difference between the fair market value of our common stock on the date of exercise and the stated exercise price multiplied by the number of shares subject to the SAR. SARs may vest based on time or achievement of
performance conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Units.</I> RSUs represent the right to receive shares of our common stock at a specified date in the future,
subject to forfeiture of that right because of termination of employment or failure to achieve certain performance conditions. If an RSU has not been forfeited, then on the date specified in the RSU agreement, we will deliver to the holder of the
RSU whole shares of our common stock (which may be subject to additional restrictions), cash or a combination of our common stock and cash. Unless otherwise determined in the award agreement or by the compensation committee, vesting will cease on
the date the holder no longer provides services to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance Awards.</I> A Performance Award is an award of a cash bonus or a number of shares
of our common stock that may be settled upon achievement of the <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals in cash or by issuance of the underlying shares. Unless otherwise determined in the award agreement or by the
compensation committee, vesting will cease on the date the holder no longer provides services to us. These awards are subject to forfeiture prior to settlement because of termination of employment or failure to achieve the performance goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Bonus Awards.</I> Stock bonuses may be granted as additional compensation for service or performance and, therefore, will not be issued in exchange
for cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance Goals.</I> Our 2016 Plan permits the grant of performance-based stock and cash awards. Our compensation committee may structure
awards so that the stock or cash will be issued or paid following the achievement of certain performance goals during a designated performance period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation committee may establish performance goals under which performance-based awards may be made by selecting from one or more of the following
performance criteria, or any other measures that the compensation committee deems appropriate: (a)&nbsp;profit before tax; (b)&nbsp;sales; (c) expenses; (d)&nbsp;billings; (e) revenue; (f)&nbsp;net revenue; (g)&nbsp;earnings (which may include
earnings before interest and taxes, earnings before taxes, net earnings, stock-based compensation expenses, depreciation and amortization); (h) operating income; (i)&nbsp;operating margin; (j)&nbsp;operating profit; (k)&nbsp;controllable operating
profit, or net operating profit; (l)&nbsp;net profit; (m)&nbsp;gross margin; (n)&nbsp;operating expenses or operating expenses as a percentage of revenue; (o)&nbsp;net income; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(p)&nbsp;earnings per share; (q)&nbsp;total stockholder return; (r)&nbsp;market share; (s)&nbsp;return on assets or net assets; (t)&nbsp;our stock price; (u)&nbsp;growth in stockholder value
relative to a <FONT STYLE="white-space:nowrap">pre-determined</FONT> index; (v)&nbsp;return on equity; (w)&nbsp;return on invested capital; (x)&nbsp;cash flow (including free cash flow or operating cash flows); (y) balance of cash, cash equivalents
and marketable securities; (z)&nbsp;cash conversion cycle; (aa) economic value added; (bb) individual confidential business objectives; (cc)&nbsp;contract awards or backlog; (dd) overhead or other expense reduction; (ee) credit rating; (ff)
completion of an identified special project; (gg) Completion of a joint venture or other corporate transaction; (hh) strategic plan development and implementation; (ii)&nbsp;succession plan development and implementation; (jj) improvement in
workforce diversity; (kk) employee satisfaction; (ll) employee retention; (mm)&nbsp;customer indicators and satisfaction; (nn) new product invention or innovation; (oo) research and development expenses; (pp) attainment of research and development
milestones; (qq) improvements in productivity; (rr) bookings; (ss) working-capital targets and changes in working capital; and (tt) attainment of objective operating goals and employee metrics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation committee may select the abovementioned performance criteria, either individually, alternatively or in any combination, and may be applied on
a company-wide basis or with respect to one or more business units or subsidiaries, either individually, alternatively or in any combination; on a GAAP or <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis; and measured in absolute terms or
relative to a <FONT STYLE="white-space:nowrap">pre-established</FONT> target. Our compensation committee may, in recognition of unusual or <FONT STYLE="white-space:nowrap">non-recurring</FONT> items such as acquisition-related activities or changes
in applicable accounting rules, provide for one or more equitable adjustments (based on objective standards) to the performance factors to preserve the compensation committee&#146;s original intent regarding the performance factors at the time of
the initial award grant. Our compensation committee may also adjust performance factors to account for changes in law and accounting and make such adjustments as our compensation committee deems necessary or appropriate to reflect the impact of
extraordinary or unusual items, events or circumstances to avoid windfalls or hardships. The compensation committee is authorized to make adjustments as it deems appropriate in the method of calculating the attainment of performance factors and may
exercise discretion with respect to performance-based awards, including, without limitation, increasing, reducing or eliminating the amount to be paid to participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Capitalization Adjustments. </I>If the number of outstanding shares of our common stock is changed by a change in our capital structure without
consideration, such as a stock split, proportionate adjustments will be made to the number of shares reserved under our 2016 Plan, the exercise prices of and number of shares subject to outstanding stock options and SAR awards, the number of shares
subject to other outstanding awards, the maximum number of shares that can be granted in a calendar year to an individual or a new employee, the maximum number of shares that may be issued upon the exercise of ISOs and the number of shares that may
be granted as awards to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, subject to any required action by board of directors or our stockholders and in compliance with applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transferability and Treatment on Termination</I>. Awards granted under our 2016 Plan may not be transferred in any manner other than by will or by the laws
of descent and distribution or as determined by our compensation committee. Unless otherwise permitted by our compensation committee, stock options may be exercised during the lifetime of the optionee only by the optionee or the optionee&#146;s
guardian or legal representative. Stock options granted under our 2016 Plan generally may be exercised for a period of three months after the termination of the optionee&#146;s service to us for any reason other than for cause, death or disability,
for a period of 12 months post-termination in the case of termination due to death or disability, or such longer period as our compensation committee may provide. Options generally terminate immediately upon termination of employment for cause.
Unless otherwise determined by our compensation committee and as set forth in a participant&#146;s award agreement, upon a termination of employment or service with us, the vesting of any shares of RSAs, RSUs, Stock Bonus Awards, stock options, SARs
or Performance Awards will cease on the date of termination of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Effect of Change in Control.</I> Our 2016 Plan provides that in the event
of specified types of acquisitions, mergers or consolidations, a sale or other disposition of all or substantially all of our assets, a corporate transaction or a change in the effective control of our company that occurs on the date that a majority
of our board members is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
replaced during any twelve month period by board members whose appointment or election is not endorsed by a majority of the board members prior to the date of the appointment or election,
(a)&nbsp;outstanding awards under our 2016 Plan may be continued if our company is the successor entity, (b)&nbsp;outstanding awards under our 2016 Plan may be assumed by any surviving or acquiring corporation; (c)&nbsp;outstanding awards under our
2016 Plan may be substituted by the surviving or acquiring corporation for similar awards; (d)&nbsp;the exercise or vesting of outstanding awards under our 2016 Plan may fully or partially accelerate, expiration of such awards may accelerate and our
right to repurchase or <FONT STYLE="white-space:nowrap">re-acquire</FONT> shares acquired under an award may lapse and forfeiture rights with respect to such shares may lapse; (e)&nbsp;outstanding awards may be settled for the full value of such
outstanding award (whether or not then vested or exercisable) in cash, cash equivalents, or securities of the successor entity with a fair market value equal to the required amount followed by the cancellation of such awards, provided that payment
may be deferred until the date or dates the award would have become exercisable or vested; or (f)&nbsp;outstanding awards may be terminated for no consideration. Our board of directors shall have full power to assign Aeglea&#146;s right to
repurchase or <FONT STYLE="white-space:nowrap">re-acquire</FONT> or forfeiture rights to such successor or acquiring corporation. Awards need not be treated similarly in a corporate transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors or its compensation committee has the discretion to provide that a stock award under our 2016 Plan will immediately vest as to all or
any portion of the shares subject to the stock award at the time of a corporate transaction or in the event a participant&#146;s service with us or a successor entity is terminated actually or constructively within a designated period following the
occurrence of the transaction. Stock awards held by participants under our 2016 Plan will generally not vest automatically on such an accelerated basis unless specifically provided in the participant&#146;s applicable award agreement. However,
following a corporate transaction, 100% of the shares subject to an award held by an employee shall become vested if the holder is subject to an involuntary termination within 12 months after the corporate transaction, subject to certain release
requirements. In addition, in the event of a corporate transaction, the vesting of all awards granted to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors shall accelerate and such awards shall become exercisable (as applicable) in full
prior to the consummation of the corporate transaction at such times and on such conditions as our compensation committee determines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment and
Termination.</I> Our board of directors may amend, suspend or terminate our 2016 Plan at any time. Our board of directors must obtain the approval of our stockholders if our board of directors amends our 2016 Plan in any manner that requires
stockholder approval. No awards may be granted under the 2016 Plan while the 2016 Plan is suspended or after it is terminated. No ISOs may be granted after the tenth anniversary of the earlier of (i)&nbsp;the date our board of directors adopted the
amendment and restatement of the 2016 Plan or (ii)&nbsp;the date of the Annual Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Federal Income Tax Consequences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a brief summary of the federal income tax consequences applicable to awards granted under the 2016 Plan, as proposed to be amended, based on
federal income tax laws in effect on the date of this Proxy Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This summary is not intended to be exhaustive and does not address all matters
that may be relevant to a particular participant. The summary does not discuss the tax laws of any state, municipality, or foreign jurisdiction, or the gift, estate, excise, payroll, or other tax laws other than federal income tax law. This summary
does not discuss the impact of Section&nbsp;280G of the Code governing parachute payments or Section&nbsp;409A of the Code governing nonqualified deferred compensation plans. The following is not intended or written to be used, and cannot be used,
for the purposes of avoiding taxpayer penalties. Because circumstances may vary, we advise all participants to consult their own tax advisors under all circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options and Stock Appreciation Rights</I>. A recipient of a stock option or SAR will not recognize taxable income upon the grant of those awards. For
NSOs and SARs, the participant will recognize ordinary income upon exercise in an amount equal to the difference between the fair market value of the shares and the exercise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
price on the date of exercise. Any gain or loss recognized upon any later disposition of the shares generally will be a capital gain or loss. The acquisition of shares upon exercise of an ISO
will not result in any taxable income to the participant, except, possibly, for purposes of the alternative minimum tax. The gain or loss recognized by the participant on a later sale or other disposition of such shares will either be long-term
capital gain or loss or ordinary income, depending upon whether the participant holds the shares for the legally required period (currently more than two years from the date of grant and more than one year from the date of exercise). If the shares
are not held for the legally required period, the participant will recognize ordinary income equal to the lesser of (i)&nbsp;the difference between the fair market value of the shares on the date of exercise and the exercise price, or (ii)&nbsp;the
difference between the sales price and the exercise price. Any additional gain recognized on the sale generally will be short-term or long-term capital gain. Different and complex rules may apply to incentive stock options that are early
exercisable, and we encourage participants holding such any such awards to seek the advice of their own tax counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards</I>. For
RSAs, unless vested or the recipient elects under Section&nbsp;83(b) of the Code to be taxed at the time of grant or purchase, the recipient will not have taxable income upon the grant, but will recognize ordinary income upon vesting equal to the
fair market value of the shares at the time of vesting less the amount paid for such shares (if any). Any gain or loss recognized upon any later disposition of the shares generally will be a capital gain or loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Units</I>. A holder of an RSU does not recognize taxable income when the RSU is granted. When vested RSUs (and dividend equivalents, if
any) are settled and distributed, the participant will recognize ordinary income equal to the amount of cash and/or the fair market value of shares received less the amount paid for such stock units (if any). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Bonus Awards</I>. The tax effects of stock bonus awards will vary depending on the type, terms and conditions of those awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance Awards</I>. No income generally will be recognized upon the grant of a performance award. Upon payment in respect of a performance award, the
recipient generally will be required to include as taxable ordinary income in the year of receipt an amount equal to the amount of cash received and the fair market value of any nonrestricted shares of common stock or other property received. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impact of Section&nbsp;162(m) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;162(m) of the
Tax Code generally disallows public companies a tax deduction for federal income tax purposes of remuneration in excess of $1&nbsp;million paid to certain executive officers. While our compensation committee may consider the deductibility of awards
as one factor in determining executive compensation, our compensation committee also looks at other factors in making its decisions and retains the flexibility to award compensation that it determines to be consistent with the goals of our executive
compensation program even if the awards are not deductible by us for tax purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New 2016 Plan Benefits </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name and Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Options&nbsp;Granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey M. Goldberg, President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jim Kastenmayer, General Counsel, Corporate Secretary and Former Interim Chief Executive
Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthony G. Quinn, M.B Ch.B, Ph.D., Former President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan Alspaugh, Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leslie Sloan, Ph.D., Former Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers as a group (5
persons)<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current <FONT STYLE="white-space:nowrap">non-employee</FONT> directors as a group (7 persons)<SUP
STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301,000&nbsp;(3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current employees, including all current officers who are not executive officers, as a group<SUP
STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Awards to executive officers, other employees and consultants are made at the discretion of our board of
directors and compensation committee. As a result, the benefits and amounts that will be received or allocated under the 2016 Plan, as amended and restated, are not determinable at this time. While Dr.&nbsp;Quinn&#146;s employment with us terminated
on August&nbsp;23, 2022, he would be eligible to receive awards under the 2016 Plan, as amended and restated, while providing services to us as a consultant. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Sloan&#146;s employment with us terminated on January&nbsp;5, 2023. Therefore, she will not be
eligible to receive any awards under the 2016 Plan, as amended and restated. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Awards granted under the 2016 Plan, as amended and restated, to our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors are made at the discretion of our board of directors and compensation committee and are not subject to set benefits or amounts under the terms of the 2016 Plan. However, pursuant to our
current <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program, on the date of each annual meeting of stockholders, each of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will receive an option grant
for the purchase of 43,000 shares of our common stock, or such other amount as determined by our board of directors. Effective as of and following the date of the Annual Meeting, any such awards will be granted under the 2016 Plan, as amended and
restated, if this Proposal No.&nbsp;5 is approved by our stockholders. For additional information regarding our current <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program, please see
<FONT STYLE="white-space:nowrap">&#147;Non-Employee</FONT> Director Compensation Arrangements&#148; above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of March 31, 2023. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional information about outstanding grants under our 2016 Plan can be found in the section of this Proxy Statement entitled &#147;Equity Compensation
Plan Information&#148; below. The material conditions of the 2016 Plan, as proposed to be amended, can be found in the section entitled &#147;Summary of the Amendment and Restatement of the 2016 Plan&#148; above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Interests of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In considering the
recommendation of our board of directors with respect to the approval of the amendment and restatement the 2016 Plan, stockholders should be aware that the members of our board of directors have certain interests that may present them with conflicts
of interest in connection with such proposal. As discussed above, directors are eligible to receive awards under the 2016 Plan. Our board of directors recognizes that approval of this proposal may benefit our directors and their successors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUR BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;FOR&#148; THE APPROVAL OF THE AMENDMENT AND RESTATEMENT OF OUR 2016 EQUITY INCENTIVE PLAN
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx449732_9"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the beneficial ownership of our common stock as of March&nbsp;31, 2023, by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each stockholder known by us to be the beneficial owner of more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors or director nominees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our directors, director nominees and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for
any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect to all shares of common
stock that they beneficially owned, subject to applicable community property laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applicable percentage ownership is based on 65,395,159 shares of our common stock outstanding on
March&nbsp;31, 2023. In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed to be outstanding all shares of common stock subject to options held by that person or
entity that are currently exercisable or that will become exercisable within 60 days of March&nbsp;31, 2023. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Unless
otherwise indicated, the address of each beneficial owner listed in the table below is c/o Aeglea BioTherapeutics, Inc. 805 Las Cimas Parkway, Suite 100, Austin, Texas&nbsp;78746. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B><br><B>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>5% Stockholders:</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Baker Bros. Advisors LP
<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,384,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Suvretta Capital Management, LLC <SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,376,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BCLS&nbsp;II&nbsp;Equity&nbsp;Opportunities,&nbsp;LP&nbsp;<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,347,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nantahala&nbsp;Capital&nbsp;Management,&nbsp;LLC&nbsp;<SUP
STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,611,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Rock Springs Capital Management LP <SUP
STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,413,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Directors and Named Executive Officers:</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey M. Goldberg</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jim Kastenmayer <SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthony G. Quinn, M.B Ch.B, Ph.D.
<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,061,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan Alspaugh <SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">362,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leslie Sloan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Armen Shanafelt, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top"> (9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">342,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russell J. Cox <SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">209,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ivana&nbsp;Magovcevic-Liebisch,&nbsp;Ph.D.&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">V. Bryan Lawlis, Ph.D. <SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alison Lawton <SUP STYLE="font-size:75%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marcio Souza <SUP STYLE="font-size:75%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">167,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hunter C. Smith <SUP STYLE="font-size:75%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Current Executive Officers and Directors as a Group (12&nbsp;people) <SUP
STYLE="font-size:75%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,173,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on the company&#146;s records and on a Schedule 13G filed by Baker Bros. Advisors LP (the
&#147;<B><I>Baker</I></B>&#148;) on February&nbsp;14, 2023 with the SEC. Represents shares of common stock held by 667, L.P. (&#147;<B><I>667</I></B>&#148;) and Baker Brothers Life Sciences, L.P. (together with 667, the
&#147;<B><I>Funds</I></B>&#148;), which may be deemed to be indirectly beneficially owned by Baker. Includes 2,973,907 shares of common stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. Baker Bros.
Advisors (GP) LLC (&#147;<B><I>Baker GP</I></B>&#148;), Felix J. Baker and Julian C. Baker as managing members of Baker GP, may be deemed to indirectly beneficially own the shares held by Baker and may be deemed to have the sole power to vote or
direct the vote of and the power to dispose or direct the disposition of such securities. The address of Baker is 860 Washington Street, 3rd Floor, New York, NY 10014. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on a Schedule 13G/A filed by Suvretta Capital Management, LLC (&#147;<B><I>Suvretta</I></B>&#148;)
on February&nbsp;13, 2023 with the SEC. Represents shares of common stock directly held by Averill Master Fund, Ltd., which may be deemed to be indirectly beneficially owned by Suvretta and Aaron Cowen, as well as shares of common stock issuable
upon the exercise of pre- funded warrants. Aaron Cowen has beneficial ownership of such shares by virtue of his role as a control person of Suvretta. The mailing address of (i)&nbsp;Suvretta and Aaron Cowen is 540 Madison Avenue, 7th Floor, New
York, NY 10022 and (ii)&nbsp;Averill Master Fund, Ltd. is c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, Grand Cayman <FONT STYLE="white-space:nowrap">KY1-1104,</FONT> Cayman Islands. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on a Schedule 13G/A filed by BCLS II Equity Opportunities, LP (&#147;<B><I>BCLS</I></B>&#148;) on
February&nbsp;14, 2023 with the SEC. Represents shares of common stock beneficially owned by BCLS. Bain Capital Life Sciences Investors, LLC, a Delaware limited liability company (&#147;<B><I>BCLSI</I></B>&#148;), is the manager of Bain Capital
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Life Sciences Investors II, LLC, a Cayman limited liability company, which is the general partner of Bain Capital Life Sciences Fund II, L.P., a Cayman exempted limited partnership, which is the
manager of BCLS II Equity Opportunities GP, LLC, a Delaware limited liability company, which is the general partner of BCLS. BCLSI may be deemed to share voting and dispositive power with respect to such shares. The address of BCLS is 200 Clarendon
Street, Boston, MA 02116. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on a Schedule 13G/A filed by Nantahala Capital Management, LLP
(&#147;<B><I>Nantahala</I></B>&#148;) on February&nbsp;14, 2023 with the SEC. Represents shares of common stock beneficially owned by Nantahala. Nantahala may be deemed to be the beneficial owner of 4,611,302 shares held by funds and separately
managed accounts under its control, and as the managing members of Nantahala, each of Wilmot B. Harkey and Daniel Mack may be deemed to be beneficial owners of such shares. Nantahala and each of Messrs. Harkey and Mack have shared voting and
dispositive power over such shares. The address of Nantahala is 130 Main Street, 2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> Floor, New Canaan, CT 06840. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on a Schedule 13G filed by Rock Springs Capital Management LP (&#147;<B><I>RSCM</I></B>&#148;) and
Rock Springs Capital LLC (&#147;<B><I>RSC</I></B>&#148;) on February&nbsp;14, 2023 with the SEC. Represents shares of common stock held directly by Rock Springs Capital Master Fund LP (the &#147;<B><I>Master Fund</I></B>&#148;), which is a Cayman
Island exempted limited partnership, and Four Pines Master Fund LP (&#147;<B><I>Four Pines</I></B>&#148;), which is a Cayman Islands exempted limited partnership, and indirectly held by RSCM, a Delaware limited partnership, and RSC, a Delaware
limited liability company. RSCM serves as the investment manager to each of the Master Fund and Four Pines. RSC is the general partner of RSCM. RSCM and RSC have shared voting and dispositive power over such shares. The address of RSCM and RSC is
650 South Exeter, Suite 1070, Baltimore, MD 21202. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 6,000 shares owned by Mr.&nbsp;Kastenmayer and (ii)&nbsp;options exercisable for 141,770 shares
of common stock within 60 days of March&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 821,922 shares of common stock held by Dr.&nbsp;Quinn and (ii)&nbsp;options exercisable for
1,239,476 shares of common stock within 60 days of March&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 171,372 shares of common stock held by Mr.&nbsp;Alspaugh and (ii)&nbsp;options exercisable for
190,833 shares of common stock within 60 days of March&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 150,000 shares of common stock held by Dr.&nbsp;Shanafelt and (ii)&nbsp;options exercisable for
192,316 shares of common stock within 60 days of March&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 7,000 shares of common stock held by Mr.&nbsp;Cox and (ii)&nbsp;options exercisable for 202,125
shares of common stock within 60 days of March&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents options exercisable for 156,716 shares of common stock within 60 days of March&nbsp;31, 2023.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents options exercisable for 156,716 shares of common stock within 60 days of March&nbsp;31, 2023.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents options exercisable for 117,438 shares of common stock within 60 days of March&nbsp;31, 2023.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 90,000 shares of common stock held by Mr.&nbsp;Souza and (ii)&nbsp;options exercisable for
77,749 shares of common stock within 60 days of March&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents options exercisable for 69,416 shares of common stock within 60 days of March&nbsp;31, 2023.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 1,246,294 shares of common stock and (ii)&nbsp;options exercisable for 2,544,555 shares of
common stock within 60 days of March&nbsp;31, 2023. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx449732_10"></A>EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The names of our current executive officers, their ages as of March&nbsp;31, 2023, and their positions are shown below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey M. Goldberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan Alspaugh</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Hanley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Business Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jim Kastenmayer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Counsel and Corporate Secretary</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Linda Neuman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Medical Officer</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors chooses executive officers, who then serve at the board&#146;s discretion. There is no family
relationship among any of our directors or executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jeffrey M. Goldberg.</I><I></I>&nbsp;Mr.&nbsp;Goldberg has served as our President and
Chief Executive Officer and as a member of our board of directors since November 2022.&nbsp;Mr.&nbsp;Goldberg&#146;s biographical information is set forth above under the heading &#147;Proposal No.&nbsp;1 Election of Directors&#151;Continuing
Directors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jonathan Alspaugh</I>. Mr.&nbsp;Alspaugh has served as our Chief Financial Officer since July 2021. Prior to joining Aeglea, between
April 2013 and June 2021, Mr.&nbsp;Alspaugh served in various roles of increasing responsibility at Evercore, including as Managing Director in the firm&#146;s corporate advisory business. Prior to that, Mr.&nbsp;Alspaugh was a member of Barclays
Capital&#146;s global healthcare investment banking team. Mr.&nbsp;Alspaugh received an S.M. from the <FONT STYLE="white-space:nowrap">Harvard-MIT</FONT> Division of Health Sciences and Technology, an M.B.A. from the Massachusetts Institute of
Technology Sloan School of Management, and a B.S.E. and an M.S.E. in Nuclear Engineering and Radiological Sciences from the University of Michigan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Michael Hanley. </I>Mr.&nbsp;Hanley joined Aeglea as our Chief Commercial Officer in October 2019 before assuming the role as Chief Business Officer in
September 2022, and he brings more than 25 years of experience in the biopharmaceutical and healthcare industries. Prior to joining our company, Mr.&nbsp;Hanley served as Vice President and U.S. Chief Commercial Officer of Esteve Pharmaceuticals,
S.A. from April 2018 to September 2019. From July 2017 to March 2018, Mr.&nbsp;Hanley served as an independent strategy consultant to various biopharmaceutical companies. From July 2015 to June 2017, Mr.&nbsp;Hanley served in various roles of
increasing responsibility within the Orphan Business Unit at Horizon Therapeutics PLC, a global biopharmaceutical company, including as Vice President, Marketing; Group Vice President and General Manager; and Group Vice President, Marketing,
Americas and Asia Pacific. From August 2010 to July 2015, Mr.&nbsp;Hanley served in various roles of increasing responsibility at the U.S. affiliate of H. Lundbeck A/S, a global pharmaceutical company, including as Director, ONFI Marketing; Senior
Director, Neurology Marketing; and Senior National Sales Director, Psychiatry. Mr.&nbsp;Hanley received a BBA in Marketing from the University of Notre Dame and an MBA from the Kellogg School of Management at Northwestern University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jim Kastenmayer</I>. Mr.&nbsp;Kastenmayer has served as our General Counsel and Corporate Secretary since July 2021. Mr.&nbsp;Kastenmayer also served as
our interim Chief Executive Officer from <FONT STYLE="white-space:nowrap">mid-August</FONT> through November 2022. Prior to Aeglea, Mr.&nbsp;Kastenmayer served as general counsel at Viela Bio, Inc. where he provided strategic guidance and legal
advice including advising the company in connection with the FDA approval and launch of Uplizna<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> as well as the company&#146;s acquisition by Horizon Therapeutics plc. Prior to Viela Bio, he
served in roles of increasing responsibility at AstraZeneca PLC including global legal director, where he advised on commercialization and market access strategies, collaboration agreements and handled legal proceedings, as well as senior patent
director, accountable for delivering global IP estates for small and large molecule therapies. Earlier in his career, Mr.&nbsp;Kastenmayer served as IP counsel at MedImmune Ltd, and as an associate at an IP boutique firm. Mr.&nbsp;Kastenmayer earned
a J.D. from Georgetown University Law Center, a Ph.D. in biochemistry and cell&nbsp;&amp; molecular biology from Michigan State University and a B.A. in biology from the University of Virginia and is a registered patent attorney. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Linda Neuman</I>. Dr.&nbsp;Neuman has served as our Chief Medical Officer since November 2022.
Dr.&nbsp;Neuman has over 20 years of experience developing therapeutics across multiple indications in the biopharmaceutical industry. Prior to joining Aeglea, Dr.&nbsp;Neuman served as vice president, clinical development at Catalyst Biosciences,
Inc. where she led the clinical development of their late-stage development program for a novel hemophilia treatment. Before Catalyst, she served as the interim chief medical officer at Adverum Biotechnologies, Inc., where she directed the early
phase development for three gene therapy programs, including two INDs in rare disease and ophthalmology indications. She previously worked at Sunesis Pharmaceuticals, Inc. where she led the filing of an IND and initiated a Phase 1b/2 clinical trial
and Puma Biotechnology, Inc., where she contributed to the successful new drug application and market authorization application for neratininb. Earlier in her career, Dr.&nbsp;Neuman held roles of increasing responsibility at Onyx Pharmaceuticals
Inc., Covidien Plc, Millennium Pharmaceuticals, Inc. and Schering-Plough Corporation. She began her career as an internist and practiced medicine for 10 years prior to joining industry. Dr.&nbsp;Neuman earned an M.D. from Southern Illinois
University School of Medicine, a B.S. in biology from Southern Illinois University, and an M.B.A from Indiana Wesleyan University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx449732_11"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section provides an overview of the
material components of our executive compensation program for our Chief Executive Officer, including anyone who served as Chief Executive Officer during any part of fiscal year 2022, and each of our two other most highly compensated executive
officers (our &#147;<B><I>Named Executive Officers</I></B>&#148;) during fiscal year 2022. The compensation provided to our Named Executive Officers for fiscal year 2022 is set forth in detail in the Summary Compensation Table and other tables that
follow in this section, as well as the accompanying footnotes and narratives relating to those tables. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Named Executive Officers for fiscal year 2022
were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jeffrey M. Goldberg, our President and Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jim Kastenmayer, our General Counsel, Corporate Secretary and Former Interim Chief Executive Officer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anthony G. Quinn, M.B Ch.B, Ph.D., our Former President and Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jonathan Alspaugh, our Chief Financial Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leslie Sloan, Ph.D., our Former Chief Operating Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides
information regarding all plan and <FONT STYLE="white-space:nowrap">non-plan</FONT> compensation awarded to, earned by or paid to each of our Named Executive Officers for the fiscal years ended December&nbsp;31, 2022 and 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nonequity<BR>Incentive Plan<BR>Compensation</B><br><B>($) <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Awards</B><br><B>($) <SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other</B><br><B>Compensation</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jeffrey M. Goldberg<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,774,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,917</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,832,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jim Kastenmayer<SUP STYLE="font-size:75%; vertical-align:top">(4)(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">443,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">253,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,200</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">865,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>General Counsel, Corporate Secretary and Former Interim Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Anthony G. Quinn, M.B Ch.B, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">424,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">779,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,188,200</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(3)(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,392,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Former President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">560,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">332,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,701,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,623,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jonathan Alspaugh<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">425,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">443,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,994</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,011,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Leslie Sloan, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">465,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,323</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,087,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Former Chief Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">410,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">822,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,449,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Cash bonuses earned in 2022 and paid in 2023, based in part on achievement of specified milestones and
performance objectives. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">The amounts reported in this column represent the aggregate grant date fair value of the awards granted to our
Named Executive Officers during the year ended December&nbsp;31, 2022, as computed in accordance with ASC 718. The assumptions used in calculating the grant date fair value of the awards reported in the Option Awards column are set forth in Note 10
to our consolidated financial statements included in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022. Note that the amounts reported in this column reflect the aggregate accounting
cost for these awards, and do not necessarily correspond to the actual economic value that may be received by the Named Executive Officers from the awards. As of the date of grant, the achievement of the performance goals applicable to the
performance-based options granted to Dr.&nbsp;Quinn during the year ended December&nbsp;31, 2022 was not deemed to be probable, and therefore, the grant date fair value ascribed to such options in accordance with ASC 718, and reported in this
column, is $0. The maximum grant date fair value of such performance-based options, assuming full achievement of the performance conditions to which such options are subject, is $78,066.61. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">For Mr.&nbsp;Goldberg, represents housing allowance. For each of our other Named Executive Officers, primarily
represents matching 401(k) or other retirement plan contributions paid by us on their behalf in the amount of $12,200. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">On August&nbsp;23, 2022, Dr.&nbsp;Quinn transitioned from our President and Chief Executive Officer to a <FONT
STYLE="white-space:nowrap">non-employee</FONT> consultant of Aeglea until September&nbsp;1, 2023. Our board of directors appointed Mr.&nbsp;Kastenmayer, who serves as our General Counsel and Corporate Secretary, to serve as our interim Chief
Executive Officer from August&nbsp;23, 2022 until the appointment of Mr.&nbsp;Goldberg as our new President and Chief Executive Officer on November&nbsp;29, 2022. Under SEC rules, as each of Dr.&nbsp;Quinn, Mr.&nbsp;Kastenmayer and Mr.&nbsp;Goldberg
served as Aeglea&#146;s principal executive officer during a portion of 2022, each is considered to be a Named Executive Officer for 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Includes severance payment of $1,176,000 in connection with Dr.&nbsp;Quinn&#146;s termination of employment.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Because Mr.&nbsp;Kastenmayer was not a Named Executive Officer in 2021, SEC rules do not require his
compensation for that year to be reported. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Because Mr.&nbsp;Alspaugh was not a Named Executive officer in 2021, SEC rules do not require his compensation
for that year to be reported. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Sloan&#146;s employment with us terminated on January&nbsp;5, 2023. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at December&nbsp;31, 2022 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following table presents, for our Named Executive Officers, information regarding outstanding equity awards held as of December&nbsp;31, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="30" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>securities</B><br><B>underlying</B><br><B>unexercised</B><br><B>options (#)</B><br><B>exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>securities</B><br><B>underlying</B><br><B>unexercised</B><br><B>options (#)</B><br><B>unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity&nbsp;Incentive<BR>Plan Awards:<BR>Number&nbsp;of<BR>securities<BR>underlying<BR>unexercised<BR>unearned<BR>options (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>exercise</B><br><B>price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>expiration</B><br><B>date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant<BR>date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity Incentive<BR>Plan Awards:<BR>Number&nbsp;of<BR>unearned&nbsp;shares,<BR>units or other<BR>rights that have<BR>not vested (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity Incentive<BR>Plan Awards:<BR>Market&nbsp;or payout<BR>value&nbsp;of&nbsp;unearned<BR>shares, units or<BR>other rights that<BR>have not vested<BR>($)<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Jeffrey&nbsp;M.&nbsp;Goldberg</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/28/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,884,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(5</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/27/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Jim&nbsp;Kastenmayer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/6/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(5</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/5/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/17/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/16/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/23/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/22/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Anthony G. Quinn, M.B Ch.B, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/20/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/19/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/17/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/8/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/18/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/28/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">268,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/27/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/14/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/13/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/15/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,000&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/15/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/17/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">178,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/16/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/17/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">277,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/16/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/18/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/18/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/15/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,000&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Jonathan&nbsp;Alspaugh</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/6/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(5</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/5/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/17/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman"></P></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">.17</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/16/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/23/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/22/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Leslie&nbsp;Sloan,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/10/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(5</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/9/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/20/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/19/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/28/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/27/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/6/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/5/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/14/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/13/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/15/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/15/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/17/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/16/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/17/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/16/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/23/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/22/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/15/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Equity award was granted under our 2016 Equity Incentive Plan. For Mr.&nbsp;Goldberg, equity award was granted
as an inducement award. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The market value was determined by multiplying the number of shares by $0.45, the closing price of our common
stock as reported on the Nasdaq Global Market on December&nbsp;30, 2022, the last trading day of the year. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">1/48th of the options vests on each monthly anniversary of the applicable vesting commencement date, subject to
the executive&#146;s continued service. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The options vest and become exercisable contingent upon achievement of certain product development, regulatory,
or stock price milestones, which have not been met as of December&nbsp;31, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">1/4th of the options vest on the one year anniversary of the applicable vesting commencement date and an
additional 1/48th vests monthly thereafter, subject to the executive&#146;s continued service. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The restricted stock units vest contingent upon achievement of certain product development or regulatory
milestones, which have not been met as of December&nbsp;31, 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative to Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation committee has historically determined our executive compensation and determines the compensation of our Named Executive Officers. Our
compensation committee typically reviews and discusses management&#146;s proposed compensation with the Chief Executive Officer for all executives other than the Chief Executive Officer. Based on those discussions and its discretion, our
compensation committee then approves the compensation of each executive officer after discussions without members of management present. We generally do not provide perquisites or personal benefits, except in situations where we believe it is
appropriate to assist an individual in the performance of his or her duties, to make our executive officers more efficient and effective, and for recruitment and retention purposes. See &#147;&#151;<I>Employment Arrangements with Our Named Executive
Officers</I>&#148; below for additional information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Welfare and Health Benefits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Named Executive Officers are eligible to participate in all of our benefit plans, such as the 401(k) plan (see description under &#147;&#151; <I>Retirement
Benefits</I>&#148; below), medical, dental, vision, short-term disability, long-term disability and group life insurance, in each case generally on the same basis as other employees. We do not currently have qualified or nonqualified defined benefit
plans or nonqualified deferred compensation plans, nor do we offer pension or other retirement benefits other than our 401(k) plan. Our board of directors may elect to adopt such plans in the future if it determines that doing so is in our best
interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Retirement Benefits </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a
<FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan that provides eligible U.S. employees, including our Named Executive Officers, with an opportunity to save for retirement on a
<FONT STYLE="white-space:nowrap">tax-advantaged</FONT> basis. Eligible employees may make voluntary contributions from their eligible pay, up to certain applicable annual limits set by the Code. The 401(k) plan is intended to be qualified under
Section&nbsp;401(a) of the Code with the 401(k) plan&#146;s related trust intended to be tax exempt under Section&nbsp;501(a) of the Code. We match our employee contributions in an amount equal to 100% of the first 3% of eligible compensation, and
50% of the next 2% of eligible compensation. All such employee contributions and matching contributions are immediately and fully vested. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Arrangements with Our Named Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jeffrey M. Goldberg </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to an offer letter dated
November&nbsp;28, 2022, Mr.&nbsp;Goldberg serves as our President and Chief Executive Officer. Mr.&nbsp;Goldberg&#146;s offer letter sets forth the principal terms and conditions of his employment, including his initial annual base salary of
$600,000, an annual target bonus opportunity of 50% of his base salary (which bonus is earned based on our achievement of specified milestones and performance objectives, as well as Mr.&nbsp;Goldberg&#146;s performance relative to one or more
performance objectives established by our board of directors, the achievement of which is evaluated by our board of directors) and an annual housing allowance of $35,000. Mr.&nbsp;Goldberg&#146;s offer letter provides for an option grant for the
purchase of 1,884,838 shares of our common stock, which vests over a 48-month period with 25% of the options vesting on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of his employment as Chief Executive Officer and the remainder
vesting in equal monthly installments thereafter, subject to Mr.&nbsp;Goldberg&#146;s continued service to us on each monthly vesting date. Pursuant to the terms of his severance agreement, Mr.&nbsp;Goldberg will be entitled to severance benefits
described in &#147;Termination or Change in Control Arrangements with Our Named Executive Officers&#148; below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jim Kastenmayer </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to an offer letter dated June&nbsp;8, 2021, Mr.&nbsp;Kastenmayer serves as our General Counsel and Corporate Secretary, and from August 2022 to
November 2022, served as our Interim Chief Executive Officer. Mr.&nbsp;Kastenmayer&#146;s offer letter sets forth the principal terms and conditions of his employment, including his initial annual base salary of $365,000 and an annual target bonus
opportunity of 40% of his base salary (which bonus is earned based on our achievement of specified financial performance objectives, as well as Mr.&nbsp;Kastenmayer&#146;s performance relative to one or more performance objectives established by our
board of directors, the achievement of which is evaluated by our board of directors). Mr.&nbsp;Kastenmayer&#146;s offer letter provides for an option grant for the purchase of 130,000 shares of our common stock, which vests over a 48-month period
with 25% of the options vesting on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of his employment as General Counsel and Corporate Secretary and the remainder vesting in equal monthly installments thereafter, subject to
Mr.&nbsp;Kastenmayer&#146;s continued service to us on each monthly vesting date. In connection with Mr.&nbsp;Kastenmayer&#146;s appointment as Interim Chief Executive Officer, in August&nbsp;2022, our board of directors approved certain adjustments
to Mr.&nbsp;Kastenmayer&#146;s compensation terms for such position, which included an increase in base salary to $588,000 and an increase in target bonus amount to 50%. The adjustments to Mr.&nbsp;Kastenmayer&#146;s compensation in relation to his
appointment as Interim Chief Executive Officer was prorated for time served. Pursuant to the terms of his severance agreement, Mr.&nbsp;Kastenmayer will be entitled to severance benefits described in &#147;Termination or Change in Control
Arrangements with Our Named Executive Officers&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anthony G. Quinn, M.B Ch.B, Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to an offer letter dated July&nbsp;18, 2018, Dr.&nbsp;Quinn served as our President and Chief Executive Officer until August 2022.
Dr.&nbsp;Quinn&#146;s offer letter set forth the principal terms and conditions of his employment, including his initial annual base salary of $507,000, an annual target bonus opportunity of 50% of his base salary (which bonus is earned based on our
achievement of specified milestones and performance objectives, as well as Dr.&nbsp;Quinn&#146;s performance relative to one or more performance objectives established by our board of directors, the achievement of which is evaluated by our board of
directors). Dr.&nbsp;Quinn&#146;s offer letter provides for (i)&nbsp;an option grant for the purchase of 300,000 shares of our common stock, which vests over a <FONT STYLE="white-space:nowrap">48-month</FONT> period subject to Dr.&nbsp;Quinn&#146;s
continued service to us on each monthly vesting date, and (ii)&nbsp;three options to purchase an aggregate of 200,000 shares of our common stock, which will vest based on the achievement of certain performance objectives set by our board of
directors. Pursuant to the terms of his severance agreement, Dr.&nbsp;Quinn will be entitled to severance benefits described in &#147;Termination or Change in Control Arrangements with Our Named Executive Officers&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jonathan Alspaugh </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to an offer letter dated
June&nbsp;14, 2021, Mr.&nbsp;Alspaugh serves as our Chief Financial Officer. Mr.&nbsp;Alspaugh&#146;s offer letter sets forth the principal terms and conditions of his employment as Chief Financial Officer, including his annual base salary and an
annual target bonus opportunity (which bonus is earned based on our achievement of specified milestones and performance objectives, as well as Mr.&nbsp;Alspaugh&#146;s performance relative to one or more performance objectives established by our
board of directors, the achievement of which is evaluated by our board of directors). Mr.&nbsp;Alspaugh&#146;s current base salary and annual bonus are set forth in the &#147;Summary Compensation Table&#148; above. Mr.&nbsp;Alspaugh&#146;s offer
letter also provides for an additional option grant for the purchase of 160,000 shares of common stock, which vests over a <FONT STYLE="white-space:nowrap">48-month</FONT> period subject to Mr.&nbsp;Alspaugh&#146;s continued service to us on each
monthly vesting date. Pursuant to the terms of his severance agreement, Mr.&nbsp;Alspaugh will be entitled to severance benefits described in &#147;Termination or Change in Control Arrangements with Our Named Executive Officers&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Leslie Sloan, Ph.D. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to an offer letter dated
March&nbsp;13, 2020, Dr.&nbsp;Sloan served as our Chief Operating Officer until January 2023. Dr.&nbsp;Sloan&#146;s offer letter set forth the principal terms and conditions of her employment as Chief Operating
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Officer, including her annual base salary of $355,000 and an annual target bonus opportunity of 40% of her base salary (which bonus is earned based on our achievement of specified milestones and
performance objectives, as well as Dr.&nbsp;Sloan&#146;s performance relative to one or more performance objectives established by our board of directors, the achievement of which is evaluated by our board of directors). Dr.&nbsp;Sloan&#146;s offer
letter also provides for an additional option grant for the purchase of 108,000 shares of common stock, which vests over a <FONT STYLE="white-space:nowrap">48-month</FONT> period subject to Dr.&nbsp;Sloan&#146;s continued service to us on each
monthly vesting date. Pursuant to the terms of her severance agreement, Dr.&nbsp;Sloan will be entitled to severance benefits described in &#147;Termination or Change in Control Arrangements with Our Named Executive Officers&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination or Change in Control Arrangements with Our Named Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jeffrey M. Goldberg </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to his severance agreement,
entered into as of November&nbsp;29, 2022, Mr.&nbsp;Goldberg will be entitled to receive the following benefits if his employment is terminated for any reason other than for cause or if he voluntarily resigns his employment for good reason: (i) 12
months of his monthly base salary;&nbsp;(ii)&nbsp;100% of his annual target bonus; (iii)&nbsp;payment for the full amount of his premiums under COBRA for 12 months; and (iv)&nbsp;any outstanding equity awards, including awards that would otherwise
vest only upon satisfaction of performance criteria, shall accelerate and become vested and exercisable as if an additional 12&nbsp;months of vesting had occurred to the then-unvested shares subject to the equity award. Additionally, if his
employment is terminated within 12 months of a change in control or within three months preceding a change in control for any reason other than for cause or he voluntarily resigns his employment for good reason during such period, we will provide
him with the following benefits: (i) 12 months of his monthly base salary;&nbsp;(ii)&nbsp;100% of his annual target bonus; (iii)&nbsp;payment for the full amount of his premiums under COBRA for 12 months; and (iv) 100% vesting for all outstanding
and unvested equity awards, including awards that would otherwise vest only upon satisfaction of performance criteria based on achievement of the performance criteria at target. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jim Kastenmayer </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to his severance agreement,
entered into as of July&nbsp;6, 2021, Mr.&nbsp;Kastenmayer will be entitled to receive the following benefits if his employment is terminated for any reason other than for cause or if he voluntarily resigns his employment for good reason: (i) 12
months of his monthly base salary; (ii) 100% of his annual target bonus; (iii)&nbsp;payment for the full amount of his premiums under COBRA for 12 months; and (iv)&nbsp;any outstanding equity awards, including awards that would otherwise vest only
upon satisfaction of performance criteria, shall accelerate and become vested and exercisable as if an additional 12 months of vesting had occurred to the then-unvested shares subject to the equity award. Additionally, if his employment is
terminated within 12 months of a change in control or within three months preceding a change in control for any reason other than for cause or he voluntarily resigns his employment for good reason during such period, we will provide him with the
following benefits: (i) 12 months of his monthly base salary; (ii) 100% of his annual target bonus; (iii)&nbsp;payment for the full amount of his premiums under COBRA for 12 months; and (iv) 100% vesting for all outstanding and unvested equity
awards, including awards that would otherwise vest only upon satisfaction of performance criteria based on achievement of the performance criteria at target. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anthony G. Quinn, M.B Ch.B, Ph.D. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;24,
2022, we entered into a certain transition and separation agreement with Dr.&nbsp;Quinn in connection with his departure as our President and Chief Executive Officer (the &#147;<B><I>Transition Agreement</I></B>&#148;). We also entered into a
consulting agreement (the &#147;<B><I>Consulting Agreement</I></B>&#148;) with Dr.&nbsp;Quinn, pursuant to which Dr.&nbsp;Quinn has agreed to serve as a <FONT STYLE="white-space:nowrap">non-employee</FONT> consultant to us until September&nbsp;1,
2023 (such transition term end date, the &#147;<B><I>Consultancy End Date</I></B>&#148;). Subject to Dr.&nbsp;Quinn&#146;s execution of a general release of claims, the terms of the Transition Agreement and the terms of the Consulting Agreement,
Dr.&nbsp;Quinn will be entitled to receive the following benefits: (i)&nbsp;a severance payment of $882,000, equal to 18 months of his annual salary; (ii)&nbsp;a lump sum bonus payment of $294,000; and (iii)&nbsp;the amount of COBRA premiums he
would be required to pay to maintain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
group healthcare coverage as in effect on September&nbsp;1, 2022 for 18 months. In exchange for providing consulting services to us through the Consultancy End Date, Dr.&nbsp;Quinn also will be
entitled to receive the following benefits: (x)&nbsp;continued vesting in his outstanding option awards with respect to the number of shares that would have vested if Dr.&nbsp;Quinn had remained in service through the Consultancy End Date; and
(y)&nbsp;acceleration of vesting of Dr.&nbsp;Quinn&#146;s outstanding option awards with respect to the number of shares that would have vested if Dr.&nbsp;Quinn had remained in service through an additional 12 months beyond the Consultancy End
Date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jonathan Alspaugh </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to his severance
agreement, entered into as of July&nbsp;6, 2021, Mr.&nbsp;Alspaugh will be entitled to receive the following benefits if his employment is terminated for any reason other than for cause or if he voluntarily resigns his employment for good reason:
(i) 12 months of his monthly base salary; (ii) 100% of his annual target bonus; (iii)&nbsp;payment for the full amount of his premiums under COBRA for 12 months; and (iv)&nbsp;any outstanding equity awards, including awards that would otherwise vest
only upon satisfaction of performance criteria, shall accelerate and become vested and exercisable as if an additional 12 months of vesting had occurred to the then-unvested shares subject to the equity award. Additionally, if his employment is
terminated within 12 months of a change in control or within three months preceding a change in control for any reason other than for cause or he voluntarily resigns his employment for good reason during such period, we will provide him with the
following benefits: (i) 12 months of his monthly base salary; (ii) 100% of his annual target bonus; (iii)&nbsp;payment for the full amount of his premiums under COBRA for 12 months; and (iv) 100% vesting for all outstanding and unvested equity
awards, including awards that would otherwise vest only upon satisfaction of performance criteria based on achievement of the performance criteria at target. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Leslie Sloan, Ph.D. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;5, 2023,
Dr.&nbsp;Sloan resigned from her position as Chief Operating Officer. Pursuant to her severance agreement, entered into as of August&nbsp;7, 2019, Dr.&nbsp;Sloan received the following benefits: (i)&nbsp;a severance payment of $435,000, equal to 12
months of her annual salary; (ii)&nbsp;a lump sum bonus payment of $174,000; (iii) payment of COBRA premiums to maintain group healthcare coverage as in effect on the date of her separation (the &#147;<B><I>Separation Date</I></B>&#148;) for 12
months; and (iv)&nbsp;acceleration of vesting of Dr.&nbsp;Sloan&#146;s outstanding option awards with respect to the number of shares that would have vested if Dr.&nbsp;Sloan had remained in service through an additional 12 months beyond the
Separation Date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pay-Versus-Performance</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation committee approves and administers our executive compensation program to align executive compensation with stockholder interests by linking
pay to performance. Our overall compensation program includes a mix of short-term and long-term components through our annual incentive plan and equity awards. During fiscal year 2022, there was a change to our executive management team when our
tenured Chief Executive Officer, Dr.&nbsp;Quinn (&#147;<B><I>PEO 2</I></B>&#148;) resigned on August&nbsp;23, 2022 and transitioned to an advisory role. Upon this transition, Mr.&nbsp;Kastenmayer (&#147;<B><I>PEO 3</I></B>&#148;) was appointed our
interim Chief Executive Officer until our new Chief Executive Officer, Mr.&nbsp;Goldberg (&#147;<B><I>PEO 1</I></B>&#148;), was appointed on November&nbsp;29, 2022. We provide the compensation actually paid during fiscal year 2022 for all three
individuals providing service as Chief Executive Officer during fiscal year 2022 in the following tables. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As required by Item 402(v) of Regulation <FONT
STYLE="white-space:nowrap">S-K,</FONT> we are providing the following information about the relationship between the compensation actually paid to our Named Executive Officers and certain aspects of our financial performance. We are a smaller
reporting company pursuant to Rule 405 of the Securities Act and, as such, are only required to include information for the past two fiscal years in the table below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pay-Versus-Performance</FONT> Table </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><B>Year</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; "><B>(a)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Summary<BR>Compensation<BR>Table Total<BR>for PEO 1</B><br><B>(b)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Compensation<BR>Actually Paid<BR>to PEO 1</B><br><B>(c)<SUP STYLE="font-size:75%; vertical-align:top">(2)(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Summary<BR>Compensation<BR>Table Total<BR>for PEO 2</B><br><B>(b)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Compensation<BR>Actually Paid<BR>to PEO 2</B><br><B>(c)<SUP STYLE="font-size:75%; vertical-align:top">(2)(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Summary<BR>Compensation<BR>Table Total<BR>for PEO 3</B><br><B>(b)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Compensation<BR>Actually Paid<BR>to PEO 3</B><br><B>(c)<SUP STYLE="font-size:75%; vertical-align:top">(2)(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Summary<BR>Compensation<BR>Table Total<BR>for <FONT STYLE="white-space:nowrap">Non-PEO</FONT><BR>NEOs</B><br><B>(d)<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Compensation<BR>Actually Paid<BR>to <FONT STYLE="white-space:nowrap">Non-PEO</FONT><BR>NEOs</B><br><B>(e)<SUP
STYLE="font-size:75%; vertical-align:top">(4)(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholder<BR>Return&nbsp;Based<BR>on Initial<BR>Fixed
$100<BR>Investment</B><br><B>(f)<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net&nbsp;Income</B><br><B>(in&nbsp;thousands)</B><br><B>(g)<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,832,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">564,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,392,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">431,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">865,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">318,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,049,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">($</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,815</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,623,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,365,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">712,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">($</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,801</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The dollar amounts reported in column (b)&nbsp;represent the amount of total compensation reported for
Mr.&nbsp;Goldberg, Dr.&nbsp;Quinn and Mr.&nbsp;Kastenmayer (collectively, our &#147;<B><I>PEOs</I></B>&#148;) for each covered fiscal year in the &#147;Total&#148; column of the Summary Compensation Table for each applicable year. Please refer to
&#147;<I>Executive Compensation&#151;Summary Compensation Table</I><I>&#148;</I> above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The dollar amounts reported in column (c)&nbsp;represent the amount of &#147;compensation actually paid&#148;
to our PEOs, as computed in accordance with Item 402(v) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> for each covered fiscal year. The dollar amounts do not reflect the actual amount of compensation earned or received by or paid to the
PEOs during the applicable fiscal year. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The equity award adjustments for each covered fiscal year include the addition (or subtraction, as applicable)
of the following: (i)&nbsp;the <FONT STYLE="white-space:nowrap">year-end</FONT> fair value of all equity awards granted during the covered fiscal year that are outstanding and unvested as of the end of the covered fiscal year; (ii)&nbsp;the amount
equal to the change as of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of any equity awards granted in any prior fiscal year that are outstanding and unvested as of the end of the covered fiscal year;
(iii)&nbsp;for equity awards that are granted and vest in same covered fiscal year, the fair value as of the vesting date; (iv)&nbsp;for equity awards granted in any prior fiscal year for which all applicable vesting conditions were satisfied at the
end of or during the covered fiscal year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value; (v)&nbsp;for equity awards granted in any prior fiscal year that fail to meet the applicable
vesting conditions during the covered fiscal year, the amount equal to the fair value at the end of the prior fiscal year; and (vi)&nbsp;the dollar value of any dividends or other earnings paid on stock or option awards in the covered fiscal year
prior to the vesting date that are not otherwise included in the total compensation for the covered fiscal year. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PEO 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PEO 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PEO 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Summary Compensation Table &#150; Total Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(a</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;1,832,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2,623,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2,392,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 865,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#150;&#8194;&#8201;&#8201;Grant Date Fair Value of Option Awards Granted in Fiscal Year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(b</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,774,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,701,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 779,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 253,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">+&#8194;&#8201;&#8201;Fair Value at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> of
Outstanding and Unvested Stock Awards and Option Awards Granted in Fiscal Year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(c</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 507,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 706,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 58,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 48,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">+&#8194;&#8201;&#8201;Change in Fair Value of Outstanding and Unvested Stock Awards and Option
Awards Granted in Prior Fiscal Years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(d</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">($</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,323,528</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">($</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">794,439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">($</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">238,617</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">+&#8194;&#8201;&#8201;Fair Value at Vesting of Stock Awards and Option Awards Granted in Fiscal
Year that Vested During Fiscal Year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(e</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;299,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 36,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 13,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PEO 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PEO 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PEO 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">+&#8194;&#8201;&#8201;Change in Fair Value as of Vesting Date of Stock Awards and Option Awards
Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(f)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">($</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">243,087</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">($</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">481,604</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">($</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116,923</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">-&#8195;&#8202;Fiscal Value as of Prior Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> of
Stock Awards and Option Awards Granted in Prior Fiscal Years that Failed to Meet Applicable Vesting Conditions During Fiscal Year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(g)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">=&#8194;&#8201;&#8201;Compensation Actually Paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;564,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 361,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 431,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 318,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The dollar amounts reported in column (d)&nbsp;represent the average of the amounts of total compensation
reported for our NEOs as a group (excluding our PEOs) for each covered fiscal year in the &#147;Total&#148; column of the Summary Compensation Table for each applicable year. The names of each NEO (excluding our PEOs) included for purposes of
calculating the average amounts of total compensation in each covered fiscal year are as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For fiscal year 2022, Jonathan Alspaugh (our Chief Financial Officer) and Leslie Sloan (our Former Chief
Operating Officer); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For fiscal year 2021, Michael Hanley (our Chief Business Officer) and Leslie Sloan (our Former Chief Operating
Officer). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The dollar amounts reported in column (e)&nbsp;represent the average amount of &#147;compensation actually
paid&#148; to our NEOs as a group (excluding our PEOs), as computed in accordance with Item 402(v) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> for each covered fiscal year. The dollar amounts do not reflect the actual average amount of
compensation earned or received by or paid to our NEOs as a group (excluding our PEOs) during the applicable fiscal year. In accordance with the requirements of Item 402(v) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> the following
adjustments were made to the average total compensation for each covered fiscal year to determine the &#147;compensation actually paid&#148; to our NEOs as a group (excluding our PEOs) for such fiscal year, using the methodology described in Note 2
above: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" COLSPAN="12" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Non-PEO</FONT> NEO Average</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Summary Compensation Table &#150; Total Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(a</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,365,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,049,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">-&#8195;&#8202;Grant Date Fair Value of Option Awards Granted in Fiscal Year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(b</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">763,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">454,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">+&#8194;&#8201;&#8201;Fair Value at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> of
Outstanding and Unvested Stock Awards and Option Awards Granted in Fiscal Year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(c</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">315,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">+&#8194;&#8201;&#8201;Change in Fair Value of Outstanding and Unvested Stock Awards and Option
Awards Granted in Prior Fiscal Years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(d</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">($</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">287,121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">($</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">318,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">+&#8194;&#8201;&#8201;Fair Value at Vesting of Stock Awards and Option Awards Granted in Fiscal
Year that Vested During Fiscal Year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(e</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">+&#8194;&#8201;&#8201;Change in Fair Value as of Vesting Date of Stock Awards and Option Awards
Granted in Prior Fiscal Years for which Applicable Vesting Conditions were Satisfied During Fiscal Year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(f</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">($</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,224</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">($</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158,597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">-&#8195;&#8202;Fair Value as of Prior Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> of
Stock Awards and Option Awards Granted in Prior Fiscal Years that Failed to Meet Applicable Vesting Conditions During Fiscal Year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(g</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">=&#8194;&#8201;&#8201;Compensation Actually Paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">712,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stock option grant date fair values are calculated based on the Black-Scholes option pricing model as of date
of grant. The valuation assumptions used to calculate the fair values of the stock options held by our PEOs </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and other NEOs on average that vested during or were outstanding as of the end of each covered fiscal year materially differed from those valuation assumptions disclosed at the time of grant
primarily based on the differing option value assumptions: fiscal year 2021 <FONT STYLE="white-space:nowrap">year-end</FONT> calculations were based on an expected life range of 3.1 to 6.51, volatility of 77.8% to 81.2%, and risk-free rate of 1.0%
to 1.4%; fiscal year 2022 <FONT STYLE="white-space:nowrap">year-end</FONT> calculations were based on an expected life of 3.1 to 6.91, volatility of 77.8% to 88.6%, and risk-free rate of 3.9% to 4.2%. More tenured executives (Dr.&nbsp;Quinn,
Ms.&nbsp;Sloan and Mr.&nbsp;Hanley) had significant decreases in year-over-year stock option valuations while compensation of more recently hired executives (Mr.&nbsp;Goldberg, Mr.&nbsp;Kastenmayer and Mr.&nbsp;Alspaugh) had less dynamic changes.
Performance-based options used a different Monte Carlo valuation at fiscal year 2021 and fiscal year 2022 year-ends than the grant date valuation based on updated probability of achievement. Performance-based RSU award grant date fair values are
calculated using the stock price as of date of grant assuming target performance. The performance-based RSU awards held by Dr.&nbsp;Quinn, Ms.&nbsp;Sloan and Mr.&nbsp;Hanley that were outstanding as of the end of each covered fiscal year were deemed
to have a de minimis chance of approval and are included as unachieved. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cumulative total stockholder return (&#147;<B><I>TSR</I></B>&#148;) is calculated by dividing the sum of the
cumulative amount of dividends during the measurement period, assuming dividend reinvestment, and the difference between our stock price at the end of the applicable measurement period and the beginning of the measurement period (December 31, 2020)
by our stock price at the beginning of the measurement period. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The dollar amounts reported represent the amount of net income (loss) reflected in our audited financial
statements for each covered fiscal year. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Analysis of Information Presented in the Pay Versus Performance Table
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with Item 402(v) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> we are providing the following descriptions of the
relationships between information presented in the Pay Versus Performance table above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Compensation Actually Paid and Company TSR </U></I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g449732g11w06.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Compensation Actually Paid and Net Income </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following graph displays our compensation actually paid compared to our net income. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g449732g90m21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All information provided above under the <FONT STYLE="white-space:nowrap">&#147;Pay-Versus-Performance&#148;</FONT> heading
will not be deemed to be incorporated by reference into any of Aeglea&#146;s filings under the Securities Act or the Exchange Act whether made before or after the date hereof and irrespective of any general incorporation language in any such filing,
except to the extent Aeglea specifically incorporates such information by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx449732_12"></A>EQUITY COMPENSATION PLAN INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents information as of December&nbsp;31, 2022 with respect to compensation plans under which shares of our common stock may be issued.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Plan category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>securities</B><br><B>to&nbsp;be&nbsp;issued&nbsp;upon</B><br><B>exercise</B><br><B>of
outstanding</B><br><B>options,&nbsp;warrants</B><br><B>and rights (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT></B><br><B>exercise&nbsp;price</B><br><B>of outstanding</B><br><B>options, warrants</B><br><B>and
rights ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;securities</B><br><B>remaining&nbsp;available</B><br><B>for&nbsp;future</B><br><B>issuance under</B><br><B>equity
compensation</B><br><B>plans (excluding</B><br><B>securities&nbsp;reflected&nbsp;in</B><br><B>column (a)) (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(a)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,931,209&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,019,736&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,195,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">789,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top"> (3)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,127,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,808,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes our 2015 Plan and 2016 Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 1,216,647 shares that remain available for purchase under the 2016 Employee Stock Purchase Plan and
1,803,089 shares of common stock that remain available for grant under the 2016 Plan. There are no shares of common stock available for issuance under our 2015 Plan, but the plan continues to govern the terms of stock options granted thereunder. Any
shares of common stock that are subject to outstanding awards under the 2015 Plan that are issuable upon the exercise of stock options that expire or become unexercisable for any reason without having been exercised in full will generally be
available for future grant and issuance under our 2016 Plan. In addition, the 2016 Plan currently provides for an automatic increase in the number of shares reserved for issuance thereunder on January&nbsp;1 of each year for the remaining term of
the plan equal to (a) 4% of the number of issued and outstanding shares of common stock on December&nbsp;31 of the immediately preceding year, or (b)&nbsp;a lesser amount as approved by the board each year. Pursuant to this provision, the number of
shares reserved for grant and issuance under our 2016 Plan increased by 2,614,013 shares on January&nbsp;1, 2023. Also, the 2016 Employee Stock Purchase Plan provides for an automatic annual increase in the number of shares reserved for issuance
thereunder on January&nbsp;1 of each year for the remaining term of the plan equal to (a) 1% of the number of issued and outstanding shares of common stock on December&nbsp;31 of the immediately preceding year, or (2)&nbsp;a lesser amount as
approved by the board each year. Pursuant to this provision, the number of shares reserved for grant and issuance under our 2016 Employee Stock Purchase Plan increased by 653,503 shares on January&nbsp;1, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects shares of common stock that remain available for grant under the 2018 Inducement Plan.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx449732_13"></A>RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than the executive officer and director compensation arrangements discussed above under &#147;Executive Compensation&#148; and &#147;Proposal No.&nbsp;1
Election of Directors&#151;Director Compensation,&#148; respectively, below we describe the transactions to which we were a party since January&nbsp;1, 2021, in which the amount involved exceeded the lesser of $120,000 and 1% of the average of
Aeglea&#146;s total assets at <FONT STYLE="white-space:nowrap">year-end</FONT> for the prior two completed fiscal years and in which our directors, executive officers, former directors, former executive officers, director nominees and holders of
more than 5% of our common stock, or other persons as may be required to be disclosed pursuant to Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> had a direct or indirect material interest. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On May&nbsp;5, 2022, we entered into a placement agent agreement with JonesTrading Institutional Services LLC, as
placement agent, relating to a registered direct offering of an aggregate of 10,752,688 shares of our common stock at a public purchase price of $1.60 per share and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase up to
17,372,312 shares of our common stock at a public purchase price of $1.5999 per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant with an exercise price of $0.0001 per share. This registered direct offering closed on May&nbsp;9, 2022.
Pursuant to this offering, on the closing date: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Baker Brothers Life Sciences, L.P. and 667, L.P. (together, the &#147;<B><I>Baker Funds</I></B>&#148;)
purchased 6,283,777 and 747,473 <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase common stock, respectively, for an aggregate purchase price of approximately $11.2&nbsp;million; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Averill Master Fund, Ltd., an entity affiliated with Suvretta, purchased 6,250,000 <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase common stock for an aggregate purchase price of approximately $10.0&nbsp;million; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Entities affiliated with Nantahala purchased 3,301,785 <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants to purchase common stock for an aggregate purchase price of approximately $5.3&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On March&nbsp;16, 2021, we entered into a registration rights agreement (the &#147;<B><I>Registration Rights
Agreement</I></B>&#148;) with the Baker Funds, pursuant to which the Baker Funds are entitled to certain resale registration rights with respect to shares of our common stock held by the Baker Funds (the &#147;<B><I>Registrable
Securities</I></B>&#148;). Under the Registration Rights Agreement, following a request by the Baker Funds, we are obligated to file a resale registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> or other appropriate form,
covering Registrable Securities. Under the Registration Rights Agreement, the Baker Funds also have the right to up to two underwritten public offerings or block trades per calendar year, but no more than three underwritten public offerings and
eight block trades in total, to effect the sale or distribution of their Registrable Securities, subject to specified exceptions, conditions and limitations. The Registration Rights Agreement also includes customary indemnification obligations in
connection with registrations conducted pursuant to the Registration Rights Agreement. The rights of the Baker Funds under the Registration Rights Agreement terminate automatically upon the earlier to occur of the following events: (i)&nbsp;all
Registrable Securities covered by the Registration Rights Agreement have been sold pursuant to an effective registration statement; (ii)&nbsp;all Registrable Securities covered by the Registration Rights Agreement have been sold pursuant to Rule
144, or other similar rule; (iii)&nbsp;at any time after the Baker Funds are no longer our affiliate, all Registrable Securities covered by the Registration Rights Agreement may be resold by the Baker Funds without limitations as to volume or manner
of sale pursuant to Rule 144; or (iv)&nbsp;ten (10) years after the date of the Registration Rights Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Review, Approval or
Ratification of Transactions with Related Parties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted a written related person transactions policy. Under this policy,
our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of our common stock, and any members of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted
to enter into a material related person transaction with us without the review and approval of our audit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
committee, or a committee composed solely of independent directors in the event it is inappropriate for our audit committee to review such transaction due to a conflict of interest. The policy
provides that any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of our common stock or with any of their immediate family members or affiliates in
which the amount involved exceeds $120,000 will be presented to our audit committee for review, consideration and approval. In approving or rejecting any such proposal, our audit committee will consider the relevant facts and circumstances available
and deemed relevant to the audit committee, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of
the related person&#146;s interest in the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx449732_14"></A>REPORT OF THE AUDIT COMMITTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The information contained in the following report of Aeglea&#146;s audit committee is not considered to be &#147;soliciting material,&#148;
&#147;filed&#148; or incorporated by reference in any past or future filing by Aeglea under the Exchange Act or the Securities Act unless and only to the extent that Aeglea specifically incorporates it by reference. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit committee has reviewed and discussed with Aeglea&#146;s management and PricewaterhouseCoopers LLP the audited financial statements of Aeglea for the
year ended December&nbsp;31, 2022. The audit committee has also discussed with PricewaterhouseCoopers LLP the matters required to be discussed under applicable requirements of the Public Company Accounting Oversight Board and the Securities and
Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit committee has received and reviewed the written disclosures and the letter from PricewaterhouseCoopers LLP required by
applicable requirements of the Public Company Accounting Oversight Board regarding the independent accountant&#146;s communications with the audit committee concerning independence, and has discussed with PricewaterhouseCoopers LLP its independence
from Aeglea. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the review and discussions referred to above, the audit committee recommended to the board of directors that the audited financial
statements be included in Aeglea&#146;s annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2022 for filing with the Securities and Exchange Commission. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Submitted by the Audit Committee </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Hunter C. Smith, Chair </P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ivana
Magovcevic-Liebisch, Ph.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">V. Bryan Lawlis, Ph.D. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx449732_15"></A>ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Proposals to be Presented at Next Annual Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aeglea&#146;s Bylaws provide that, for stockholder nominations to the board or other proposals to be considered at an annual meeting, the stockholder must give
timely notice thereof in writing to the Corporate Secretary at Aeglea BioTherapeutics, Inc., 805 Las Cimas Parkway, Suite 100, Austin, Texas 78746, Attn: Corporate Secretary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be timely for the 2024 Annual Meeting, a stockholder&#146;s notice must be delivered to or mailed and received by our Corporate Secretary at our principal
executive offices not earlier than 5:00 p.m. Central Time on February&nbsp;22, 2024 and not later than 5:00 p.m. Central Time on March&nbsp;23, 2024. However, if the date of our 2024 Annual Meeting is advanced by more than 30 days before or delayed
by more than 60 days after the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the date of our 2023 Annual Meeting, then, for notice to the stockholder to be timely, it must be delivered to the Corporate Secretary at our principal
executive offices not earlier than the close of business on the 105th day prior to the then-proposed annual meeting date and not later than the close of business on the later of (1)&nbsp;the 75th day prior to such annual meeting date or (2)&nbsp;the
close of business on the 10th day following the day on which public announcement of the date of such meeting is first made by Aeglea. A stockholder&#146;s notice to the Corporate Secretary must set forth as to each matter the stockholder proposes to
bring before the annual meeting the information required by Aeglea&#146;s Bylaws. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholder proposals submitted pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14a-8</FONT> under the Exchange Act and intended to be presented at Aeglea&#146;s 2024 Annual Meeting must be received by Aeglea not later than December&nbsp;22, 2023 in order to be considered for inclusion in
Aeglea&#146;s proxy materials for the 2023 Annual Meeting. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delinquent Section&nbsp;16(a) Reports </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;16(a) of the Exchange Act requires our directors, executive officers and any persons who own more than 10% of our common stock, to file initial
reports of ownership and reports of changes in ownership with the SEC. Based solely on our review of the forms filed with the SEC and written representations from the directors and executive officers, we believe that all Section&nbsp;16(a) filing
requirements were timely met in the year ended December&nbsp;31, 2022, with the exception of (1)&nbsp;a Form 3 filing on behalf of Dr.&nbsp;Linda Neuman reporting her initial beneficial ownership interest information (filed on January&nbsp;27, 2023)
and (2)&nbsp;a Form 4 filing on behalf of Dr.&nbsp;Linda Neuman reporting her subsequent beneficial ownership interest information (filed on January&nbsp;27, 2023). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aeglea will mail without
charge, upon written request, a copy of Aeglea&#146;s annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2022, including the financial statements and list of exhibits, and any exhibit
specifically requested. Requests should be sent to: </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Aeglea BioTherapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>805 Las Cimas Parkway </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 100 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Austin, TX
78746 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Attn: Investor Relations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Delivery of Stockholder Communications</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
encourage you to help us conserve natural resources, as well as significantly reduce printing and mailing costs, by signing up to receive your stockholder communications electronically via <FONT STYLE="white-space:nowrap">e-mail.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With electronic delivery, you will be notified via <FONT STYLE="white-space:nowrap">e-mail</FONT> as soon as
future Annual Reports and proxy statements are available on the Internet, and you can submit your stockholder votes online. Electronic delivery can also eliminate duplicate mailings and reduce the amount of bulky paper documents you maintain in your
personal files. To sign up for electronic delivery: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registered Owner</I>&nbsp;(you hold our common stock in your own name through our transfer agent,
American Stock Transfer&nbsp;&amp; Trust Company,&nbsp;LLC, or you are in possession of stock certificates): visit <U>www.amstock.com</U> to enroll. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner</I>&nbsp;(your shares are held by a brokerage firm, a bank, a trustee or a nominee): If you hold shares beneficially, please follow the
instructions provided to you by your broker, bank, trustee or nominee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your electronic delivery enrollment will be effective until you cancel it.
Stockholders who are record owners of shares of our common stock may call American Stock Transfer&nbsp;&amp; Trust Company,&nbsp;LLC, our transfer agent, at <FONT STYLE="white-space:nowrap">(800)&nbsp;937-5449</FONT> or visit <U>www.amstock.com</U>
with questions about electronic delivery. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Householding&#148;&#151;Stockholders Sharing the Same Last Name and Address</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC has adopted rules that permit companies and intermediaries (such as brokers) to implement a delivery procedure called &#147;householding.&#148; Under
this procedure, multiple stockholders who reside at the same address may receive a single copy of our annual report and proxy materials, unless the affected stockholder has provided contrary instructions. This procedure reduces printing costs and
postage fees, and helps protect the environment as well. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This year, a number of brokers with account holders who are Aeglea stockholders will be
&#147;householding&#148; our annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and proxy materials. A set of annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and other proxy materials will be delivered to
multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that it will be &#147;householding&#148; communications to your address,
&#147;householding&#148; will continue until you are notified otherwise or until you revoke your consent. Stockholders may revoke their consent at any time by contacting American Stock Transfer&nbsp;&amp; Trust Company,&nbsp;LLC, either by calling
toll-free <FONT STYLE="white-space:nowrap">(800)&nbsp;937-5449,</FONT> or by writing to American Stock Transfer&nbsp;&amp; Trust Company,&nbsp;LLC, Operations Center, 6201 15th&nbsp;Avenue, Brooklyn, New York 11219. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon written or oral request, Aeglea will promptly deliver a proxy statement, proxy card, annual report on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and other proxy materials to any stockholder at a shared address to which a single copy of any of those documents was delivered. To receive a separate copy of the proxy statement, proxy card,
annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and other proxy materials, you may write or call Aeglea&#146;s Investor Relations department at 805 Las Cimas Parkway, Suite 100, Austin, Texas 78746, Attn: Investor Relations,
telephone number&nbsp;(512) <FONT STYLE="white-space:nowrap">942-2935.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any stockholders who share the same address and currently receive multiple
copies of Aeglea&#146;s annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and other proxy materials who wish to receive only one copy in the future can contact their bank, broker or other holder of record to request information
about householding or Aeglea&#146;s Investor Relations department at the address or telephone number listed above. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx449732_16">
</A>OTHER MATTERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The board of directors does not presently intend to bring any other business before the Annual Meeting and, so far as is known to
the board of directors, no matters are to be brought before the Annual Meeting except as specified in the Notice of Annual Meeting of Stockholders. As to any business that may arise and properly come before the Annual Meeting, however, it is
intended that proxies, in the form enclosed, will be voted in respect thereof in accordance with the judgment of the persons voting such proxies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="tx449732_17"></A>Annex A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTATED
CERTIFICATE OF INCORPORATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pursuant to
Section&nbsp;242 of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">the General Corporation Law of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">State of Delaware </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AEGLEA
BIOTHERAPEUTICS, INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the &#147;<B><I>Corporation</I></B>&#148;), does hereby certify as follows:<SUP
STYLE="font-size:75%; vertical-align:top">1</SUP> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FIRST</B>: Upon the filing and effectiveness (the &#147;<B><I>Effective
Time</I></B>&#148;) pursuant to the General Corporation Law of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;) of this Certificate of Amendment to the Restated Certificate of Incorporation of the Corporation, each
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of the Corporation&#146;s common stock, par value $0.0001 per share (&#147;<B><I>Common Stock</I></B>&#148;), issued and outstanding immediately prior to the Effective
Time shall automatically be combined into one (1)&nbsp;validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> share of Common Stock without any further action by the Corporation or the holder thereof, subject to the
treatment of fractional share interests as described below. No fractional shares shall be issued at the Effective Time and, in lieu thereof, the Corporation&#146;s transfer agent shall aggregate all fractional shares and sell them as soon as
practicable after the Effective Time at the then-prevailing prices on the open market, on behalf of those stockholders who would otherwise be entitled to receive a fractional share, and after the transfer agent&#146;s completion of such sale,
stockholders shall receive a cash payment (without interest or deduction) from the transfer agent in an amount equal to their respective pro&nbsp;rata shares of the total net proceeds of that sale and, where shares are held in certificated form,
upon the surrender of the stockholder&#146;s Old Certificates (as defined below). Each certificate that immediately prior to the Effective Time represented shares of Common Stock (&#147;<B><I>Old Certificates</I></B>&#148;) shall thereafter
represent that number of shares of Common Stock into which the shares of Common Stock represented by the Old Certificate shall have been combined, subject to the elimination of fractional share interests as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECOND</B>: The text currently under Section&nbsp;1 of &#147;ARTICLE IV: AUTHORIZED STOCK&#148; of the Restated Certificate of
Incorporation of the Corporation is amended and restated in its entirety to read as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>1. </B><B><U>Total
Authorized</U></B><B>. </B>The total number of shares of all classes of stock that the Corporation has authority to issue is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) shares, consisting of two classes: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) shares of Common Stock, $0.0001 par value per share (&#147;<B><I>Common Stock</I></B>&#148;), and Ten Million (10,000,000) shares of Preferred Stock, $0.0001 par value per
share (&#147;<B><I>Preferred Stock</I></B>&#148;).&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIRD</B>: This Certificate of Amendment shall become effective as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FOURTH</B>: This Certificate of Amendment was duly adopted in accordance with Section&nbsp;242 of the DGCL. The Board of Directors of the
Corporation duly adopted resolutions setting forth and declaring advisable this Certificate of Amendment and directed that the proposed amendments be considered by the stockholders of the Corporation. An annual meeting of stockholders was duly
called upon notice in accordance with Section&nbsp;222 of the DGCL and held on June &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, at which meeting the necessary number of shares were voted in favor of the proposed
amendments. The stockholders of the Corporation duly adopted this Certificate of Amendment. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP> The Certificate of Amendment that will be filed with the Secretary of State of the State of Delaware and
become effective will reflect the final ratio (ranging from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-10</FONT></FONT> to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-25)</FONT></FONT>
determined by the Board of Directors and a corresponding proportionate decrease in the number of authorized shares of Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be duly executed in its
corporate name as of the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AEGLEA BIOTHERAPEUTICS, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="tx449732_18"></A>Annex B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2016 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS AMENDED AND RESTATED EFFECTIVE &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. </B><B><U>PURPOSE</U></B>. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and
potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Company&#146;s future performance through the
grant of Awards. The Plan was originally effective as of the Original Effective Date, was amended and restated as of October&nbsp;8, 2018 (the &#147;<B><I>2018 Amendment and Restatement</I></B>&#148;) and is hereby amended and restated effective as
of the Stockholder Approval Date. Capitalized terms not defined elsewhere in the text are defined in Section&nbsp;28. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. <U>SHARES SUBJECT TO THE
PLAN</U><U>.</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1. </B><U>Number of Shares Available</U>. Subject to Sections 2.6 and 21 and any other applicable provisions
hereof, the total number of Shares reserved and available for grant and issuance pursuant to this Plan (the &#147;<B><I>Share Reserve</I></B>&#148;) is the sum of (a) 5,797,690 Shares, which is inclusive of Shares initially reserved under the Plan
as of the Original Effective Date and Shares added to the Share Reserve between the Original Effective Date and the Stockholder Approval Date as a result of (i)&nbsp;the 2018 Amendment and Restatement and (ii)&nbsp;the &#147;evergreen&#148;
provision in Section&nbsp;2.4 of the Plan, (b)&nbsp;an additional 5,000,000 Shares added to the Share Reserve as of the Stockholder Approval Date, and (c)&nbsp;the Prior Plan Returning Shares, less any Shares issued under the Plan on or prior to, or
subject to outstanding Awards as of, the Stockholder Approval Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2. </B><U>Lapsed, Returned Awards</U>. Shares subject to Awards,
and Shares issued under the Plan under any Award, will again be available for grant and issuance in connection with subsequent Awards under this Plan to the extent such Shares: (a)&nbsp;are subject to issuance upon exercise of an Option or SAR
granted under this Plan but which cease to be subject to the Option or SAR for any reason other than exercise of the Option or SAR; (b)&nbsp;are subject to Awards granted under this Plan that are forfeited or are repurchased by the Company at the
original issue price; (c)&nbsp;are subject to Awards granted under this Plan that otherwise terminate without such Shares being issued; or (d)&nbsp;are surrendered pursuant to an Exchange Program. To the extent an Award under the Plan is paid out in
cash or other property rather than Shares, such cash payment will not result in reducing the number of Shares available for issuance under the Plan. Shares used to pay the exercise price of an Award or withheld to satisfy the tax withholding
obligations related to an Award will become available for future grant or sale under the Plan. For the avoidance of doubt, Shares that otherwise become available for grant and issuance because of the provisions of this Section&nbsp;2.2 shall not
include Shares subject to Awards that initially became available because of the substitution clause in Section&nbsp;21.2 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3.
</B><U>Minimum Share Reserve</U>. At all times the Company shall reserve and keep available a sufficient number of Shares as shall be required to satisfy the requirements of all outstanding Awards granted under this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4. </B><U>Automatic Share Reserve Increase</U>. The number of Shares available for grant and issuance under the Plan shall be increased
on January&nbsp;1, of each of 2024 through 2033, by the lesser of (a)&nbsp;five percent (5%) of the number of Outstanding Shares on each December&nbsp;31 immediately prior to the date of increase or (b)&nbsp;such number of Shares determined by the
Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5. </B><U>Limitations</U>. No more than 17,400,000 Shares shall be issued pursuant to the exercise of ISOs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6. </B><U>Adjustment of Shares</U>. If the number of outstanding shares of Common Stock of the Company is changed by a stock dividend,
recapitalization, stock split, reverse stock split, subdivision, combination, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reclassification or similar change in the capital structure of the Company, without consideration, then (a)&nbsp;the number of Shares reserved for issuance and future grant under the Plan set
forth in Section&nbsp;2.1, including Shares reserved under <FONT STYLE="white-space:nowrap">sub-clauses</FONT> (a)-(c) of Section&nbsp;2.1, (b) the Exercise Prices of and number of Shares subject to outstanding Options and SARs, (c)&nbsp;the number
of Shares subject to other outstanding Awards, and (d)&nbsp;the maximum number of Shares that may be issued as ISOs set forth in Section&nbsp;2.5 shall be proportionately adjusted, subject to any required action by the Board or the stockholders of
the Company and in compliance with applicable securities laws; provided that fractions of a Share will not be issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.
</B><B><U>ELIGIBILITY</U></B>. ISOs may be granted only to Employees. All other Awards may be granted to Employees, Consultants, Directors and <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors; <U>provided</U> such Consultants,
Directors and <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors render bona fide services not in connection with the offer and sale of securities in a capital-raising transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. <U>ADMINISTRATION</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1.
</B><U>Committee Composition; Authority</U>. This Plan will be administered by the Committee or by the Board acting as the Committee. Subject to the general purposes, terms and conditions of this Plan, and to the direction of the Board, the
Committee will have full power to implement and carry out this Plan, except, however, the Board shall establish the terms for the grant of an Award to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors. The Committee will have the
authority to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) construe and interpret this Plan, any Award Agreement and any other agreement or document executed pursuant to this
Plan; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) prescribe, amend and rescind rules and regulations relating to this Plan or any Award; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) select persons to receive Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) determine the form and terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and
conditions include, but are not limited to, the exercise price, the time or times when Awards may vest and be exercised (which may be based on performance criteria) or settled, any vesting acceleration or waiver of forfeiture restrictions, the
method to satisfy tax withholding obligations or any other tax liability legally due and any restriction or limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Committee will determine; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) determine the number of Shares or other consideration subject to Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) determine the Fair Market Value in good faith and interpret the applicable provisions of this Plan and the definition of Fair Market Value
in connection with circumstances that impact the Fair Market Value, if necessary; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) determine whether Awards will be granted singly, in
combination with, in tandem with, in replacement of, or as alternatives to, other Awards under this Plan or any other incentive or compensation plan of the Company or any Parent, Subsidiary or Affiliate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) grant waivers of Plan or Award conditions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) determine the vesting, exercisability and payment of Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) correct any defect, supply any omission or reconcile any inconsistency in this Plan, any Award or any Award Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) determine whether an Award has been earned; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) determine the terms and conditions of any, and to institute any Exchange Program; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) reduce or waive any criteria with respect to Performance Factors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) adjust performance goals or Performance Factors as the Committee deems necessary or appropriate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) adopt rules and/or procedures (including the adoption of any subplan under this Plan) relating to the operation and administration of the
Plan to accommodate requirements of local law and procedures outside of the United States; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) make all other determinations necessary or
advisable for the administration of this Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) delegate any of the foregoing to a subcommittee consisting of one or more executive
officers pursuant to a specific delegation as permitted by applicable law, including Sections 152 and 157 of the Delaware General Corporation Law, as provided in Section&nbsp;4.3; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) to exercise discretion with respect to Performance Awards, including, without limitation, increasing, reducing or eliminating the amount
to be paid to Participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2. </B><U>Committee Interpretation and Discretion</U>. Any determination made by the Committee with
respect to any Award shall be made in its sole discretion at the time of grant of the Award or, unless in contravention of any express term of the Plan or Award, at any later time, and such determination shall be final and binding on the Company and
all persons having an interest in any Award under the Plan. Any dispute regarding the interpretation of the Plan or any Award Agreement shall be submitted by the Participant or Company to the Committee for review. The resolution of such a dispute by
the Committee shall be final and binding on the Company and the Participant. The Committee may delegate to one or more executive officers the authority to review and resolve disputes with respect to Awards held by Participants who are not Insiders,
and such resolution shall be final and binding on the Company and the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3. </B><U>Delegation to Other Person or Body</U>.
The Board or any Committee may delegate to one or more persons or bodies the authority to do one or more of the following to the extent permitted by applicable law: (i)&nbsp;designate recipients, other than executive officers, of Awards, provided
that no person or body may be delegated authority to grant an Award to themselves; (ii)&nbsp;determine the number of Shares subject to such Awards; and (iii)&nbsp;determine the terms of such Awards; provided, however, that the Board or Committee
action regarding such delegation will fix the terms of such delegation in accordance with applicable law, including without limitation Sections 152 and 157 of the Delaware General Corporation Law. Unless provided otherwise in the Board or Committee
action regarding such delegation, each Award granted pursuant to this section will be granted on the applicable form of Award Agreement most recently approved for use by the Board or the Committee, with any modifications necessary to incorporate or
reflect the terms of such Award. Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to any person or body (who is not a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director or that is not
comprised solely of <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors, respectively) the authority to determine the Fair Market Value of the Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4. </B><U>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> Compliance</U>. The Committee administering the Plan in accordance with the
requirements of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> shall consist of at least two individuals, each of whom qualifies as a <FONT STYLE="white-space:nowrap">Non-</FONT> Employee Director under Rule
<FONT STYLE="white-space:nowrap">16b-3.</FONT> Awards granted to Participants who are subject to Section&nbsp;16 of the Exchange Act must be approved by two or more <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> directors&#148; (as
defined in the regulations promulgated under Section&nbsp;16 of the Exchange Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5. </B><U>Documentation</U>. The Award Agreement
for a given Award, the Plan and any other documents may be delivered to, and accepted by, a Participant or any other person in any manner (including electronic distribution or posting) that meets applicable legal requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.6. </B><U>Foreign Award Recipients</U>. Notwithstanding any provision of the Plan to
the contrary, in order to comply with the laws in other countries in which the Company and its Subsidiaries and Affiliates operate or have employees or other individuals eligible for Awards, the Committee, in its sole discretion, shall have the
power and authority to: (a)&nbsp;determine which Subsidiaries and Affiliates shall be covered by the Plan; (b)&nbsp;determine which individuals outside the United States are eligible to participate in the Plan; (c)&nbsp;modify the terms and
conditions of any Award granted to individuals outside the United States to comply with applicable foreign laws; (d)&nbsp;establish subplans and modify exercise procedures and other terms and procedures, to the extent the Committee determines such
actions to be necessary or advisable (and such subplans and/or modifications shall be attached to this Plan as appendices); provided, however, that no such subplans and/or modifications shall increase the share limitations contained in
Section&nbsp;2.1 hereof; and (e)&nbsp;take any action, before or after an Award is made, that the Committee determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals.
Notwithstanding the foregoing, the Committee may not take any actions hereunder, and no Awards shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United
States governing statute or law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. </B><B><U>OPTIONS</U></B>. An Option is the right but not the obligation to purchase a Share, subject to certain
conditions, if applicable. The Committee may grant Options to eligible Employees, Consultants and Directors and will determine whether such Options will be Incentive Stock Options within the meaning of the Code (&#147;<B><I>ISOs</I></B>&#148;) or
Nonqualified Stock Options (&#147;<B><I>NSOs</I></B>&#148;), the number of Shares subject to the Option, the Exercise Price of the Option, the period during which the Option may vest and be exercised, and all other terms and conditions of the
Option, subject to the following terms of this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1. </B><U>Option Grant</U>. Each Option granted under this Plan will
identify the Option as an ISO or an NSO. An Option may be, but need not be, awarded upon satisfaction of such Performance Factors during any Performance Period as are set out in advance in the Participant&#146;s individual Award Agreement. If the
Option is being earned upon the satisfaction of Performance Factors, then the Committee will: (a)&nbsp;determine the nature, length and starting date of any Performance Period for each Option; and (b)&nbsp;select from among the Performance Factors
to be used to measure the performance, if any. Performance Periods may overlap and Participants may participate simultaneously with respect to Options that are subject to different performance goals and other criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2. </B><U>Date of Grant</U>. The date of grant of an Option will be the date on which the Committee makes the determination to grant such
Option, or a specified future date. The Award Agreement will be delivered to the Participant within a reasonable time after the granting of the Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3. </B><U>Exercise Period</U>. Options may be vested and exercisable within the times or upon the conditions as set forth in the Award
Agreement governing such Option; <U>provided</U>, <U>however</U>, that no Option will be exercisable after the expiration of ten (10)&nbsp;years from the date the Option is granted; and <U>provided further</U> that no ISO granted to a person who, at
the time the ISO is granted, directly or by attribution owns more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or of any Parent or Subsidiary (&#147;<B><I>Ten Percent Stockholder</I></B>&#148;)
will be exercisable after the expiration of five (5)&nbsp;years from the date the ISO is granted. The Committee also may provide for Options to become exercisable at one time or from time to time, periodically or otherwise, in such number of Shares
or percentage of Shares as the Committee determines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4. </B><U>Exercise Price</U>. The Exercise Price of an Option will be
determined by the Committee when the Option is granted; provided that: (a)&nbsp;the Exercise Price of an Option will be not less than one hundred percent (100%) of the Fair Market Value of the Shares on the date of grant and (b)&nbsp;the Exercise
Price of any ISO granted to a Ten Percent Stockholder will not be less than one hundred ten percent (110%) of the Fair Market Value of the Shares on the date of grant. Payment for the Shares purchased may be made in accordance with Section&nbsp;11
and the Award Agreement and in accordance with any procedures established by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5. </B><U>Method of Exercise</U>. Any
Option granted hereunder will be vested and exercisable according to the terms of the Plan and at such times and under such conditions as determined by the Committee and set forth in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Award Agreement. An Option may not be exercised for a fraction of a Share. An Option will be deemed exercised when the Company receives: (a)&nbsp;notice of exercise (in such form as the
Committee may specify from time to time) from the person entitled to exercise the Option, and (b)&nbsp;full payment for the Shares with respect to which the Option is exercised (together with applicable withholding taxes). Full payment may consist
of any consideration and method of payment authorized by the Committee and permitted by the Award Agreement and the Plan. Shares issued upon exercise of an Option will be issued in the name of the Participant. Until the Shares are issued (as
evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder will exist with respect to the Shares, notwithstanding
the exercise of the Option. The Company will issue (or cause to be issued) such Shares promptly after the Option is exercised. No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are
issued, except as provided in Section&nbsp;2.6 of the Plan. Exercising an Option in any manner will decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under the Option, by the number of Shares as to which
the Option is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6. </B><U>Termination of Service</U>. If the Participant&#146;s Service terminates for any reason except
for Cause or the Participant&#146;s death or Disability, then the Participant may exercise such Participant&#146;s Options only to the extent that such Options would have been exercisable by the Participant on the date Participant&#146;s Service
terminates no later than three (3)&nbsp;months after the date Participant&#146;s Service terminates (or such shorter or longer time period as may be determined by the Committee, with any exercise beyond three (3) months after the date
Participant&#146;s employment terminates deemed to be the exercise of an NSO), but in any event no later than the expiration date of the Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Death</U>. If the Participant&#146;s Service terminates because of the Participant&#146;s death (or the Participant dies within three
(3)&nbsp;months after Participant&#146;s Service terminates other than for Cause or because of the Participant&#146;s Disability), then the Participant&#146;s Options may be exercised only to the extent that such Options would have been exercisable
by the Participant on the date Participant&#146;s Service terminates and must be exercised by the Participant&#146;s legal representative, or authorized assignee, no later than twelve (12)&nbsp;months after the date Participant&#146;s Service
terminates (or such shorter time period not less than six (6)&nbsp;months or longer time period as may be determined by the Committee), but in any event no later than the expiration date of the Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Disability</U>. If the Participant&#146;s Service terminates because of the Participant&#146;s Disability, then the Participant&#146;s
Options may be exercised only to the extent that such Options would have been exercisable by the Participant on the date Participant&#146;s Service terminates and must be exercised by the Participant (or the Participant&#146;s legal representative
or authorized assignee) no later than twelve (12)&nbsp;months after the date Participant&#146;s Service terminates (with any exercise beyond (a)&nbsp;three (3) months after the date Participant&#146;s employment terminates when the termination of
Service is for a Disability that is not a &#147;permanent and total disability&#148; as defined in Section&nbsp;22(e)(3) of the Code, or (b)&nbsp;twelve (12) months after the date Participant&#146;s employment terminates when the termination of
Service is for a Disability that is a &#147;permanent and total disability&#148; as defined in Section&nbsp;22(e)(3) of the Code, deemed to be exercise of an NSO), but in any event no later than the expiration date of the Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Cause</U>. If the Participant is terminated for Cause, then Participant&#146;s Options shall expire on such Participant&#146;s date of
termination of Service, or at such later time and on such conditions as are determined by the Committee, but in any no event later than the expiration date of the Options. Unless otherwise provided in the Award Agreement, Cause shall have the
meaning set forth in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7. </B><U>Limitations on Exercise</U>. The Committee may specify a minimum number of Shares that may
be purchased on any exercise of an Option, provided that such minimum number will not prevent any Participant from exercising the Option for the full number of Shares for which it is then exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.8. </B><U>Limitations on ISOs</U>. With respect to Awards granted as ISOs, to the extent that the aggregate Fair Market Value of the
Shares with respect to which such ISOs are exercisable for the first time by the Participant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
during any calendar year (under all plans of the Company and any Parent or Subsidiary) exceeds one hundred thousand dollars ($100,000), such Options will be treated as NSOs. For purposes of this
Section&nbsp;5.8, ISOs will be taken into account in the order in which they were granted. The Fair Market Value of the Shares will be determined as of the time the Option with respect to such Shares is granted. In the event that the Code or the
regulations promulgated thereunder are amended to provide for a different limit on the Fair Market Value of Shares permitted to be subject to ISOs, such different limit will be automatically incorporated herein and will apply to any Options granted
after the effective date of such amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.9. </B><U>Modification, Extension or Renewal</U>. The Committee may modify, extend or
renew outstanding Options and authorize the grant of new Options in substitution therefor, provided that any such action may not, without the written consent of a Participant, impair any of such Participant&#146;s rights under any Option previously
granted. Any outstanding ISO that is modified, extended, renewed or otherwise altered will be treated in accordance with Section&nbsp;424(h) of the Code. Subject to Section&nbsp;18 of this Plan, by written notice to affected Participants, the
Committee may reduce the Exercise Price of outstanding Options without the consent of such Participants; <U>provided</U>, <U>however</U>, that the Exercise Price may not be reduced below the Fair Market Value on the date the action is taken to
reduce the Exercise Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.10. </B><U>No Disqualification</U>. Notwithstanding any other provision in this Plan, no term of this
Plan relating to ISOs will be interpreted, amended or altered, nor will any discretion or authority granted under this Plan be exercised, so as to disqualify this Plan under Section&nbsp;422 of the Code or, without the consent of the Participant
affected, to disqualify any ISO under Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. </B><B><U>RESTRICTED STOCK AWARDS</U></B>. A Restricted Stock Award is an offer
by the Company to sell to an eligible Employee, Consultant, or Director of Shares that are subject to restrictions (&#147;<B><I>Restricted Stock</I></B>&#148;). The Committee will determine to whom an offer will be made, the number of Shares the
Participant may purchase, the Purchase Price, the restrictions under which the Shares will be subject and all other terms and conditions of the Restricted Stock Award, subject to the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1. </B><U>Restricted Stock Purchase Agreement</U>. All purchases under a Restricted Stock Award will be evidenced by an Award Agreement.
Except as may otherwise be provided in an Award Agreement, a Participant accepts a Restricted Stock Award by signing and delivering to the Company an Award Agreement with full payment of the Purchase Price, within thirty (30)&nbsp;days from the date
the Award Agreement was delivered to the Participant. If the Participant does not accept such Award within thirty (30)&nbsp;days, then the offer of such Restricted Stock Award will terminate, unless the Committee determines otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2. </B><U>Purchase Price</U>. The Purchase Price for a Restricted Stock Award will be determined by the Committee and may be less than
Fair Market Value on the date the Restricted Stock Award is granted. Payment of the Purchase Price must be made in accordance with Section&nbsp;11 of the Plan, and the Award Agreement and in accordance with any procedures established by the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3. </B><U>Terms of Restricted Stock Awards</U>. Restricted Stock Awards will be subject to such restrictions as the Committee may
impose or are required by law. These restrictions may be based on completion of a specified number of years of service with the Company or upon completion of Performance Factors, if any, during any Performance Period as set out in advance in the
Participant&#146;s Award Agreement. Prior to the grant of a Restricted Stock Award, the Committee shall: (a)&nbsp;determine the nature, length and starting date of any Performance Period for the Restricted Stock Award; (b)&nbsp;select from among the
Performance Factors to be used to measure performance goals, if any; and (c)&nbsp;determine the number of Shares that may be awarded to the Participant. Performance Periods may overlap and a Participant may participate simultaneously with respect to
Restricted Stock Awards that are subject to different Performance Periods and having different performance goals and other criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4. </B><U>Termination of Service</U>. Except as may be set forth in the Participant&#146;s Award Agreement, vesting ceases on such date
Participant&#146;s Service terminates (unless determined otherwise by the Committee). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. </B><B><U>STOCK BONUS AWARDS</U></B>. A Stock Bonus Award is an award to an eligible Employee,
Consultant, or Director of Shares for Services to be rendered or for past Services already rendered to the Company or any Parent, Subsidiary or Affiliate. All Stock Bonus Awards shall be made pursuant to an Award Agreement. No payment from the
Participant will be required for Shares awarded pursuant to a Stock Bonus Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1. </B><U>Terms of Stock Bonus Awards.</U> The
Committee will determine the number of Shares to be awarded to the Participant under a Stock Bonus Award and any restrictions thereon. These restrictions may be based upon completion of a specified number of years of service with the Company or upon
satisfaction of performance goals based on Performance Factors during any Performance Period as set out in advance in the Participant&#146;s Stock Bonus Agreement. Prior to the grant of any Stock Bonus Award the Committee shall: (a)&nbsp;determine
the nature, length and starting date of any Performance Period for the Stock Bonus Award; (b)&nbsp;select from among the Performance Factors to be used to measure performance goals; and (c)&nbsp;determine the number of Shares that may be awarded to
the Participant. Performance Periods may overlap and a Participant may participate simultaneously with respect to Stock Bonus Awards that are subject to different Performance Periods and different performance goals and other criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2. </B><U>Form of Payment to Participant</U>. Payment may be made in the form of cash, whole Shares, or a combination thereof, based on
the Fair Market Value of the Shares earned under a Stock Bonus Award on the date of payment, as determined in the sole discretion of the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3. </B><U>Termination of Service</U>. Except as may be set forth in the Participant&#146;s Award Agreement, vesting ceases on such date
Participant&#146;s Service terminates (unless determined otherwise by the Committee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. </B><B><U>STOCK APPRECIATION RIGHTS</U></B>. A Stock
Appreciation Right (&#147;<B><I>SAR</I></B>&#148;) is an award to an eligible Employee, Consultant, or Director that may be settled in cash, or Shares (which may consist of Restricted Stock), having a value equal to (a)&nbsp;the difference between
the Fair Market Value on the date of exercise over the Exercise Price multiplied by (b)&nbsp;the number of Shares with respect to which the SAR is being settled (subject to any maximum number of Shares that may be issuable as specified in an Award
Agreement). All SARs shall be made pursuant to an Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1. </B><U>Terms of SARs</U>. The Committee will determine the
terms of each SAR including, without limitation: (a)&nbsp;the number of Shares subject to the SAR; (b)&nbsp;the Exercise Price and the time or times during which the SAR may be settled; (c)&nbsp;the consideration to be distributed on settlement of
the SAR; and (d)&nbsp;the effect of the Participant&#146;s termination of Service on each SAR. The Exercise Price of the SAR will be determined by the Committee when the SAR is granted, and may not be less than Fair Market Value. A SAR may be
awarded upon satisfaction of Performance Factors, if any, during any Performance Period as are set out in advance in the Participant&#146;s individual Award Agreement. If the SAR is being earned upon the satisfaction of Performance Factors, then the
Committee will: (x)&nbsp;determine the nature, length and starting date of any Performance Period for each SAR; and (y)&nbsp;select from among the Performance Factors to be used to measure the performance, if any. Performance Periods may overlap and
Participants may participate simultaneously with respect to SARs that are subject to different Performance Factors and other criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2. </B><U>Exercise Period and Expiration Date</U>. A SAR will be exercisable within the times or upon the occurrence of events determined
by the Committee and set forth in the Award Agreement governing such SAR. The SAR Agreement shall set forth the expiration date; provided that no SAR will be exercisable after the expiration of ten (10)&nbsp;years from the date the SAR is granted.
The Committee may also provide for SARs to become exercisable at one time or from time to time, periodically or otherwise (including, without limitation, upon the attainment during a Performance Period of performance goals based on Performance
Factors), in such number of Shares or percentage of the Shares subject to the SAR as the Committee determines. Except as may be set forth in the Participant&#146;s Award Agreement, vesting ceases on the date Participant&#146;s Service terminates
(unless determined otherwise by the Committee). Notwithstanding the foregoing, the rules of Section&nbsp;5.6 also will apply to SARs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3. </B><U>Form of Settlement</U>. Upon exercise of a SAR, a Participant will be
entitled to receive payment from the Company in an amount determined by multiplying (a)&nbsp;the difference between the Fair Market Value of a Share on the date of exercise over the Exercise Price; times (b)&nbsp;the number of Shares with respect to
which the SAR is exercised. At the discretion of the Committee, the payment from the Company for the SAR exercise may be in cash, in Shares of equivalent value, or in some combination thereof. The portion of a SAR being settled may be paid currently
or on a deferred basis with such interest or dividend equivalent, if any, as the Committee determines, provided that the terms of the SAR and any deferral satisfy the requirements of Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4. </B><U>Termination of Service</U>. Except as may be set forth in the Participant&#146;s Award Agreement, vesting ceases on such date
Participant&#146;s Service terminates (unless determined otherwise by the Committee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. </B><B><U>RESTRICTED STOCK UNITS</U></B>. A Restricted Stock
Unit (&#147;<B><I>RSU</I></B>&#148;) is an award to an eligible Employee, Consultant, or Director covering a number of Shares that may be settled in cash, or by issuance of those Shares (which may consist of Restricted Stock). All RSUs shall be made
pursuant to an Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1. </B><U>Terms of RSUs</U>. The Committee will determine the terms of an RSU including, without
limitation: (a)&nbsp;the number of Shares subject to the RSU; (b)&nbsp;the time or times during which the RSU may be settled; (c)&nbsp;the consideration to be distributed on settlement; and (d)&nbsp;the effect of the Participant&#146;s termination
of Service on each RSU; provided that no RSU shall have a term longer than ten (10)&nbsp;years. An RSU may be awarded upon satisfaction of such performance goals based on Performance Factors during any Performance Period as are set out in advance in
the Participant&#146;s Award Agreement. If the RSU is being earned upon satisfaction of Performance Factors, then the Committee will: (x)&nbsp;determine the nature, length and starting date of any Performance Period for the RSU; (y)&nbsp;select from
among the Performance Factors to be used to measure the performance, if any; and (z)&nbsp;determine the number of Shares deemed subject to the RSU. Performance Periods may overlap and participants may participate simultaneously with respect to RSUs
that are subject to different Performance Periods and different performance goals and other criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2. </B><U>Form and Timing of
Settlement</U>. Payment of earned RSUs shall be made as soon as practicable after the date(s) determined by the Committee and set forth in the Award Agreement. The Committee, in its sole discretion, may settle earned RSUs in cash, Shares, or a
combination of both. The Committee may also permit a Participant to defer payment under a RSU to a date or dates after the RSU is earned provided that the terms of the RSU and any deferral satisfy the requirements of Section&nbsp;409A of the Code.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3. </B><U>Termination of Service</U>. Except as may be set forth in the Participant&#146;s Award Agreement, vesting ceases on such
date Participant&#146;s Service terminates (unless determined otherwise by the Committee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. </B><B><U>PERFORMANCE AWARDS</U></B>. A Performance
Award is an award to an eligible Employee, Consultant, or Director of the Company or any Parent, Subsidiary or Affiliate of a cash bonus or an award of Performance Shares denominated in Shares that may be settled in cash, or by issuance of those
Shares (which may consist of Restricted Stock). Grants of Performance Awards shall be made pursuant to an Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1.
</B><U>Types of Performance Awards</U>. Performance Awards shall include Performance Shares, Performance Units, and cash-based Awards as set forth in Sections 10.1(a), 10.1(b), and 10.1(c) below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Performance Shares</U>. The Committee may grant Awards of Performance Shares, designate the Participants to whom Performance Shares are
to be awarded and determine the number of Performance Shares and the terms and conditions of each such Award. Performance Shares shall consist of a unit valued by reference to a designated number of shares of Common Stock, the value of which may be
paid to the Participant by delivery of shares of Common Stock or, if set forth in the instrument evidencing the Award, of such property as the Committee shall determine, including, without limitation, cash, shares of Common Stock, other property, or
any combination thereof, upon the attainment of performance goals, as established by the Committee, and other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terms and conditions specified by the Committee. The amount to be paid under an Award of Performance Shares may be adjusted on the basis of such further consideration as the Committee shall
determine in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance Units</U>. The Committee may grant Awards of Performance Units, designate the
Participants to whom Performance Units are to be awarded and determine the number of Performance Units and the terms and conditions of each such Award. Performance Units shall consist of a unit valued by reference to a designated amount of property
other than shares of Common Stock, which value may be paid to the Participant by delivery of such property as the Committee shall determine, including, without limitation, cash, shares of Common Stock, other property, or any combination thereof,
upon the attainment of performance goals, as established by the Committee, and other terms and conditions specified by the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Cash-Settled Performance Awards</U>. The Committee may also grant cash-settled Performance Awards to Participants under the terms of this Plan. Such awards will be based on the attainment of performance goals using the Performance Criteria within
this Plan that are established by the Committee for the relevant performance period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2. </B><U>Terms of Performance Awards</U>. The
Committee will determine, and each Award Agreement shall set forth, the terms of each Performance Award including, without limitation: (a)&nbsp;the amount of any cash bonus, (b)&nbsp;the number of Shares deemed subject to an award of Performance
Shares; (c)&nbsp;the Performance Factors and Performance Period that shall determine the time and extent to which each award of Performance Shares shall be settled; (d)&nbsp;the consideration to be distributed on settlement, and (e)&nbsp;the effect
of the Participant&#146;s termination of Service on each Performance Award. In establishing Performance Factors and the Performance Period the Committee will: (x)&nbsp;determine the nature, length and starting date of any Performance Period;
(y)&nbsp;select from among the Performance Factors to be used; and (z)&nbsp;determine the number of Shares deemed subject to the award of Performance Shares. Prior to settlement the Committee shall determine the extent to which Performance Awards
have been earned. Performance Periods may overlap and Participants may participate simultaneously with respect to Performance Awards that are subject to different Performance Periods and different performance goals and other criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3. </B><U>Termination of Service</U>. Except as may be set forth in the Participant&#146;s Award Agreement, vesting ceases on the date
Participant&#146;s Service terminates (unless determined otherwise by the Committee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. </B><B><U>PAYMENT FOR SHARE PURCHASES</U></B>. Payment from
a Participant for Shares purchased pursuant to this Plan may be made in cash or by check or, where approved for the Participant by the Committee and where permitted by law (and to the extent not otherwise set forth in the applicable Award
Agreement): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) by cancellation of indebtedness of the Company to the Participant; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) by surrender of shares of the Company&#146;s common stock by the Participant that have a Fair Market Value on the date of surrender equal
to the aggregate exercise price of the Shares as to which said Award will be exercised or settled; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) by waiver of compensation due or
accrued to the Participant for services rendered or to be rendered to the Company or a Parent or Subsidiary of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) by
consideration received by the Company pursuant to a broker-assisted or other form of cashless exercise program implemented by the Company in connection with the Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) by any combination of the foregoing; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) by any other method of payment as is permitted by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. </B><B><U>GRANTS TO <FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTORS</U></B>. <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors are eligible to receive any type of Award offered under this Plan except ISOs. Awards pursuant to this Section&nbsp;12 may be automatically made </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to policy adopted by the Board, or made from time to time as determined in the discretion of the Board. The aggregate value of all compensation granted or paid, as applicable, to any
individual for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director with respect to any fiscal year, including Awards granted and cash fees paid by the Company to such <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director for his or her service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, will not exceed (i) $750,000 in total value or (ii)&nbsp;in the event such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director is first
appointed or elected to the Board during such fiscal year, $1,000,000 in total value, in each case calculating the value of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.1. </B><U>Eligibility</U>. Awards pursuant to this Section&nbsp;12 shall be granted only to
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors. A <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director who is elected or <FONT STYLE="white-space:nowrap">re-elected</FONT> as a member of the Board will be eligible to receive
an Award under this Section&nbsp;12. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.2. </B><U>Vesting, Exercisability and Settlement</U>. Except as set forth in Section&nbsp;21,
Awards shall vest, become exercisable and be settled as determined by the Board. With respect to Options and SARs, the exercise price granted to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors shall not be less than the Fair Market
Value of the Shares at the time that such Option or SAR is granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.3. </B><U>Election to receive Awards in Lieu of Cash</U>. A <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director may elect to receive his or her annual retainer payments and/or meeting fees from the Company in the form of cash or Awards or a combination thereof, as determined by the Committee. Such Awards
shall be issued under the Plan. An election under this Section&nbsp;12.3 shall be filed with the Company on the form prescribed by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.
<U>WITHHOLDING TAXES</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.1. </B><U>Withholding Generally</U>. Whenever Shares are to be issued in satisfaction of Awards
granted under this Plan or a tax event occurs, the Company may require the Participant to remit to the Company, or to the Parent, Subsidiary or applicable Affiliate employing the Participant, an amount sufficient to satisfy applicable U.S. federal,
state, local and international withholding tax requirements or any other tax or social insurance liability legally due from the Participant prior to the delivery of Shares pursuant to exercise or settlement of any Award. Whenever payments in
satisfaction of Awards granted under this Plan are to be made in cash, such payment will be net of an amount sufficient to satisfy applicable U.S. federal, state, local and international withholding tax or social insurance requirements or any other
tax liability legally due from the Participant. The Fair Market Value of the Shares will be determined as of the date that the taxes are required to be withheld and such Shares shall be valued based on the value of the actual trade or, if there is
none, the Fair Market Value of the Shares as of the previous trading day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.2. </B><U>Stock Withholding</U>. The Committee, or its
delegate(s), as permitted by applicable law, in its sole discretion and pursuant to such procedures as it may specify from time to time and to limitations of local law, may require or permit a Participant to satisfy such tax withholding obligation
or any other tax liability legally due from the Participant, in whole or in part by (without limitation)&nbsp;(a) paying cash, (b)&nbsp;electing to have the Company withhold otherwise deliverable cash or Shares, (c)&nbsp;delivering to the Company
already-owned shares of the Company&#146;s common stock or (d)&nbsp;withholding from proceeds of the sale of otherwise deliverable Shares acquired pursuant to an Award either through a voluntary sale or through a mandatory sale arranged by the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. <U>TRANSFERABILITY</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.1. </B><U>Transfer Generally</U>. Unless determined otherwise by the Committee or pursuant to Section&nbsp;14.2, an Award may not be
sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution. If the Committee makes an Award transferable, including, without limitation, by instrument to an inter
vivos or testamentary trust in which the Awards are to be passed to beneficiaries upon the death of the trustor (settlor) or by gift or by domestic relations order to a Permitted Transferee, such Award will contain such additional terms and
conditions as the Committee deems appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
All Awards shall be exercisable: (a)&nbsp;during the Participant&#146;s lifetime only by (i)&nbsp;the Participant, or (ii)&nbsp;the Participant&#146;s guardian or legal representative;
(b)&nbsp;after the Participant&#146;s death, by the legal representative of the Participant&#146;s heirs or legatees; and (c)&nbsp;in the case of all awards except ISOs, by a Permitted Transferee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.2. </B><U>Award Transfer Program</U>. Notwithstanding any contrary provision of the Plan, the Committee shall have all discretion and
authority to determine and implement the terms and conditions of any Award Transfer Program instituted pursuant to this Section&nbsp;14.2 and shall have the authority to amend the terms of any Award participating, or otherwise eligible to
participate in, the Award Transfer Program, including (but not limited to) the authority to (a)&nbsp;amend (including to extend) the expiration date, post-termination exercise period and/or forfeiture conditions of any such Award, (b)&nbsp;amend or
remove any provisions of the Award relating to the Award holder&#146;s continued Service to the Company or its Parent, Subsidiary, or Affiliate, (c)&nbsp;amend the permissible payment methods with respect to the exercise or purchase of any such
Award, (d)&nbsp;amend the adjustments to be implemented in the event of changes in the capitalization and other similar events with respect to such Award, and (e)&nbsp;make such other changes to the terms of such Award as the Committee deems
necessary or appropriate in its sole discretion. Notwithstanding anything to the contrary in the Plan, in no event will the Committee have the right to determine and implement the terms and conditions of any Award Transfer Program without
stockholder approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. <U>PRIVILEGES OF STOCK OWNERSHIP; RESTRICTIONS ON SHARES</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.1. </B><U>Voting and Dividends</U>. No Participant will have any of the rights of a stockholder with respect to any Shares until the
Shares are issued to the Participant, except for any dividend equivalent rights permitted by an applicable Award Agreement (&#147;<B><I>Dividend Equivalent Rights</I></B>&#148;). After Shares are issued to the Participant, the Participant will be a
stockholder and have all the rights of a stockholder with respect to such Shares, including the right to vote and receive all dividends or other distributions made or paid with respect to such Shares; <U>provided</U>, that if such Shares are
Restricted Stock, then any new, additional or different securities the Participant may become entitled to receive with respect to such Shares by virtue of a stock dividend, stock split or any other change in the corporate or capital structure of the
Company will be subject to the same restrictions as the Restricted Stock; <U>provided</U>, <U>further</U>, that the Participant will have no right to retain such stock dividends or stock distributions with respect to Shares that are repurchased at
the Participant&#146;s Purchase Price or Exercise Price, as the case may be, pursuant to Section&nbsp;15.2. However, the Committee, in its discretion, may provide in the Award Agreement evidencing any Award that the Participant shall be entitled to
Dividend Equivalent Rights with respect to the payment of cash dividends on Shares underlying an Award during the period beginning on the date the Award is granted and ending, with respect to each Share subject to the Award, on the earlier of the
date on which the Award is exercised or settled or the date on which it is forfeited. Such Dividend Equivalent Rights, if any, shall be credited to the Participant in the form of additional whole Shares as of the date of payment of such cash
dividends on Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.2. </B><U>Restrictions on Shares</U>. At the discretion of the Committee, the Company may reserve to itself
and/or its assignee(s) a right to repurchase (a &#147;<B><I>Right of Repurchase</I></B>&#148;) a portion of any or all Unvested Shares held by a Participant following such Participant&#146;s termination of Service at any time within ninety
(90)&nbsp;days (or such longer or shorter time determined by the Committee) after the later of the date Participant&#146;s Service terminates and the date the Participant purchases Shares under this Plan, for cash and/or cancellation of purchase
money indebtedness, at the Participant&#146;s Purchase Price or Exercise Price, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. </B><B><U>CERTIFICATES</U></B>. All Shares or
other securities whether or not certificated, delivered under this Plan will be subject to such stock transfer orders, legends and other restrictions as the Committee may deem necessary or advisable, including restrictions under any applicable U.S.
federal, state or foreign securities law, or any rules, regulations and other requirements of the SEC or any stock exchange or automated quotation system upon which the Shares may be listed or quoted and any
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> exchange controls or securities law restrictions to which the Shares are subject. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. </B><B><U>ESCROW; PLEDGE OF SHARES</U></B>. To enforce any restrictions on a Participant&#146;s
Shares, the Committee may require the Participant to deposit all certificates representing Shares, together with stock powers or other instruments of transfer approved by the Committee, appropriately endorsed in blank, with the Company or an agent
designated by the Company to hold in escrow until such restrictions have lapsed or terminated, and the Committee may cause a legend or legends referencing such restrictions to be placed on the certificates. Any Participant who is permitted to
execute a promissory note as partial or full consideration for the purchase of Shares under this Plan will be required to pledge and deposit with the Company all or part of the Shares so purchased as collateral to secure the payment of the
Participant&#146;s obligation to the Company under the promissory note; <U>provided</U>, <U>however</U>, that the Committee may require or accept other or additional forms of collateral to secure the payment of such obligation and, in any event, the
Company will have full recourse against the Participant under the promissory note notwithstanding any pledge of the Participant&#146;s Shares or other collateral. In connection with any pledge of the Shares, the Participant will be required to
execute and deliver a written pledge agreement in such form as the Committee will from time to time approve. The Shares purchased with the promissory note may be released from the pledge on a pro rata basis as the promissory note is paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. </B><B><U>REPRICING; EXCHANGE AND BUYOUT OF AWARDS</U></B>. Without prior stockholder approval, the Committee may (a)&nbsp;reprice Options or SARs (and
where such repricing is a reduction in the Exercise Price of outstanding Options or SARs, the consent of the affected Participants is not required provided written notice is provided to them, notwithstanding any adverse tax consequences to them
arising from the repricing), and (b)&nbsp;with the consent of the respective Participants (unless not required pursuant to Section&nbsp;5.9 of the Plan), pay cash or issue new Awards in exchange for the surrender and cancellation of any, or all,
outstanding Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. </B><B><U>SECURITIES LAW AND OTHER REGULATORY COMPLIANCE</U></B>. An Award will not be effective unless such Award is in
compliance with all applicable U.S. and foreign federal and state securities and exchange control laws, rules and regulations of any governmental body, and the requirements of any stock exchange or automated quotation system upon which the Shares
may then be listed or quoted, as they are in effect on the date of grant of the Award and also on the date of exercise or other issuance. Notwithstanding any other provision in this Plan, the Company will have no obligation to issue or deliver
certificates for Shares under this Plan prior to: (a)&nbsp;obtaining any approvals from governmental agencies that the Company determines are necessary or advisable; and/or (b)&nbsp;completion of any registration or other qualification of such
Shares under any state or federal or foreign law or ruling of any governmental body that the Company determines to be necessary or advisable. The Company will be under no obligation to register the Shares with the SEC or to effect compliance with
the registration, qualification or listing requirements of any foreign or state securities laws, exchange control laws, stock exchange or automated quotation system, and the Company will have no liability for any inability or failure to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. <U>MISCELLANEOUS</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.1.
</B><U>No Obligation to Employ</U>. Nothing in this Plan or any Award granted under this Plan will confer or be deemed to confer on any Participant any right to continue in the employ of, or to continue any other relationship with, the Company or
any Parent, Subsidiary or Affiliate or limit in any way the right of the Company or any Parent, Subsidiary or Affiliate to terminate Participant&#146;s employment or other relationship at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.2.</B> <U>Change in Time Commitment</U>. In the event that a Participant&#146;s regular level of time commitment in the performance of
his or her services for the Company or any Affiliate is reduced (for example, and without limitation, if the Participant is an Employee and has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of
absence) after the date of grant of any Award to Participant, the Committee has the right in its sole discretion to (i)&nbsp;make a corresponding reduction in the number of Shares or cash amount subject to any portion of such Award that is scheduled
to vest or become payable after the date of such change in time commitment, and (ii)&nbsp;in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the
Participant will have no right with respect to any portion of the Award that is so reduced or extended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. <U>CORPORATE TRANSACTIONS</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.1. </B><U>Assumption or Replacement of Awards by Successor</U>. In the event that the Company is subject to a Corporate Transaction,
outstanding Awards acquired under the Plan shall be subject to the agreement evidencing the Corporate Transaction, which need not treat all outstanding Awards in an identical manner. Such agreement, without the Participant&#146;s consent, shall
provide for one or more of the following with respect to all outstanding Awards as of the effective date of such Corporate Transaction: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The continuation of an outstanding Award by the Company (if the Company is the successor entity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The assumption of an outstanding Award by the successor or acquiring entity (if any) of such Corporate Transaction (or by its parents, if
any), which assumption, will be binding on all selected Participants; provided that the exercise price and the number and nature of shares issuable upon exercise of any such option or stock appreciation right, or any award that is subject to
Section&nbsp;409A of the Code, will be adjusted appropriately pursuant to Section&nbsp;424(a) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The substitution by the
successor or acquiring entity in such Corporate Transaction (or by its parents, if any) of equivalent awards with substantially the same terms for such outstanding Awards (except that the exercise price and the number and nature of shares issuable
upon exercise of any such option or stock appreciation right, or any award that is subject to Section&nbsp;409A of the Code, will be adjusted appropriately pursuant to Section&nbsp;424(a) of the Code). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The full or partial acceleration of exercisability or vesting and accelerated expiration of an outstanding Award and lapse of the
Company&#146;s right to repurchase or <FONT STYLE="white-space:nowrap">re-acquire</FONT> shares acquired under an Award or lapse of forfeiture rights with respect to shares acquired under an Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The settlement of the full value of such outstanding Award (whether or not then vested or exercisable) in cash, cash equivalents, or
securities of the successor entity (or its parent, if any) with a Fair Market Value equal to the required amount, followed by the cancellation of such Awards; provided however, that such Award may be cancelled if such Award has no value, as
determined by the Committee, in its discretion. Subject to Section&nbsp;409A of the Code, such payment may be made in installments and may be deferred until the date or dates the Award would have become exercisable or vested. Such payment may be
subject to vesting based on the Participant&#146;s continued service, provided that the vesting schedule shall not be less favorable to the Participant than the schedule under which the Award would have become vested or exercisable. For purposes of
this Section&nbsp;21.1(e), the Fair Market Value of any security shall be determined without regard to any vesting conditions that may apply to such security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The cancellation of outstanding Awards in exchange for no consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board shall have full power and authority to assign the Company&#146;s right to repurchase or <FONT STYLE="white-space:nowrap">re-</FONT>
acquire or forfeiture rights to such successor or acquiring corporation. In addition, in the event such successor or acquiring corporation refuses to assume, convert, replace or substitute Awards, as provided above, pursuant to a Corporate
Transaction, the Committee will notify the Participant in writing or electronically that such Award will be exercisable for a period of time determined by the Committee in its sole discretion, and such Award will terminate upon the expiration of
such period. Awards need not be treated similarly in a Corporate Transaction. In addition, following a Corporate Transaction, 100% of the total number of Shares subject to each Award held by an Employee shall become vested if the holder is subject
to an Involuntary Termination within 12 months after the Corporate Transaction; it being understood that the vesting acceleration set forth in the preceding clause is in addition to vesting of the Award or Shares that has occurred prior to the
Involuntary Termination, subject to the Participant executing a general release (in a form prescribed by the Company) of all known and unknown claims that he or she may then have against the Company or persons affiliated with the Company and such
release has become effective and agreeing not to prosecute any legal action or other proceeding based upon any of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
claims except to the extent otherwise provided in an individual award agreement. The provisions of this Section&nbsp;21.1 shall apply to Awards outstanding on the Original Effective Date under
the Prior Plan; provided the vesting acceleration provisions set forth in any employment agreement or letter or similar agreement between the Company and an employee in effect on the Original Effective Date, to the extent more favorable to such
employee, will continue to apply to the equity awards held by the employee on the Original Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.2. </B><U>Assumption of
Awards by the Company</U>. The Company, from time to time, also may substitute or assume outstanding awards granted by another company, whether in connection with an acquisition of such other company or otherwise, by either; (a)&nbsp;granting an
Award under this Plan in substitution of such other company&#146;s award; or (b)&nbsp;assuming such award as if it had been granted under this Plan if the terms of such assumed award could be applied to an Award granted under this Plan. Such
substitution or assumption will be permissible if the holder of the substituted or assumed award would have been eligible to be granted an Award under this Plan if the other company had applied the rules of this Plan to such grant. In the event the
Company assumes an award granted by another company, the terms and conditions of such award will remain unchanged (except that the Purchase Price or the Exercise Price, as the case may be, and the number and nature of Shares issuable upon exercise
or settlement of any such Award will be adjusted appropriately pursuant to Section&nbsp;424(a) of the Code). In the event the Company elects to grant a new Option in substitution rather than assuming an existing option, such new Option may be
granted with a similarly adjusted Exercise Price. Substitute Awards shall not be credited toward the number of Shares authorized for grant under the Plan or authorized for grant to a Participant in a calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.3. </B><U><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors&#146; Awards</U>. Notwithstanding any provision to the contrary
herein, in the event of a Corporate Transaction, the vesting of all Awards granted to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors shall accelerate and such Awards shall become exercisable (as applicable) in full prior to the
consummation of such event at such times and on such conditions as the Committee determines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. </B><B><U>ADOPTION AND STOCKHOLDER APPROVAL</U></B>.
This Plan shall be submitted for the approval of the Company&#146;s stockholders, consistent with applicable laws, within twelve (12)&nbsp;months before or after the date this Plan is adopted by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23. </B><B><U>GOVERNING LAW</U></B>. This Plan and all Awards granted hereunder shall be governed by and construed in accordance with the laws of the State
of Delaware (excluding its conflict of law rules). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>24. </B><B><U>AMENDMENT OR TERMINATION OF PLAN</U></B>. The Board may at any time terminate or
amend this Plan in any respect, including, without limitation, amendment of any form of Award Agreement or instrument to be executed pursuant to this Plan; <U>provided</U>, <U>however</U>, that the Board will not, without the approval of the
stockholders of the Company, amend this Plan in any manner that requires such stockholder approval; <U>provided</U> <U>further</U>, that a Participant&#146;s Award shall be governed by the version of this Plan then in effect at the time such Award
was granted. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. No ISOs may be granted after the tenth anniversary of the earlier of (i)&nbsp;the Adoption Date or (ii)&nbsp;the Stockholder Approval Date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25. </B><B><U>NONEXCLUSIVITY OF THE PLAN</U></B>. Neither the adoption of this Plan by the Board, the submission of this Plan to the stockholders of
the Company for approval, nor any provision of this Plan will be construed as creating any limitations on the power of the Board to adopt such additional compensation arrangements as it may deem desirable, including, without limitation, the granting
of stock awards and bonuses otherwise than under this Plan, and such arrangements may be either generally applicable or applicable only in specific cases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26. </B><B><U>INSIDER TRADING POLICY</U></B>. Each Participant who receives an Award shall comply with any policy adopted by the Company from time to time
covering transactions in the Company&#146;s securities by Employees, officers and/or directors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27. </B><B><U>ALL AWARDS SUBJECT TO COMPANY CLAWBACK OR RECOUPMENT POLICY</U></B>. All Awards shall be
subject to clawback or recoupment pursuant to any compensation clawback or recoupment policy adopted by the Board or required by law during the term of Participant&#146;s employment or other service with the Company that is applicable to executive
officers, employees, directors or other service providers of the Company, and in addition to any other remedies available under such policy and applicable law, may require the cancelation of outstanding Awards and the recoupment of any gains
realized with respect to Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>28. </B><B><U>DEFINITIONS</U></B>. As used in this Plan, and except as elsewhere defined herein, the following terms
will have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.1.</B> &#147;<B><I>Adoption Date</I></B>&#148; means
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, which is the date that this Plan, as amended and restated, was adopted by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.2.</B> &#147;<B><I>Affiliate</I></B>&#148; means any person or entity that directly or indirectly through one or more intermediaries
controls, or is controlled by, or is under common control with, the Company, including any general partner, managing member, officer or director of the Company, in each case as of the date on which, or at any time during the period for which, the
determination of affiliation is being made. For purposes of this definition, the term &#147;control&#148; (including the correlative meanings of the terms &#147;controlled by&#148; and &#147;under common control with&#148;), as used with respect to
any person or entity, means the possession, directly or indirectly, of the power to direct or cause the direction of the management policies of such person or entity, whether through the ownership of voting securities or by contract or otherwise.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.3.</B> &#147;<B><I>Award</I></B>&#148; means any award under the Plan, including any Option, Restricted Stock, Stock Bonus, Stock
Appreciation Right, Restricted Stock Unit or award of Performance Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.4.</B> &#147;<B><I>Award Agreement</I></B>&#148; means,
with respect to each Award, the written or electronic agreement between the Company and the Participant setting forth the terms and conditions of the Award, and country-specific appendix thereto for grants to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Participants, which shall be in substantially a form (which need not be the same for each Participant) that the Committee (or in the case of Award agreements that are not used for Insiders, the
Committee&#146;s delegate(s)) has from time to time approved, and will comply with and be subject to the terms and conditions of this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.5.</B> &#147;<B><I>Award Transfer Program</I></B>&#148; means any program instituted by the Committee which would permit Participants
the opportunity to transfer any outstanding Awards to a financial institution or other person or entity approved by the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.6.</B> &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.7.</B> &#147;<B><I>Cause</I></B>&#148;<B> </B>means (i)&nbsp;an unauthorized use or disclosure by Participant of the Company&#146;s
confidential information or trade secrets, which use or disclosure causes material harm to the Company or is reasonably likely to cause material harm to the Company, (ii)&nbsp;a material breach of any agreement between Participant and the Company,
(iii)&nbsp;a material failure to comply with the Company&#146;s written policies or rules that has caused or is reasonably likely to cause material injury to the Company, its successor, or its affiliates, or any of their business,
(iv)&nbsp;conviction of, or plea of &#147;guilty&#148; or &#147;no contest&#148; to, a felony under the laws of the United States or any state thereof, (v)&nbsp;willful misconduct that has caused or is reasonably likely to cause material injury to
the Company, its successor, or its affiliates, or any of their business, (vi)&nbsp;embezzlement, (vii) failure to cooperate with the Company in any investigation or formal proceeding if the Company has requested Participant&#146;s reasonable
cooperation, (viii)&nbsp;violation of any applicable federal, state or foreign statutes or laws that govern or regulate employment, pharmaceutical drugs or securities, including but not limited to the laws enforced by the federal Equal Employment
Opportunity Commission, Department of Labor, Food and Drug Administration, Securities and Exchange Commission and Department of Justice or (ix)&nbsp;a continued failure to perform assigned duties after receiving written notification of such failure
from the Company&#146;s Chief Executive Officer; <I>provided that</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I></I>Participant must be provided with written notice of Participant&#146;s termination for &#147;Cause&#148; and Participant must be provided with a thirty (30)&nbsp;day period following
Participant&#146;s receipt of such notice to cure the event(s) that trigger &#147;Cause,&#148; with the Company&#146;s Chief Executive Officer making the final determination whether Participant has cured any Cause. The determination as to whether a
Participant is being terminated for Cause shall be made in good faith by the Company and shall be final and binding on the Participant. The foregoing definition does not in any way limit the Company&#146;s ability to terminate a Participant&#146;s
employment or consulting relationship at any time as provided in Section&nbsp;20 above, and the term &#147;Company&#148; will be interpreted to include any Parent, Subsidiary or Affiliate, as appropriate. Notwithstanding the foregoing, the foregoing
definition of &#147;Cause&#148; may, in part or in whole, be modified or replaced in each individual employment agreement or Award Agreement with any Participant, provided that such document supersedes the definition provided in this
Section&nbsp;28.7. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.8.</B> &#147;<B><I>Code</I></B>&#148; means the United States Internal Revenue Code of 1986, as amended, and the
regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.9.</B> &#147;<B><I>Committee</I></B>&#148; means the Compensation Committee of the Board or
those persons to whom administration of the Plan, or part of the Plan, has been delegated as permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.10.</B>
&#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.11.</B> &#147;<B><I>Company</I></B>&#148; means
Aeglea BioTherapeutics, Inc., or any successor corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.12.</B> &#147;<B><I>Consultant</I></B>&#148; means any person,
including an advisor or independent contractor, engaged by the Company or a Parent, Subsidiary or Affiliate to render services to such entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.13.</B> &#147;<B><I>Corporate Transaction</I></B>&#148; means the occurrence of any of the following events: (a)&nbsp;any
&#147;Person&#148; (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the &#147;beneficial owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act), directly or indirectly, of
securities of the Company representing more than fifty percent (50%) of the total voting power represented by the Company&#146;s then-outstanding voting securities; provided, however, that for purposes of this subclause (a)&nbsp;the acquisition of
additional securities by any one Person who is considered to own more than fifty percent (50%) of the total voting power of the securities of the Company will not be considered a Corporate Transaction; (b)&nbsp;the consummation of the sale or
disposition by the Company of all or substantially all of the Company&#146;s assets; (c)&nbsp;the consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the
voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the
total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation; (d)&nbsp;any other transaction which qualifies as a &#147;corporate
transaction&#148; under Section&nbsp;424(a) of the Code wherein the stockholders of the Company give up all of their equity interest in the Company (except for the acquisition, sale or transfer of all or substantially all of the outstanding shares
of the Company) or (e)&nbsp;a change in the effective control of the Company that occurs on the date that a majority of members of the Board is replaced during any twelve (12)&nbsp;month period by members of the Board whose appointment or election
is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purpose of this subclause (e), if any Person is considered to be in effective control of the Company, the acquisition of additional
control of the Company by the same Person will not be considered a Corporate Transaction. For purposes of this definition, Persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger,
consolidation, purchase or acquisition of stock, or similar business transaction with the Company. Notwithstanding the foregoing, to the extent that any amount constituting deferred compensation (as defined in Section&nbsp;409A of the Code) would
become payable under this Plan by reason of a Corporate Transaction, such amount shall become payable only if the event constituting a Corporate Transaction would also qualify as a change in ownership or effective control of the Company or a change
in the ownership of a substantial portion of the assets of the Company, each as defined within the meaning of Code Section&nbsp;409A, as it has been and may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amended from time to time, and any proposed or final Treasury Regulations and IRS guidance that has been promulgated or may be promulgated thereunder from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.14.</B> &#147;<B><I>Director</I></B>&#148; means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.15.</B> &#147;<B><I>Disability</I></B>&#148; means in the case of incentive stock options, total and permanent disability as defined in
Section&nbsp;22(e)(3) of the Code and in the case of other Awards, that the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in
death or can be expected to last for a continuous period of not less than 12 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.16.</B> &#147;<B><I>Employee</I></B>&#148;
means any person, including Officers and Directors, employed by the Company or any Parent, Subsidiary or Affiliate. Neither service as a Director nor payment of a director&#146;s fee by the Company will be sufficient to constitute
&#147;employment&#148; by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.17.</B> &#147;<B><I>Exchange Act</I></B>&#148; means the United States Securities Exchange
Act of 1934, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.18.</B> &#147;<B><I>Exchange Program</I></B>&#148; means a program pursuant to which (a)&nbsp;outstanding
Awards are surrendered, cancelled or exchanged for cash, the same type of Award or a different Award (or combination thereof) or (b)&nbsp;the exercise price of an outstanding Award is increased or reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.19.</B> &#147;<B><I>Exercise Price</I></B>&#148; means, with respect to an Option, the price at which a holder may purchase the Shares
issuable upon exercise of an Option and with respect to a SAR, the price at which the SAR is granted to the holder thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.20.</B>
&#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of a share of the Company&#146;s Common Stock determined as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) if such Common Stock is publicly traded and is then listed on a national securities exchange, its closing price on the date of
determination on the principal national securities exchange on which the Common Stock is listed or admitted to trading as reported in <I>The Wall Street </I>Journal or such other source as the Committee deems reliable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) if such Common Stock is publicly traded but is neither listed nor admitted to trading on a national securities exchange, the average of
the closing bid and asked prices on the date of determination as reported in <I>The Wall Street Journal </I>or such other source as the Committee deems reliable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) in the case of an Option or SAR grant made on the Original Effective Date, the price per share at which shares of the Company&#146;s
Common Stock were initially offered for sale to the public by the Company&#146;s underwriters in the initial public offering of the Company&#146;s Common Stock pursuant to a registration statement filed with the SEC under the Securities Act; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) if none of the foregoing is applicable, by the Board or the Committee in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.21.</B> &#147;<B><I>Good Reason</I></B>&#148; means, without the Participant&#146;s consent, (i)&nbsp;a material reduction in the
Participant&#146;s level of responsibility and/or scope of authority, (ii)&nbsp;a reduction by more than 10% in Participant&#146;s base salary (other than a reduction generally applicable to Participant officers of the Company and in generally the
same proportion as for the Participant), or (iii)&nbsp;relocation of the Participant&#146;s principal workplace by more than thirty-five (35)&nbsp;miles from Participant&#146;s then current place of employment. For the purpose of clause (i), a
change in responsibility shall not be deemed to occur (A)&nbsp;solely because Participant is part of a larger organization or (B)&nbsp;solely because of a change in title. For the Participant to receive the benefits under this Agreement as a result
of a voluntary resignation for Good Reason, all of the following requirements must be satisfied: (1)&nbsp;the Participant must provide notice to the Company of his or her intent to assert Good Reason within sixty (60)&nbsp;days of the initial
existence of one or more of the conditions set forth in subclauses (i)&nbsp;through (iii); (2) the Company will have thirty (30)&nbsp;days (the &#147;<B><I>Company Cure Period</I></B>&#148;) from the date of such notice to remedy the condition
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and, if it does so, the Participant may withdraw his or her resignation or may resign with no benefits; and (3)&nbsp;any termination of employment under this provision must occur within ten
(10)&nbsp;days of the earlier of expiration of the Company Cure Period or written notice from the Company that it will not undertake to cure the condition set forth in subclauses (i)&nbsp;through (iii). Should the Company remedy the condition as set
forth above and then one or more of the conditions arises again within twelve months following the occurrence of a Change in Control, the Participant may assert Good Reason again subject to all of the conditions set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.22.</B> &#147;<B><I>Insider</I></B>&#148; means an officer or director of the Company or any other person whose transactions in the
Company&#146;s Common Stock are subject to Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.23.</B> &#147;<B><I>Involuntary
Termination</I></B>&#148; means either (a)&nbsp;termination of Service without Cause or (b)&nbsp;resignation from Service for Good Reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.24.</B> &#147;<B><I>IRS</I></B>&#148; means the United States Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.25.</B> <B></B>&#147;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#148; means a Director who is not an
Employee of the Company or any Parent, Subsidiary or Affiliate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.26.</B> &#147;<B><I>Option</I></B>&#148; means an award of an
option to purchase Shares pursuant to Section&nbsp;5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.27.</B> &#147;<B><I>Original Effective Date</I></B>&#148; means the day
immediately prior to the date of the underwritten initial public offering of the Company&#146;s Common Stock pursuant to a registration statement that was declared effective by the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.28.</B> &#147;<B><I>Outstanding Shares</I></B>&#148; means, as of a specified date, the sum of (a)&nbsp;the then-issued and outstanding
Shares, and (ii)&nbsp;the number of Shares issuable pursuant to the exercise of any outstanding, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to acquire Shares for a nominal exercise price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.29.</B> &#147;<B><I>Parent</I></B>&#148; means any corporation (other than the Company) in an unbroken chain of corporations ending with
the Company if each of such corporations other than the Company owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.30.</B> &#147;<B><I>Participant</I></B>&#148; means a person who holds an Award under this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.31.</B> <I>&#147;</I><B><I>Performance Award</I></B><I>&#148; </I>means cash or stock granted pursuant to Section&nbsp;10 of the Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.32.</B> &#147;<B><I>Performance Factors</I></B>&#148;<B><I> </I></B>means any of the factors selected by the Committee and
specified in an Award Agreement, from among the following measures or any other measures not listed herein that the Committee deems appropriate, either individually, alternatively or in any combination, applied to the Company as a whole or any
business unit or Subsidiary, either individually, alternatively, or in any combination, on a GAAP or <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis, and measured, to the extent applicable on an absolute basis or relative to a <FONT
STYLE="white-space:nowrap">pre-established</FONT> target, to determine whether the performance goals established by the Committee with respect to applicable Awards have been satisfied: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Profit Before Tax; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Sales; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Expenses; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Billings; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Revenue; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Net revenue; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Earnings (which may include earnings before interest and taxes, earnings before taxes, net earnings, stock-based
compensation expenses, depreciation and amortization); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Operating income; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Operating margin; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Operating profit; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Controllable operating profit, or net operating profit; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Net Profit; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Gross margin; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Operating expenses or operating expenses as a percentage of revenue; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) Net income; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) Earnings per share; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) Total stockholder return; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) Market share; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) Return on assets or net assets; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) The Company&#146;s stock price; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) Growth in stockholder value relative to a <FONT STYLE="white-space:nowrap">pre-determined</FONT> index; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Return on equity; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) Return on invested capital; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) Cash Flow (including free cash flow or operating cash flows) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) Balance of cash, cash equivalents and marketable securities; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) Cash conversion cycle; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) Economic value added; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) Individual confidential business objectives; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) Contract awards or backlog; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) Overhead or other expense reduction; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) Credit rating; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) Completion of an identified special project; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) Completion of a joint venture or other corporate transaction; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) Strategic plan development and implementation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Succession plan development and implementation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) Improvement in workforce diversity; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) Employee satisfaction; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) Employee retention; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) Customer indicators and satisfaction; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) New product invention or innovation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) Research and development expenses; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) Attainment of research and development milestones; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) Improvements in productivity; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) Bookings; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) Working-capital targets and changes in working capital; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) Attainment of objective operating goals and employee metrics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee may, in recognition of unusual or <FONT STYLE="white-space:nowrap">non-recurring</FONT> items such as acquisition-related
activities or changes in applicable accounting rules, provide for one or more equitable adjustments (based on objective standards) to the Performance Factors to preserve the Committee&#146;s original intent regarding the Performance Factors at the
time of the initial award grant. It is within the sole discretion of the Committee to make or not make any such equitable adjustments. The Committee is authorized to make adjustments as it deems appropriate in the method of calculating the
attainment of Performance Factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.33.</B> &#147;<B><I>Performance Period</I></B>&#148; means one or more periods of time, which
may be of varying and overlapping durations, as the Committee may select, over which the attainment of one or more Performance Factors will be measured for the purpose of determining a Participant&#146;s right to, and the payment of, a Performance
Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.34.</B> &#147;<B><I>Performance Share</I></B>&#148; means an Award granted pursuant to Section&nbsp;10 of the Plan, the
payment of which is contingent upon achieving certain performance goals established by the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.35.</B>
&#147;<B><I>Performance Unit&#148; </I></B>means a right granted to a Participant pursuant to Section&nbsp;10 to receive Shares, the payment of which is contingent upon achieving certain performance goals established by the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.36.</B> &#147;<B><I>Permitted Transferee</I></B>&#148; means any child, stepchild, grandchild, parent, stepparent, grandparent, spouse,
former spouse, sibling, niece, nephew, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law</FONT></FONT> (including adoptive relationships) of the Employee, any
person sharing the Employee&#146;s household (other than a tenant or employee), a trust in which these persons (or the Employee) have more than 50% of the beneficial interest, a foundation in which these persons (or the Employee) control the
management of assets, and any other entity in which these persons (or the Employee) own more than 50% of the voting interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.37.</B> &#147;<B><I>Plan</I></B>&#148; means this Aeglea BioTherapeutics, Inc. 2016 Equity Incentive Plan, as amended from time to time.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.38.</B> &#147;<B><I>Prior Plan Returning Shares</I></B>&#148; means (a)&nbsp;shares that are subject to stock options or other
awards granted under the Prior Plan that cease to be subject to such stock options or other awards by forfeiture or otherwise after the Original Effective Date, (b)&nbsp;shares issued under the Prior Plan before or after the Original Effective Date
pursuant to the exercise of stock options that are, after the Original Effective Date, forfeited, (c)&nbsp;shares issued under the Prior Plan that are repurchased by the Company at the original issue price and (d)&nbsp;shares that are subject to
stock options or other awards under the Prior Plan that are used to pay the exercise price of an option or withheld to satisfy the tax withholding obligations related to any award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.39.</B> &#147;<B><I>Purchase Price</I></B>&#148; means the price to be paid for Shares acquired under the Plan, other than Shares
acquired upon exercise of an Option or SAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.40.</B> &#147;<B><I>Restricted Stock Award</I></B>&#148; means an award of Shares
pursuant to Section&nbsp;6 of the Plan, or issued pursuant to the early exercise of an Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.41.</B> &#147;<B><I>Restricted Stock Unit</I></B>&#148; means an Award granted
pursuant to Section&nbsp;9 of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.42.</B> &#147;<B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#148; means
Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act or any successor to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.43.</B> &#147;<B><I>SEC</I></B>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.44.</B> &#147;<B><I>Securities Act</I></B>&#148; means the United States Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.45.</B> &#147;<B><I>Service</I></B>&#148; shall mean service as an Employee, Consultant, Director or
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, to the Company or a Parent, Subsidiary or Affiliate, subject to such further limitations as may be set forth in the Plan or the applicable Award Agreement. An Employee will not be deemed
to have ceased to provide Service in the case of (a)&nbsp;sick leave, (b)&nbsp;military leave, or (c)&nbsp;any other leave of absence approved by the Company; <U>provided</U>, that such leave is for a period of not more than 90 days (x)&nbsp;unless
reemployment upon the expiration of such leave is guaranteed by contract or statute, or (y)&nbsp;unless provided otherwise pursuant to formal policy adopted from time to time by the Company&#146;s Board and issued and promulgated to employees in
writing. In the case of any Employee on an approved leave of absence or a reduction in hours worked (for illustrative purposes only, a change in schedule from that of full-time to part-time), the Committee may make such provisions respecting
suspension of or modification to vesting of the Award while on leave from the employ of the Company or a Parent, Subsidiary or Affiliate or during such change in working hours as it may deem appropriate, except that in no event may an Award be
exercised after the expiration of the term set forth in the applicable Award Agreement. In the event of military leave, if required by applicable laws, vesting shall continue for the longest period that vesting continues under any other statutory or
Company approved leave of absence and, upon a Participant&#146;s returning from military leave (under conditions that would entitle him or her to protection upon such return under the Uniform Services Employment and Reemployment Rights Act), he or
she shall be given vesting credit with respect to Awards to the same extent as would have applied had the Participant continued to provide Service to the Company throughout the leave on the same terms as he or she was providing Service immediately
prior to such leave. An employee shall have terminated employment as of the date he or she ceases to provide Service (regardless of whether the termination is in breach of local employment laws or is later found to be invalid) and employment shall
not be extended by any notice period or garden leave mandated by local law, <I>provided however</I>, that a change in status from an employee to a consultant or advisor shall not terminate the service provider&#146;s Service, unless determined by
the Committee, in its discretion. The Committee will have sole discretion to determine whether a Participant has ceased to provide Service and the effective date on which the Participant ceased to provide Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.46.</B> &#147;<B><I>Shares</I></B>&#148; means shares of Common Stock and the common stock of any successor entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.47.</B> &#147;<B><I>Stock Appreciation Right</I></B>&#148; means an Award granted pursuant to Section&nbsp;8 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.48.</B> &#147;<B><I>Stock Bonus</I></B>&#148; means an Award granted pursuant to Section&nbsp;7 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.49.</B> &#147;<B><I>Stockholder Approval Date</I></B>&#148; means June&nbsp;6, 2023, the date of the Company&#146;s 2023 annual meeting
of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.50.</B> &#147;<B><I>Subsidiary</I></B>&#148; means any corporation (other than the Company) in an unbroken chain
of corporations beginning with the Company if each of the corporations other than the last corporation in the unbroken chain owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the
other corporations in such chain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.51.</B> &#147;<B><I>Treasury Regulations</I></B>&#148; means regulations promulgated by the
United States Treasury Department. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.52.</B> &#147;<B><I>Unvested Shares</I></B>&#148; means Shares that have not yet vested or are
subject to a right of repurchase in favor of the Company (or any successor thereto). </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:2.86em; font-size:7pt; font-family:Times New Roman"><I>AEGLEA BIOTHERAPEUTICS, INC.</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.86em; font-size:7pt; font-family:Times New Roman"><I>805 LAS CIMAS PARKWAY</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.86em; font-size:7pt; font-family:Times New Roman"><I>SUITE 100</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.86em; font-size:7pt; font-family:Times New Roman"><I>AUSTIN,
TX 78746</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">&nbsp;&nbsp;&nbsp;&nbsp;


<IMG SRC="g449732g82k44.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><B>VOTE BY INTERNET</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><I>Before The Meeting</I> - Go to <B><U>www.proxyvote.com</U> or scan the QR Barcode above</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">Use the Internet to transmit your voting instructions and for electronic delivery of
information up until 11:59 p.m. Eastern Time on June&nbsp;5, 2023. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><I>During The Meeting</I> - Go to
<B><U>www.virtualshareholdermeeting.com/AGLE2023</U></B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">You may attend the meeting
via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><B>VOTE BY PHONE - 1-800-690-6903</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">Use any touch-tone telephone
to transmit your voting instructions up until 11:59 p.m. Eastern Time on June&nbsp;5, 2023. Have your proxy card in hand when you call and then follow the instructions.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><B>VOTE BY MAIL</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman">Mark, sign and date your proxy card and return
it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.</P></TD></TR>
</TABLE> <P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="right">V09332-P90097&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;KEEP THIS
PORTION FOR YOUR RECORDS </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;
&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;
&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;
&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;
&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>THIS PROXY CARD IS VALID ONLY WHEN SIGNED
AND DATED.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B><FONT STYLE="font-family:Times New Roman; font-size:7pt">DETACH AND RETURN THIS PORTION ONLY</FONT><FONT STYLE="font-family:Times New Roman; font-size:8pt"> </FONT></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1.50pt;border-radius:5pt; background-color:;;padding-top:2pt;padding-bottom:3pt">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>AEGLEA BIOTHERAPEUTICS, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>For</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>All</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Withhold</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>All</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>For&nbsp;All&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Except&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:7pt; font-family:Times New Roman">To withhold authority to vote for any individual nominee(s), mark &#147;For All Except&#148; and write the
number(s) of the nominee(s) on the line below.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:1pt; margin-left:2.00em; font-size:7pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD ROWSPAN="2" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:7pt; font-family:Times New Roman"><B>The Board of Directors recommends you vote FOR</B> <B>the following listed nominees:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B></B>&#9744;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B></B>&#9744;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B></B>&#9744;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000"><FONT STYLE="font-size:4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.71em; text-indent:-1.86em; font-size:7pt; font-family:Times New Roman">1.&#8195;&#8202;Election of Class I Directors, each to serve until the 2026 annual
meeting of stockholders.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;01)&nbsp;&nbsp;&nbsp;Alison Lawton</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;02)&nbsp;&nbsp;&nbsp;Hunter C. Smith, M.B.A.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="11"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:7pt; font-family:Times New Roman"><B>The Board of Directors recommends you vote FOR the following proposals:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Against</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Abstain</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="14"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="13"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.71em; text-indent:-1.86em; font-size:7pt; font-family:Times New Roman">2.&#8195;&#8202;To ratify the appointment of PricewaterhouseCoopers LLP as
Aeglea&#146;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2023.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="14"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="13"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.71em; text-indent:-1.86em; font-size:7pt; font-family:Times New Roman">3.&#8195;&#8202;To approve, on a <FONT STYLE="white-space:nowrap">non-binding</FONT>
advisory basis, the compensation of Aeglea&#146;s named executive officers as disclosed in the Proxy Statement.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="14"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="13"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.71em; text-indent:-1.86em; font-size:7pt; font-family:Times New Roman">4.&#8195;&#8202;To approve an amendment to Aeglea&#146;s restated certificate of
incorporation to effect a reverse stock split of Aeglea&#146;s common stock at a ratio ranging from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-10</FONT></FONT> shares up to a ratio of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-for-25</FONT></FONT> shares, which ratio will be selected by Aeglea&#146;s Board of Directors and set forth in a public announcement.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="14"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="13"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.71em; text-indent:-1.86em; font-size:7pt; font-family:Times New Roman">5.&#8195;&#8202;To approve an amendment and restatement of Aeglea&#146;s 2016 Equity
Incentive Plan.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="11"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:7pt; font-family:Times New Roman"><B>NOTE</B>: Such other business as may properly come before the meeting or any adjournment
thereof.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="54"></TD>
<TD HEIGHT="54" COLSPAN="10"></TD>
<TD HEIGHT="54" COLSPAN="2"></TD>
<TD HEIGHT="54" COLSPAN="2"></TD>
<TD HEIGHT="54" COLSPAN="6"></TD>
<TD HEIGHT="54" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="9"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:7pt; font-family:Times New Roman">Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or
other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:1.00em; font-size:8pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:7pt">Signature&nbsp;[PLEASE&nbsp;SIGN&nbsp;WITHIN&nbsp;BOX]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:7pt">Date</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:7pt">Signature&nbsp;(Joint&nbsp;Owners)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:7pt">Date</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> </div>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The Notice&nbsp;&amp; Proxy Statement and Annual Report are available at <U>www.proxyvote.com</U>. </P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;
&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;
&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;
&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;
&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp;&#150;&nbsp; </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">V09333-P90097 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1.50pt;border-radius:5pt; background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:30pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF
DIRECTORS</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF AEGLEA BIOTHERAPEUTICS, INC.</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:1.00em; margin-right:1.00em; font-size:10pt; font-family:Times New Roman">The undersigned hereby appoints
Jeffrey M. Goldberg and Jonathan D. Alspaugh, and either of them, with power to act without the other and with power of substitution, as proxies and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT>
and hereby authorizes them to represent and vote, as provided on the other side, all the shares of common stock of Aeglea BioTherapeutics, Inc. which the undersigned is entitled to vote and, in their discretion, to vote upon such other business as
may properly come before the Annual Meeting of Stockholders of Aeglea BioTherapeutics, Inc. to be held June&nbsp;6, 2023 or any adjournment thereof, with all powers which the undersigned would possess if present at the Annual Meeting.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:1.00em; margin-right:1.00em; font-size:10pt; font-family:Times New Roman"><B>THIS PROXY CARD, WHEN PROPERLY EXECUTED,
WILL BE VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED. IF NO DIRECTION IS MADE BUT THE CARD IS SIGNED, THIS PROXY CARD WILL BE VOTED &#147;FOR ALL&#148; FOR PROPOSAL 1, &#147;FOR&#148; PROPOSAL 2, &#147;FOR&#148; PROPOSAL 3, &#147;FOR&#148;
PROPOSAL 4, &#147;FOR&#148; PROPOSAL 5 AND IN THE DISCRETION OF THE PROXIES WITH RESPECT TO SUCH OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE MEETING.</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:42pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:42pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Continued and to be signed on reverse side</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> </div>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g449732g11w06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g449732g11w06.jpg
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M6!DD-#5S=)>R)3(Y0E=G>)%#87&!L=CP_\0 '0$!  $$ P$
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M^A6X'3GP<8X X X X X X X X X X X X X X X X X X X X X X X X X
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M@Q56W[S;?-?638L[JBS>%'T1Q(>+!#6>>2SA4._8K<^W)%S53R377>F'J+.
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MBGR?<J.U$V>.M"!>L!<\M!@-L-RJTJ&0%281%V4[(=E#UQA<0'&W?9[))/\
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M/0_2.LLL)EN2W\/27@;N[Y+F6PPYTMY->BZ+U=W$U;4MW;PD0^Z6U=K[NO\
M:9TK7$2W4C:.Y(D*);;3K(@ UV%A!78WLP9,KT$Z.LD$1.@,/X8D(7(9?$N)
MMPNR]BDE:^Q;-Y==MZ%5/9%RO>T=C['M9_;ESZOVOJ%%V0(KE!K1D!J&\EF3
M5OF,CV*S.!EK[89T6$Y*-E1S]8#IAI:IU)JS)*PM&A%W:VZ][<^SOZR!=2>1
MWT3I"Q=.+SKC;6]*]L;I=4;!J^H7Z$0UK'.[6TQ82<DN]I[>,:/K5D'=:8,F
MDC+X)8X37; )E%Y).*:29BC"4!Z>GIVVM+C;UEE:)W:SLGQ6??V(VW\%(X X
M X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
M X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
M X X X X X X X X X X X X X X X X X X X!K8.^6%\F/639BMGNZ&F!9
MVOE2 0T,E%R29(XL)EO0",&0E(I24OQ)D=Z.]A*E)PXVK&%9Q\.;FEZ&:4S9
M<$V7@E='+F00S)<:EPVB@CA44,2]ELBA::YF<+GR4VG,ANLGZ6*5_P M#Y+'
M_C>TC]<D_NGE?VDZ6?D*O_PX?]X]<2?QD/;W$^=>>_O33MC;#%%ZX]A]>;>M
MX"NO6PR J$^9*(#JW')#0[QB0W(A1D)AMDS R$I:5J5A^:PGS?!6<X\_$='L
M;PB3!48GAM31R9DQ28)DZ%0PQ37#%&H$U$_9."".*W"%E4$V7&VH(U$TKM+@
M5DSV3(S[UNN@:AU:8VT9Z\#P6=HXBV0+54KN%GIT/8(+5=$R61(:LNQWZ27K
M%EFQ3K],I@\?<ZJT[=W"4PG $>,<MME\K[/)?HO=>)Y$C3^P&E0C!IRT;3U_
M4GZO6C=MMT2SV\"#>J@&JQADJY$+!DE.BMC(U*;-!O?!Z2IM%8R8$9-Y@8*C
M_61!1T=I>M*U&$XW]IS'NZ.MI>P*<V146FP0NA1H\ZYD3#KI9#8R%6!TJ,5,
MR9JV&8(B0R7>6D:XF5D39\'U'J8[,==I5?*VR-O+4\BL CLRM'+ Q?JPZ'"'
MAT$84(##!!LDJ*+D0 YH,;F^O.,(B@BXLV^ML40B3'A%GP*A^V"T3FS62F8W
M+J[-MIT&S$K;6\7NLY-5B!2X8<A<)5@'8)^LAV:K L .=8E$&X_L:&6@22/J
M[,II:@L^![WMVZACRAL"1LJEL$#'ITCAS]A'-$9+L:>>$O1L#W'TS&IJ2]6L
MX9,%YAN8X9K9\2VPLB&(QHP%BT+M%IW8\!FTUB]TB5KTCJ;5FWPUK>N(>$0D
MUK;)6TBZP^7ID]<2RUB"3>K\:* *'(L5FS&YI.N"65F*T6CI KDSLOUW'.U^
M.0WGJ:#*M;[T6N0YFP*O%FF946XQM=S(T&$^3;E/2(&P)<>CD6,,X='V]S%;
MFH8,I7#2)L^#ZCS]BNPE'ZRZ[QLW8+)AZMM62NA""@L-,R0)$D9V'[9<B6''
M6&8U5UI1X-HV;=YRW<.PJ93C[\%B<21"'2P2OZ>F9>UOVOK/7\F##N]]J54F
M$\PTCXATZ.&R9JB4M0X4B.Q)?;==<+DT^R0[:4967,+:$C4RB+S458BSX%DT
MKLYH#8(.H6"K;:H\V%>Q.M3-8CR3T$66(0MQ1RTC5Z5A";L0M#F7K( _%K,"
M9#8F%B $V.ALNSA,]A@39YY/*]_%MZBBE^S^MT6/30*F%@NR(^W]JKU0T7I]
ME#$H=7*O:1V1O8*7*XCO/YE!K!5-<2<")4):DSVSH4M!5+$O.2D!;;S*_:EY
MSYZJ[3ZLV12 5K)GP5"+EZK:;Q*I=ELH9-@$4VH7<A0#%KF-(?;RJMQ[!!:B
M/&TM8'1I$Z'%D/MR'4(4#5NSM5T6'V+[CC>NUWF54KKLS;!X3K3N?M18C :Q
MUX5(A:ZT*>U^$V /'P+(Z*'3K1E&RJ\1KL*=8 PHI'BG&9QH/)B#VRP)7WK:
MEOWWSV;%;/?P3)+(]G-1(K:C8:]4660;8J<V17K%>*_1R0Z%9[!5 *TETV.1
M'4*+B9%P"Q9@"6R@MBPDPE5=CQC9\5'D!;.W\_(?<QV(I(W>VO=!P7HIVT7H
M=LB;+D"C U_%2DZW%U,P0%G1Z7%S$SYT*X"7D,-XPZ/:D0WB+;#108J4(/1%
M[-Z"DP[21=VM3A8^EVVZ4BRSCQ>/7XHL_KF0U$OJ'W32H.,#*A)=2T?.^'L0
M:C'K<@@B"XS*="SX;=A:>\NR:].7[5&OX-"DW<CM@#MBPBY,6U@ZU&'P]/UD
M=;; S)E'T,B\/DQ!!* ;\LH/%*G-+09)!H'B22)M?K2ZR%M4>4"KF[B+F=>T
M)20"Z=UIOPE^\W@)0K98:UVCK$"UT1@-3C,%67;2-@3DPC=<F&X2G#.&!H0@
M7=F,*R#5NWHRO?/TZK7O&O\ =RG':MJ_;7NF8A:"W1MH5IK6^TG",!V21L-J
MN$S7NNK6:J*&TR VN-J7B./K=!/L%RUBE2K73IEEIU7$EIY ,%LVMZW=&U=*
M\Q/IG;XL+O;7NAI $VX9V-JO;6UA-F;4*]W8HW3]JTY5#X28C)'!O!F;)W57
M)P]2!.1:H4$EAPBF4EJ,H+97YTNN_<2[P0. . . . . . . . . . . . .
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M\^.UEU%>@Z[I=X.[#MJIV-D6D65K^SZK?M*5S8FLS>O[7KS4=)+TY%!(7LE
M@7,+^!^N$0]_>MUQ@MS9]G#D@%FI16)7X(7RMPV<=]L]^WFYK%SF^B3)RYW:
MU3MA!"L"[6O?-E(U6R:PBG@,J-N[0VO=$O5XY!<M\2 =#"A>OHQ<O$<@0HUI
M27(!L1@,7#,A(F^5K<,[YY-O++GL41OH39HI36WJ_8BP%ZGK,]K^P JU>ZT;
MOA&"_KW>>P=K#(0ZZFME8M4N&NFWUC4L>9?9VP;&)"4NKF!=@CN3[X*NPB_;
MMMXO.KY%.JWD[GP%.I-7F;H7-E:WTCTLU)3C(W7Z@ZFB?17<1+<.I;:?@/WD
MPP;B6,C*@A=B5=ET4V7A19LFO&JM)G1<"A.LV[\6V_[RL_Y<.<]%N\G=#LI*
MY&HFU<""NP!.T6[.YBBJFP7;'M7>>J-SF#(N!BZ0\#1PYO48*J#@N9$N0\F:
M0L90V0*OO-O@HK;5?_AKS^8REVQU]!;ML"%;%(+,Z]:UU<J1^#Z*[:@#1"=?
M5P(5F+GSE9N85PX(FUD?BM(J\D8AA$(F>6Z3?05S&CBD@S473O8FK9>OW)G8
MEZ]Q1.B-1Z#VA[T:P@S"^Q >@S]].:LMX(M)N4U-'O66]A&1NPC,\?>8UN0S
M", A]&LS"#B1-[];>7/;LR+!I_D\S%4>TWC&[XDV%J[7_36BE6$:N5$E6G]I
M/:-B&-=E84M>Q)C5;S: VQR0NZ0GH5BP^6&"S@*6$A8G5V9%DNI+Q+83K;<M
MM]^QO:>O5?06V4"Y:RNUAWU#O!?7USUC=R,Q_53P0A<S.M]!;IZ\JE%9+>S"
M4,?(LE8V\D]-0+&," UAKV(E<#"JA-&5:N2+Y6M;;VM/S6\Y[P?4F6"LW5>C
MNP[66A=?B5_O!G>(Y-*K%4N%9N]G-VZ7H2=6'KM9MAKD2-HB-,;-GK16F*A,
M@:N')5>6"SLBJS7IZ>FX76?/9);;6MG?HNO'LWD[7SJ]6MC=F]:=AK:Y5[%
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M4_(;<3#4P%\K<Z?5?O)MX(' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ,?9O;3JJ-F2QQ'LSU]@$($E^%.@S=S:YBS(4R*ZM
MB3$EQG[(V_'DQWVULOL/(0ZRZA;;B$K3G&+A@T2TKFP03)>C.D,R7,AACES(
M,%Q*."."-**"."*&F<,4,4+44,4+:B333:9YD6-8/!%%!'BV&0Q0MPQ0Q5]+
M#%#%"[.&).:FFFFFFDTU9GF_;@]2?^*3KI_XVZT_6;E7VG:7?^+:1_Y'B?\
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M6):9E<%S#<,0^-:S)R%G9OAM\FS;O1*7! X X X X X X X X X X X X X
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MSAL(Y(KH:21-UJXP9;Y.I'!">3Y_Y>G/U,RFX(' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' *7/.!14L(/*%Q@Z?92
M3P:N0I\^+$EGS$8,6L4@4%CR'6WBA%BO@3AQZ%"0_):$!RA);288^6\T!5.
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MC?8+N-NIW8$2_ ^N>P>HW7'6!DM626O8HO8U@UQO;?\ L.T:]*+)1#^P <!
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M]@=Q;PI&Z-5 KQH/.M.NU\UI,)E8E2*V&UW#:^Z.N%M'5LC4JOLL4Y8M>:E
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M1IYQ:(V94C+*49?=\X#V< < < < < < < < < < < < < < < < < < < <
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MF[YIVM;;?@]^S--(SJX(' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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MC(X ]RZI\@#/HR. /<NJ?( SZ,C@#W+JGR ,^C(X ]RZI\@#/HR. /<NJ?(
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MD;/]T\:WQ8NH6?-UKO'O6/\ B%F^R-G^Z>-;XL74+/FZUWCWK'_$+-]D;/\
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M#%!,ES((G#'+F01)101P1)PQ0Q)10Q)II--'UY)0. . . . . . . . . .
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MT@QF(( A%4XN+/"Q,1<1Q4V,MYU3$J"VP^RIUQ3;B<K5G(%Q\ < < < < <
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M]6=RZW[!:KNEP'.U3M"49)[FP-V./@E;&EBH4ZB-"X)7UMZ37A+=5H=<&-Q
M.1ZF5,39S+S9$J3ERNY]G<$_+.%?YC2?QC&RG0)IJ9!=;/90]_.7*+H.BHFQ
MHNT#FV9=[L0<XJU4^+?-I#K&!U[:YFOE:O.V'7@9Y]F+3I%EITDK ,"@OJU:
M1(L-FGB 8J98S3LU]G<#_+.%?YA2?QB/"R]GA(/TH>GB9+B3H,^R[)!&11J.
MR[Z!Y\40B$66GO,2YZ)QV(\\A#OF+2OT:E85YJDJ\/#.,\[E-64E;!%,HZJF
MJX((M2*.FGRI\$,=E%JQ12HHTHK-/5;3LT[6:*E%#%[6)1=#3\A5>=DD< <
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MZY8_2-MS9T6*XMOV9!3YZ$/NMJ4CSL93YR<93YV,X\?'&>9LY-&EA5?=I?\
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MG!.4KE2)=;6RQCUF/GSW$1#TJ2I/P>'@S'=7XYQ^Y\/'.+=TL;^US%KPV_\
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M\>D;])EKST>EPC#F6_.3Z3#:E*2E>4>/G80I25)PK./-RI*L8SXXSP#]\ <
M< < < BW=GXJKM_(ZOZS'Y;NEOO<Q?Y*_K(#BG_>H^A>5&JGFN)Y@X X!GUU
M)_V-LW\YL?V5 YFCDT]RL0^</]-).]2^TB_.\R,KN9(.T6_;*I6[W6#],N(0
M=9*K:1,X%80):.B6-+B"<=R+.@3(Z\>:XS(8<6A7AE*TYSA;:D.)2K'%/D2:
MF3-IY\N"=)G012ILJ8E%!,EQIPQ0Q)[4TVF>G@V,XKH]BV&X[@=?4X7C&$5M
M/B.&8C1S8I-515M)-AG4]1(F0YPS)4R"&)7O"[.&)10MIZ&-86>T>2%[$Q]
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MO9I?E%9]?$;6/9UI^<\+[.H^]>8F+V'LZT_.>%]G4?>O 'LZT_.>%]G4?>O
M'LZT_.>%]G4?>O 'LZT_.>%]G4?>O 'LZT_.>%]G4?>O 'LZT_.>%]G4?>O
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MV0K*%>L,8\<86\I.?@SG]].<<MW2WWN8O\E?UD!Q3_O4?0O*C61S7$\P< <
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MV>8?:/\ ](8_[9K_ ,Z>>3C_ +A8U\TXC^YSCDD_?97]I!^TB0N?-4OP< <
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MSNG;V7,)2YG:%_RM*%96A*_>LMYV$+4E"E)PKQPE64(RK'AG*4YSX8W6P_\
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( < < < __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g449732g82k44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g449732g82k44.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M ,-!:I_T K7_ +^M0.QZIX \7/XT\-_VG):+:R+,T3(K[@2 #D?G0(ZF@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \\^,ZJ_@:-&
M&5:]A!'MDT :?_"K?!/_ $ (?^^W_P#BJ #_ (5;X)_Z $/_ 'V__P 50 ?\
M*M\$_P#0 A_[[?\ ^*H S_A'!';>']7MX4"11:M<(BCL!M % 'H% !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 9FN:_IWARSCO-4F,%L\JQ>9M)"D
MYQG';CK2NKJ/<=FTVNA>MKF"\MX[BVF2:"0;DDC8,K#U!'6J::=F2FGL2TAA
M0 4 >>_&7_D28?\ K^A_F: /0J "@ H X/X5?\@?6_\ L,7/\Q0!WE !0 4
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MX5@.I-<]3W(2DMRH/F<8O:YYW\(?!/AW6_"XU?4M.\^]@NVV2>=(N-H4CA6
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M/[QR=&^G!]JI6E\/W=27>.LMN_0ZFD,* //?C+_R),/_ %_0_P S0!Z%0 4
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M7]J^TR&5I7DV[02<#@>F *!'34 % !0 4 % !0 4 % !0 4 % !0 4 % !0
04 % !0 4 % !0 4 % '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g449732g90m21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g449732g90m21.jpg
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M 0$! 0$! 0$!_\  $0@!:0&I P$1  (1 0,1 ?_$ !\  0 " @,! 0$!
M       '" 8)! 4* P(+ ?_$ %P0  $$ @(  08(!@P)"08'  4" P0& 0<
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MP?K&!+M_LNUU\5!:F;(S;9+%4B^P!:A6),^9,$Z[UM:BKX\7SX^2A;/M'U%
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M!\'9I;;;UJMMY[_$8O\ XJ9Y.C_WK]QO_,?3G_\ 0//K[*>D/_27/^CVS_\
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M((5@7:U[YLI&JV36$4\!E1MW:&U[HEZO'(+EOB0#H84+U]&+EXCD"%&M*2Y
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MV.WM5!:FU3879'8E8H\VCY38(1'M"99N%^$D+ZBX*8)A@]W44*4YI-,A3!(
MBBKSIA5L; )M W79L2X8>3/>\3$IG1-URT7BRP-LJB9N<?ME6ECI=%:)Q(E
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MD)/FP"[8&13LSTL5R79XEHE1PK@4ZO2I/7! X X X X X X X X X X X X
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MP5!&QZXZ>>JYHE4*N_+-89!#C-A(R6B;A; R(''G[/3@65X(' ' ' ' ' '
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M3AQZ%"0_):$!RA);288^6\T!VG ' ' ' (MM.\=+4<U(KETVYK2I6"(R)D3
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M:(V94C+*49?=\X#F< < < < < < < < < < < < < < < < < < < < < <
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MO':G-4?!ZYH&OZAL_8>PYJ1SDT48I%'I=^II,W8*>4LK#LH_% B6B5CBE!$
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M5D2Q1M>4MZ[*!2-@$*G5IVPRE<Q#6)-WC-;$Q;&7ARX(X3'(Q94Z*I$&>@;
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M+ E(8DU^SRXE>,-PC$J/"=$4>[TS\F),? ' ' ' ' ' ' ' ' ' ' ' ' '
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M8=<@L0:$ BX#T&P&\Y-':6-]%ZG5S!?*BA,(S!FD%*EOO*R*'F_KS\9.G '
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M\PNM)-O2'WBV!GK[KSKDA3BA2\WC7%X[^<F_@@< < < < < < < < < < <
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M< M%U'_&?/\ Y'E?Z3!\R717WRF?))OG9)@_*![QR_G"S^9M)LFYL,TN. .
M>T'R+T,Z]T*H#D W&@QLW+9>$QW0Z9BTJQ;R&%JR_F>QE6%*\<X3Z/'FX^#Q
MS^_SB?EL3?*!>%'3_<KLV)_\G+.@N3[[V;+\HMGGXC:Q[.M/SGA?9U'WKS4M
M(OA?11FP]G6GYSPOLZC[UXI%\+Z* ]G6GYSPOLZC[UXI%\+Z* ]G6GYSPOLZ
MC[UXI%\+Z* ]G6GYSPOLZC[UXI%\+Z* ]G6GYSPOLZC[UXI%\+Z* ]G6GYSP
MOLZC[UXI%\+Z* ]G6GYSPOLZC[UXI%\+Z*!W(]B>PRI!&<T0?RZI27FH6(*4
MM90C"6LLXD2<*4E>%KRYZ3'CA>$^;CS/%4JNUU\5 <[D@< < < Z*TLV&16;
M''J,L= M;X(NS6)Q=IQ\3#L+H^0@++*,LMO.O#HY)49Z:TTRZXY&0ZA#:U9P
MG(=)K ZA^3SV9U9/V+;E@W30.P_9[;=EKL[?O9+:&J;,QM&YU%JR#)9R@T<F
MQM@M7M7T<-6V90ZCTFK5&-6(TN$#66A/8A1)0X5.)/"C262K5+J57O;=>%#:
MYP4FE;RM2]QS[OU/I^KC>V\L7?\ ;Q$>XVF>WVA^I-RNEXBC==3:TU!G;?IU
MS/;+]0I>-HYDU:BCDMCX$F84LKOH<BFGA5#3&M-F:;P\3HL:9^+GV:]7XI&#
MUHZ\0C"2B"\31FI8Q5)NX!=AFDDF*#7VIV#&P*W%@UV\E,2DN^T+B!A1 MGE
M^F-BXK$&<PT@0\WTOF)TX(' ' .))@09KL%Z9"B2WADO,\:[)C,ONCYV8DN!
MF;!<=0M<27F!/G0LR8^6WLQ)DN-E?H9#R%@<O@#@#@#@#@#@#@#@#@&M/REG
M>>W=&:-K2V5&C5R\R;U;"U=F1+'/)P&(+ X.DDB1&6,SAQQUQS/HEI=_ PCX
M<?A<V9R::"V/3JW7G9+9;K388;!9)-H@CLT$J.*9%,G.6X8E-3222JJ8U,2T
MMTCGZ.6:R3Y%FE6EVF?'*BAFQ1PJ%0R]=-.#%MO#$T]_XPCNG_=\U?\ :.U_
MGYN'^CW<G_<%Z_H]D_=,$]E"\/P78_[Z>/\ &$=T_P"[YJ_[1VO\_']'NY/^
MX+U_1[)^Z/90O#\%V/\ OIYT[W[(QV:P7C 'M(:B;,S&7GXPY=JM.)+K;&&E
M.82CSO##F4.I=:85E+S[*'WF&W&HTA;5E'R&:*R[;*N^/2JWPVV=!',E69RK
M'W6.&7JN*BU:*)PQ:T$$34<R"&9'+AB@E37!<P\HE\QV>.UPW)9W9I<4,,<Y
M3)^I"XFTL<W#6%PQ1).&&)PPQ-11P*+T*=<NU]&W+UST[O.R6*G5I[:0\+";
M@03.) R5?2<9YY^C5&1(6J3:3\=^+-AX"A\$2_KH\C!7%Q-'S6&.>=([MLUS
MW[>UUV2T^O+-=]NGV63:FY;<Z"3&X-=N4W+JVFGJNB::V&T+JM4ZW7;8K9/D
M^MYUILTJ?,DTB7<W,A46K2-**E&J:RJTT]I;3GBE^. 1;NS\55V_B=7_ !,?
MF.Z6_>Y>_P E?G(#Y3_<H^A>5&JGG.)Y@X X!?KJ3_H;9OY38_HJ!S=')I[U
M7A\X?Y:27UE]I%^-]2+7<V070X X!_''W?\ CIV]_.A?_P"M9;G7]B^X[)\F
MD>:@/(BS?2_*1?RY(' +1=1_QGS_ .1Y7^DP?,ET5]\IGR2;YV28/R@>\<OY
MPL_F;2;)N;#-+C@#@'M7\BQEW'D^Z)EA32'L6_:.65OI4ME#N+<2]&IY"%MK
M6TE?AEQ*%H4I&,X2M.<XSCBCEL^_^\/D5V?L<LZ"Y/OO9LORBV>?B*.4KNMV
M^NG4KMK5WML3ZCWDU'6"=\UHY7B?7 YK+=3:I&Y# RX==K3L&HO#;_J.<)UG
M9B=AUJ?J838U6$TUF)!O08191IYO4QG5(=9-*L+P>>&-,:/!Y;UCDR9MJ]VN
MT4(WW.'ZUM<)DY4M5>2BL?7VAWZE :D19V!W!W!>J;<M<&):05I=JMIV@R-K
M-!%F[^Y9Z?J>V$HUA,*C5P>;D."*+O:[=:K6."VYXTSPI4V.^3^W/;^P74G5
MFV=@23CUWL<K8X^U1;+7 E7/@3M0VM>*41J!>#6LXK9*?29%=74)%NKS \%?
M' F;N($!1]ACB80I:HVO3ZGXMA<G@@< < < < < < BPGN_4 79@'31;9-.'
M[2L\ J2 T:4<@LV DP&2$=FLLPU.XR@DJ+81<^ '>4T6+BU3BHF%-'!S$J %
M,*[,CX&M]:4KL*Q$36U*' @5*PQZA99CMF%+C!+?)],INH$'F9+C<>V):CO2
M'ZRI7MR+$3B9*@,Q5H>4!)@PF--C1YD,0@E@Y:#$)BBHR7'GC28V>PW*@D!\
MZ*X[%FP9L5UJ3$EQG78\EAUMYEQ;:TJR!SN . . :$?+=7'V$]UGKH?==2ZY
M7 ZK:5B@;6N?=B!TR'R:U12^H)9Z@AS,K4^X7K;9CI@U5#0J7$KP:92FJY,G
M1+$Q[8D098K@S>#>&2A<6>VE5ET[<LS8UY/S>'7C=W5;4+O6JRU<S1=;Z[UI
MK.?7*OL&%M-.KCH+65,G_M66"_#Y$N+9;53 9<) .D\RG9<R2K$R=AJ5)<:2
M*6FGBFF\<4U7GQH74X(' ' (+VQV2T[I(_3JQL2U9$G+O[:D"1T$27/2H02N
MA29T[:[ P#A$'P%0$PA,K!"R%&XXJ*XE:WY"(L0C)A"4F^C?DN+,,/\ =CJ]
M4[WLK6UMVP.J=OU'K ]NB\P[37[A7!</5E5-,5JT78#:#5=@U:[A:W9Y,>KG
MW*.:L;X>SNHKA%B,;SZCP*.E:85IX]U,^T_TMW9ZL 1XXF;W+6Q$<B;OE>6R
M2B'X1(&2U;;@M$V4JXAI ALO1!E!MUEK82XG;I!  ZY*L=?66(Q(QL8_*"CW
M9?7EQS7-5Y%IN"!P!P!P!P!P!P#SV?LA+\377K^<VS_U51SH7U/7OSI%\V67
M]J9J_E0][[K^63O,'E2YU6:7/A);>=C2&H[_ *K(<8=;8E8:0_F,\MM26G_0
MN?Y-[T*\I<]$O\!SS?,5^#G/*)L,<<N9#+F=RF101PRYNJH^YQN%J&9J1=['
MJ1-1:L6$5*/!E4#AAC@BC@UX%%"XH-9PZ\*:<4&LL8=956LL56JQ17"WZCNI
MJPM$P]EP,*3JI8:_8;8R[F,T9:F#F(0SU^KMQW8D4K DO*D#RH>1&?3''L*E
M2<.0XD25K.^=#[\MUXPVJQ7IZTM<^Y[RNV\;W@C[G!;H+19Y<FR^N+HAE129
M5JL\V**99[78YLN8I=GE]VG5DR9$[,[NT@NRS6.*1:+%W:1*M]DM=DL#AUXK
M-%+G139W<;=%&IDRSS8(=2=(M,$<+CG1:D#4R.9!ZE.HWDX>]%OZX=4MFU+L
MPP!73-:VN)UQ%OW6Y9D=<!VQ074N/#L@Z:T-4W<Q<9>H=]P)NMS*)8+%-VZ*
MID);022?@B./]++&[NTCO>[W!!+=BM<5D<N7'%'+@=G@@E.&5'%2**6G!_5N
M)0O4U4X(/:K>=S6J&UW58K2G%,5IDPSW''##!'&ID<R.L<,.$,;44.NH6UK)
MTB>$3]87,>/0' (MW9^*J[?Q.K_B8_,=TM^]R]_DK\Y ?*?[E'T+RHU4\YQ/
M,' ' +]=2?\ 0VS?RFQ_14#FZ.33WJO#YP_RTDOK+[2+\;ZD6NYL@NAP!P#^
M./N_\=.WOYT+_P#UK+<Z_L7W'9/DTCS4!Y$6;Z7Y2+^7) X!:+J/^,^?_(\K
M_28/F2Z*^^4SY)-\[),'Y0/>.7\X6?S-I-DW-AFEQP!P#UM^23[(T36G2BC5
M4^-M,DC&M>PI;CHJ +D0\MS;60>:PAR4:A/96E.?!S&8Z<85\"5*Q\/.3>5G
M16\;UTTMULLTVQP2H[)=\"AG3)T,Q.799<,55!9YD-&\J1/#.F1NS0F^;+8M
M'[/(G03W&IUJBK+@@<-(I\36,4R%UWX%Y(F[>J$&(Q!BZ80W"B6V??8<7.O*
M(XQ#NY22_+(6Z$TZ76B)8Y4B3(<<,1L-3_\ *K2E]*,^;S6WVAWQ\?=W]]:/
M_4,L^V2P?%VK^[E?QCMI'8OK3+FG2<O5<F42M$/ ^S$)%"H[TVQ0$J97B"=E
MN&%/EX>%QXZL1B#DAG"F&581XM(RE]H=\?'W=_?6C_U!]LE@^+M7]W*_C&95
MWMCI]K(6L :S:Q,/#D *)@0P-=@"Q[*UM0X<9B+#/X9B0H^%(0AJ,QYC+2?-
M::\$X3SYS="+VDRIDV*?=[AE2XYD2AG6AQ.&"%Q.B=E2;HG1-I5VHJ@TBL,R
M."!2[2G'%# FY<NE8FDJTG-TJ\:)]!;GF''O#@#@#@#@#@&(WV->YM,LL36)
MFJ5W8,@1+:J!R\UPM;Z@*.J;\(,VQU@%9Z48.BF7/!4H:-ME?ER4?@-%(JOP
M\ J;<N9TZZ/R&BC=W43NU)[IZ^V_HTY+INSK]K:PUSL_?T0!$KJ1LIP34.O]
M;B[/I.N;3=;YL30FUPI 2/8KC0LF;L-H5I'7#KL\Y6Q]V,#'IZ>G\ZTX:.N^
MJ^$L<LJ-4\5<=M"L.GO)^>4*IM-ZN@K(%+3]3=6S_7NY-:0)76@FK04VZ5ZI
M]@]9=N;Q4K&JPYB%:^:W;LJIW -$M]H0_/\ :^R#M?B#6U11Y\3%%"]:F;K1
MY46LFETT3KEA1;S?1T#TA=^M?2?JSH/912.7O^I-':]H]NE0YBB ^.>!UZ'%
M("!<]6$YG"0#R5 A,S"&D21PZ*^AEE"TM(%$33B;6";;7C+=\$#@#@&E3RL]
MAV]#N_6JMZJ5O/SRM7WN:-(T#I/IQLZVY0#*Z0A0E$['W+F0ZE6*[A1^1B6%
MIB\6*R$LB9Q!+@VMHRT*X=7'6U=E*N);\M5/K-D74P)%%]<-(D5!UC+':=1Z
MMLEWF$:Y3:S:;#<9^O:R@T=O ^@(]T??&6ZPE!S(!^6%8E,YAA93HB-!S@4O
M-\V7\BQ/! X X!J!\IWTUVGV4MN@;WH"&2H&_P#6,VZL:N[,4R\N5>P:J*EZ
M'='X@/9==F#B@&\Z'MENB4F->QD@-:#. B;)7@H#+ES?E)%4+I5/)TJO'Y5C
M3+IV.!^Z7DZ^Q7>&=N&Z?Y30.Q2_7_9'7D@.F;DG['U9O,76-QZJVMU\. @[
M8W"]."S4V@V27L]B%6 Y<1-M4$2Y&V<Q%G6) E1)4VXIY4>3JN?/"M<ME<:[
M;6\C5V)O=D[6; #V6O1R'<YOO/42M1.'&ULZ6!]G]K]<CFO[5)=B*DC3>0U+
MTB8*[%"UJ5-F-6<X$#5UVR0FB!Z()4:5*+)P/=75K7?FWGXWN7IN#CDAQ(L2
MB1)EH%CH0Y$J8YZ67)3"C-1DR)3OACTLE[#6''W/#'GNJ4KPQX\'S.QX!C;M
M1KCSCCS@QI;CJUN.*R]*QE2UJRI:LXP_C&,Y5G.?@QC'P_!C&.4ZL.[R@_'N
M96?DIK\M*_O^-2'=UOM ]S*S\E-?EI7]_P :D.[K?:![F5GY*:_+2O[_ (U(
M=W6^T#W,K/R4U^6E?W_&I#NZWV@\_O[(!!"A.GNOS@Z&B,M[9=F0XI+CR_.2
MFKH5C&<.N+QCPS\/CC&,_P#;SH;U/22OG2*GX,LNU_\ 5,U?RH>]]U_+)WF#
MRT<ZL-+C@'!G/O,M8RTG_E9\%.?!GT?[WA^#G&?A5\./.S\&/#P_Y2L>&@/5
M#Z?Z;\G^AOV0T,N29:8[5',L]X:2ZLJU2-%Y42@AE6F*P-3(ILZT11Q2Y%KM
M$J*[K)-@@5I4V9/D28NY_4%<A?(YRZ<K+N/E;TQD7?+NR3(MUP\GG=;3=MLY
M1[3 YLRU6"5?<,4F7(LMWRI4$ZVW7=]H@O\ O.SS9D=WQ6:S6*W6J7Z>NA/E
M3.M&M]':CTIV>I]UU!8JM5!@<'?9=9L)FB72KLHP@%9FEB4OV* ].CK2B7F-
M7B(#*FL$(IM#$I4*!PFN5+[,6R;;=,9$Z[[YO"-6JU6J&Q395CM44Z&")6J"
M1 G,D>N$U-<,N5%9UK:\J*"5%#+@[=Y3O]GYI%=UOO2V>I^O.Y-.M"[%:;19
M9&CKTCL'VSZ/6JS39DNV7%/M5KFRKLO!7;,@BDRH[1>=FOBD/K2V6*;:I,5K
MM>]K5M^Z[;O$>W=07J@;(&);0Y(?I]LB''8'I/#S6BD*$1=G"9.,YQA<0G&B
M2FU9PEQE*O@YEMCMUW7C+[K8;79K7 LW(G03'#79'##$XH'X,:A:VHXBTOY/
M].- +;]C]-=$M(-%K6XHH9<N^[JMEWP6C5K6.QSY\J"SVV4TFX9UDFSI423<
M,;6)*?N96?DIK\M*_O\ EYJ0[NM]IB!&NXJL A:RN,J*.;:D,B5+:<P[(5E"
MO6&,>.,+>4G/P9S^^G..8[I9"EHY>S2_Y5[7\9 ?*?[E'T+RHUD<YS/,' '
M+Q]6@(DM4K$\0A(DNMV/T2%J<>1E*/9D)7F^#;B,9QYRLY\<XSGX?W_#FY^3
M5)W5;ZK_ /H?Y:27UE]I%^-]2+/>YE9^2FORTK^_YL?4AW=;[2Z'N96?DIK\
MM*_O^-2'=UOM ]S*S\E-?EI7]_QJ0[NM]H/X]F[4I1N;;B$X\$HV=?4IQ\/P
M)3:BV,8^'X?@QC&/A^'G8-B^X[)\FD>:@/(BS?2_*1CRY(' +1=1_P 9\_\
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M\U7C^R3CZ2?=97Y2#]9$E<_-0SP< < N+U#_ .M+Q_X '_Q!+FTN3'[HO?\
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M4/;I!^+9!#@FW/%D>D&1JW.Q,]7,RIZ?'U6(/6_)>RE24-94E2<!1[LLS.>
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H!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
